var title_f27_61_28624="Glucagon injection sites PI";
var content_f27_61_28624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Where to give a glucagon shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 639px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJ/AScDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsfxN4m0fwxZG61y/htY/4VY5dz6Ko5P4VzXxQ+I+neCbFogy3OsyofItVP3fRn9F/U9vWvkjXtY1HXtUkv8AWbuS5u5PvPIeg9AOgHsK56tdQ0W5vTouer2Pc9d/aJRJ2j0LQWmQdJbqbZn32qD/ADrl7z4+eMbgkWtrpNqD0xE7kfm39K8pRlxgCpPOjTjcQfauZ1pvqdKow7Hp+n/HXxraSbr2HTL2P+40BjP4FT/Su78L/tC6RdziDxJps+lk9J4mM8f44AYfka+b5Z2PR8r71XZwx5waca011FKjBn31oms6brlil5o97b3ls3SSFww+h9D7Gr9fCPgjxTqPg7xFb6lpEjDDATwbjsnjzyrD+R7Gvqj4cfFbS/GV0bGS3fTtSwWSGRwyygf3WwMn2x+ddMK8ZaPRnNOi46rY9GooBzyKK3MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwPHXiW38JeF73V7ld/kriOMf8ALSQ8Kv4n9M1v14d+1PfvFoWh2CthJ7l5nGeuxcD/AND/AEqKkuWLZdOPNJI8Dvr281nVLvUr92ub+5kyTjJZj2A/QCtzTfhv4hvVaSW2WAkgKskgyc9TxnAH51P8J7JL7xEZHjLx2q+Zu7BzwP619BabCMBq8ec2nZHrQgmrs8Tg+D+sy3Ji862jtwBmd2J3fRRz+dX5vgtdIg8nUo3buGQqPwxmvc0XIp4WkpMTseDRfBG8mRjPq8EL4+ULGXH4nii2+BlwJx9t1qIw9xBCdx/M8V7ww4qCQUOckJRTPKNa+Hen2Xhe707SoQs7pkTOcuzjkZNeL297d2F4hJe2v7OQFWHDI6mvq/UIg0TV88/GXSRY63b6hEMJdqUfA/jX/EH9KKUruzKqRsro+rPAGvr4n8Jabqy4D3EWZVHRZBw4/MGuhrxb9ly9afwhqFmzEi2u96g9ldB/UGvaa9mnLmimeTUjyyaCiiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnz9qyzlb/AIR67HMOZYT7N8pH5gH8q+g68o/aVs5Ln4dCWOMuLa8jlcgfdXDLn8yKyrq8Ga0XaaPN/g1axxaHczqPnluCC3qFAA/rXr9n8sK4rzX4VWzQeC9ODptaQvJz3BY4P5V0mo+NNF05hFJfRu44KwgyEfXFeJK7k7HsLSKOxWTFPEteZzfFDQYp/LNxMf8AaEXH+NdL4f8AElnrVqZ7KRnjBwdylSD9DR7y3J5UzpmkyKids1Qnv0iRmY8KCSfQVxDfFTQ1uHjf7UoU4D+V1+gzmlrLYLKO53l3/qjXi/xxRv7CtGHQXQz+Kmu2i+IGh3W0C5kQNwGkhZR+eMVhfE+0j1nwjdSWhWby8ToYzkHaecY9s1UNJK5UtYOxq/snhjpfiBiRt82FcZ5BAb/H9K98rw/9lawmh8M6vfSKViurhEjyOuxTk/m2Pwr3CvaofAjx63xsKKKK1MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryD4m6zLd+Ir/AEWa+vLSygtUBW3QOrmQHc0oI5UDAx9T9PX68n+LYj0fXbbVwmTdWckDDH3njO9M/UM/5Vhib+zfKb4bl9olIxPCIVfD+nR5WREi8rI6MFJXP44reuVuQ6QaZb2UQKErLMMKP9kAdz+Arm/BJY+HrTfjdukBAGAD5jV2kdsJYceteM9JM9feJ5dpE+sa14oubK8FtHZxwo7zT2AUK+0lo2yc4DYAOec5xXS6VAbC6SBIYoY5iQREMLuHceorpX0ss2Xf5evAqK4tgJ4VUZ2uCDRKd9LCjG3W5ieKJJLbTiEOHkYID9awNYtLvStDbUbMW4ZVZdsdsJpCQhK7+RgMwA9gc+1dP8QIWXTY5gOI5FY/nirOn2ou7eKSN8ZUE470RlyobXN1Ob8MTa9f+HrS/wBQtrQGTANuflcDAyQDwRnPp0qXVgLTR9SmWOOPbA7kKABnaa6q5tWhtzk8gVxPiiYnw5qaZ5dAg/F1H9aF70hpWidD8KdXk0/VNJ0O1vmu9OmhkTymgEQgdV3ho8DJVvmznOTzXsteO/CC3/tbxG2qzoBLYWC2/HALu7jdj/dj/wDHq9ir2cNf2auePibe00CiiitzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L4y2SXPhq0uJVzFbXsZlPpG4MTH/yID+Fd7VXVbC21TTrmxvoxJbXEZjkX1BFTOPNFxKhLlkpHiPg+3ktLK6spWDSWt06lh3DAMD+td9ZYMa1yzaK3hnxXeafJdz3UV5ax3MMs4G4lCUZTgAEgFDn3rorGT5Bg14dSLhNqR7MZKcLxL04AXNc7eX8cOsRxyuqRRRGaRj7nCj9CT9BW5JJketZd9p1hdR+ZqlvBJjPMo4A9Pp7VDabHFWRV8R6npd9pZge4jxKu0EkAEnpj1NReAnJ0hN5BIJUHscHGRVKDT9EN6++CxMX8ClVx+HpWwkYtP8AUACE/d29BQ2VyNKxZ1mVVgYA84rzvxHBJc2MdrCQst1cxRKT0Hzbs/8AjtdfqcxkTFZlnor69r+m6bFdyWjosl600ahmUKAg4PHJf9KqknKVkE2oQuzrvg9aJBaazJEP3Yuxaof7wijUE/8AfRavQqzPDei23h/R4NOst7Rx5JeQ5eRmJLMx7kkk1p17lOPJFRPEqS55OQUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcl8SNGm1HR473T49+p6a5uIVHWRcYkj/wCBL+oWuS0TUIp4onikDxSKHjf+8DXrVfP/AIvkl8M+O9XtoIt2lyFLtYYx80RkHzMg9CysSPfiuDG0bpTR34OrvBnoE6NLCyxytEx6OuMj865a80hI7kyX8s2oD/prKVI+gHFT6Nr8M9tHIkglhbo6nI/+sfattRZ34+dlIPY15qbiz0VJx2OUNjaTP5aWjOD086dmA/Wtew0i2sIzKjybv7gdgg/DNay6fp1mCyBA3qKzdWv4I4CIyOnXtTk3sP2jkZ9zN5kpAwAOSewFdJ8JrP7SNS8QOMpdMLa0b/phGT8w9mcsfoBXj2v6q+pWtzFaOyWQjcvIpwZiAeB/s+/evpTw9BHa6BpsEChYo7aNFA6YCiu3BUtXJnDjanuqKNCiiivTPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8X+JUaTfEG4Ujpp8AP1LyV7RXhmpXa694v1XUrb5rWSRbeBx0dIxt3D2LFse1cmMklTOvBRbqXOaudLutPma409zGX5dcZR/8AeHr7jmkg8Q3Fvhbq2miYdWiHmIfy5H5V6TaWMckOJFBqC48O2kuTtA/CvKUk9z1Ho9DgZ/ErSDEa3Mp9AhQfm2KpTSXerAJdnZAP+WEZyG/3m7/Tp9a7yTwtaLzjJqKTTbe2ISNRmhSS2C19zj5LFVtJYgP9YhX8xXvXw91Aan4J0W6/jNsiP7Og2t+qmvJb6wLAso5FdN8HNTNne6h4fuTtVyb20z0IOBIo+jYbH+0a7MFUtLlfU5cbTvBSXQ9Vooor1DygooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKrajfWmm2cl3qFxFbW0Yy8krBVH4mua8UeNINNuH07SY11DWAOYVbEcH+1K/wDD9PvH071xslndaxfJe67cm+uEOYkK7YYD/wBM09f9o5PvXNWxUKWm7OmjhpVddkaHiDxbe+IoHs9BSWy06UFZL2VSs0qnqI06qD/ebn0Heo9I0qO0ijVUVEQBVUDgAdBV23tVjOcc+9W/pXk1a0qrvI9KnTjSVoELjySCPumkmZjGWiI3DsasMoeMqevas2K5CTNE/DCsy1qQTXdww2rGAfWqDxyNNzy1bN1KhX5QM1XsofOYn3pFpqxAls5XkZrL1Cw/eRSRSzW1xC/mQzwth426ZH4Egg8EV1wjULjFVbu0V16U02ndCunox2hePpLIJb+LAgQttXUoUxEfTzV/5Zn35X6V6LG6yxq8bK6MAyspyCD0INeQzWfUYBB4IPOaj0TU9T8KNt04G60zdltPkP3B38lj90/7J+X0xXoUMb9mp95w18EvipfceyUVleHdf07xDZm50u4EgU7ZI2G2SJv7rqeVNateknfVHnNNaMKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqG8uYLO2lubuaOG3iUs8kjBVUepJrI8S+KdO8P8Alx3LPPeyjMVnbjfLJ747D3OB71wuoPqXiW6SXWmSKyjYPDp0JygI6NK38bD0+6PfrWFbEQpLXc3pYeVT0N2bx5NdMToGjTXVuDxc3Un2ZH91BBYj3IFczr/iLxLeuYr5zpVkeo07czuPeUjK/wDAQD710duDGowcnvmpmdWGGWvOni5z0vY7oYeEHtc4vSZbGCERWQhSPO4hO57k9yfc810FrdwYAyAaL3QNNvDve3QOf40+VvzFZ7eGvLP+jX06D+64Dj/GuVo6uZM3BNG3RhTt6+orFi0i5jPN0rD/AHcVYSyuEP8ArgakLI0SSMFelZ+p2ZnXz4OJl5+tTLBcd5Rj2qzEmxQCc0xbHNwyXF1KIlQ7u5Ixit+NUsrYIpye59TVgAdgKgubYT4O4qR6UDvcWOVdmWcU2S5h2n5xVVtMyeZmpj6Mrj/Xuv0oDQJZIichs1VuZYCvzMo9yasJ4etz/rLq4f234/lVmDRNMhYN9nWRh3kJb+dHKHNY5d4WnufP0drqLUANq3dodjAejN0ZfY5rpLTV/GljAplu9L1Ajqs8DRMfbehx+O2tUFFUKigKOgAxTHJYVtCtOnpFmU4RqO8kbHhXxXba60lrNC9jqsIzJZysCSP76MOHT3HTuBXSV5PqmlLcNHKryQXUDb4LiI4khb1U/wAweCOtbOkeOJbAR2/ixEjXO1dSgU+S3p5i9Yz78r7ivQoYuM/dnozhr4Vx96GqO/opsciSxrJE6vGw3KynIIPcGnV2nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXHeNfFUthcLpOimJ9VdQ8sjjclrGejMO7H+FfxPHXc8U6sND0G8v9gkkjTEUeceZIThF/FiBXlmlWskeTcSGe8mbzbmY9ZJD1P0HQDsAK48XiPZRtHdnXhKHtXzS2Rd0vTlieWZnknupzumuZjuklPufT0A4HatqOMIoHeltYtqAAVO8RAzXk6vVnpNpaIavrTiM0i4wKfRYRGRijJqXFNIFFguR0Up60lIoM0yRsCn4qOcfLQIbG/rT93pVMNhsVZQZWgY/caQsaMU4LxQBEztmhXNPKZpNmKaE2ODHvTs1CePWhGxVaCsSH5uGFVLm1BU8AqRggjIIq+ibhx1pzxkDkcUnEFI5vStSu/CEpNhG9xo27dPYDloh3eH09SnQ9sGvVrG7gv7OG7s5Vmt5kDxyKchgehrzXUotp3L1FO+H2pHSdfbSJGxp+obpbUHpFOOXQegYfMB6hvWu7B4l39nL5HNi8OnH2kT0+iiivTPMCiiigAooooAKKKKACiiigAooooAKKKKAPOPiZeG517SNKUny4FbUJh6kfJGPzLH/AIDVPTogTk1U1SX7d418Q3OciKWKzT2CIGP/AI87VqaevArw8VPnqvyPaw8eSijWtY+MmnztxSo4WPFV5n/WpbsrE7sYDxS7qjDDp3p1ZGthwajdTaKLhYKKKUDJoGORe9RzjCmrca/LVW8+VTVNWRCd2Z2C0nFXoxhBmqFo26fmtRxjFTbQuT1sNwKKKCKACkJ4opKAIXpF61L5eaayBeaALNucVbYb46zYpcNir8UmOtaQfRmU11M69iyCDXK6zJJY2/263XM1jIt3GPUockfiu4fjXZXuDkiufuog7MrjKNlSPUGovyyujaPvRsz1W1njurWG4gbdFKgkQ+qkZBqWuU+Fly0/gXTUkbdJah7Rv+2TlB+iiurr6GLukzwZLlbQUUUUxBRRRQAUUUUAFFFFABRRRQAUUUyaVIYZJZWCxopZiewHWgDxvTcvc6pM3Jm1K6fP/bVgP0AroLP2rn9A3TabBcEYNyz3OPTzHZwPyauithjAr52bvNs99K0Ei4GOKqSS/NljirJPy4rB1q5a1tZpUXcY0LY9cc0riijUDZORVhDlRWTpt0lzEGQ5BGRWlCe1IbViWiiimIKliXJpi1MnWnFEyZYUYWs7UD8rVdaQAVm3r8Maub0sRTWpRsh+9J9612+bFYVjMDcEVsq3IrNM2mtRaKU0lAgpQuaVcd6eKEiWxNvFV5+KsM2KpXMgAJNDY4leSQRsDnFX7eXzEGK4nxHqTR25ETYlmdYo/wDeJrrNJBW2UHnAAoRcloW5uVOayLrqa15fumsu6TJyKTFA2PhO2LDXLf8A55anIQPQMiP/ADY13Nee/DKXydc8R2TfekaG8Q+qsmw/kY/1r0Kvew7vSieNiFapIKKKK2MQooooAKKKKACiiigAooooAK5f4l3b2vg2/jhbbNd7bOM+8jBD+hJ/CuorgfijMWuvD9mOjXElyw9o4yB+risq0uSm2a0Y89RIyLKNY1SKMYjRQqj0AGBWlECDVPTl3EE9K14468FK57UnYjPSsXU1EisjDhgVP41tzDaCawNQf5s0mENTk/BeplrHy2b97bO1vIP904B/LFdvZ3IdOvNeZ2FtJDe3s9kFMqXMiTRE48xSdwIPZhn8a6W0vnQAkMuezcEVU1rdFpXWp0up6k9osbKo8sg7mIzg9hVWy8QLcXHlpiYblUbFIPP+HeoYdUiZNsgBHcHvVuDULWPPlLGhP91QKWhLi0binBqQMAKxf7Wi7mmPrEeDg0J2J5GzXmmA4BrH1C4wp5qjcapnO01RLTXcgC5x60N3NIwsWLGU+bv7A10ltKJAKyLWxZUHFW4AYmpBOzNSimRtleajmn2DimZk+eOK5m58RyQttZCHwcoEJ+bP3fb8a1W1JF6sKp3OpxE5+Qt6kCi6KUWWrXUHntfMlTZk8Z4yPWs7UL7flVPHc1QvNSL53Nx7VjX5lvE8tHaOJvvEHBI+tLctRsZSX51bxfEic2lmCVP9584z/MV6tpv/AB7ivLNBhUavevGoCRskK47bRk/zr07SH3QKKqe9kS17ty9IDiqc6/KeK1FTK1VuY/3Z9aTRnGRneHrn7F420xui3kUto59wPMX/ANBYfjXqNeL6rMbSWyvP+fS9gmz7bwG/RjXtFetgJXp27Hn46Npp9wooortOIKKKKACiiigAooooAKKKKACvM/iAxl8a2cWeINPZ/wAXkA/9kr0yvLvGRJ8d3bf3LGBPzeQ1y4x2pM6sEr1UWdNX5RWuoG2srTfuCtUH5fwryYHo1Nytc/daua1M4U10d0cAiuT1OTMhHaoka0kczpp267q0RHUxzD8Vx/StpYVlrm7OY/8ACZ3iYO1rdVB7bgc4/Jq6aJWyGXmnJamkXuMOnknAapk0uXs1adkRJjcORWxCsZHTmpE52OYGly92NPGkuTyTXVbF9BS7F9BQT7RnOQ6OM/NWpb2KQrkCtDA9KZLwlAnNsZF6U4xKTmobd90uKubTTsS3Yj24GBUMsG8YqweKYXpAZVxp6sPmArNnsY0Bropcnmse7jaRjjpQaRkYNzEin5R+NVvbvWpcwBU+btWJqU4trW5nHSOJm/IULUu+hX8JqHtJJuvmzyNn/gR/wr0XRv8AVjFefeFraSwtJrCfPnWs7I2ffDD9GrvdFb93VTVptEN3ppm/F92oLpflNTQn5ajufumrexzLc43xTEZNJ1BR18hyPqBkfyr2DS5/tWm2lx182FJPzUGvKdWXfHPH/fRl/MGvQ/As32jwXoUp6tZQ/wDoAFdmXvWSMMetIs3KKKK9M80KKKKACiiigAooooAKKKKACvLvFf8AyOmok94rcfo5/rXqNeVeIm83xnq2OivEn5Rqf/Zq48c/3XzOzAr978jSsBhBV8NxVG0GIxVjfxXkp2PRkrla+kCg1yd3lpGPrW9qMuSa5rV7gWllc3DdIo2f8hmpeptTVlcoCwdPCcHiJV/djW5Fc+sLKIQfoGUfnWtb/L8613Gn+G/O+EcOhyL++l04Z46SsN+f++zXn2gXQutOtpmHMkYLD0Pf9c12Yulycr8jlwlXn5l5m9ZYf5k/KtSFSMVlWSmOTK8qa2UPy8VxnRIlzilBzVWSTDYqaJsimQSUycHb7VKq5pZR8lNIlsz7VcXNarDis6EYuBWp1AqooUmU5jjNVS3zVaueM1lyy4eoZcdS4W+Ws29kEamriNuXrVK9VeSaRSRiXTPICT0rC1GA3tzZacoJN9dQ25A/ulxu/QGugvJB0UYApfAdmdQ+IWnkjMdjFLdt9SPLX/0In8K1oR5qiQ60uSm2S+Krf7J8Q9biC7Unjgul98psP6pWjo8m0bTU3xSt/s/i/Rrz+G6tZbVvqhDr+haqFi21uKvFR5arM8M+egjq4W+QUSnKmq1pJmMVKxzWN9BctmYd+AJR7nFdn8NxjwJogPa2UflxXHamMOrejV1vwyfd4J05e8fmRH/gMjD+lduXv35HPjv4cWdRRRRXqnlhRRRQAUUUUAFFFFABRRRQAjEBSScDufSvGtLuv7U1K/1IZMd5dySxE94xhUP4hQfxrufifqL2PhWaC3Yrc6g4s4yOo3/eP4IGNcjoVssSRpGoVI1CqB2ArzcfU2gelgKdk6j9DdRdq4pXOFNKTgZNVLi4ABHavNOxK5mX7fMaw720GpXFjpp5+3XUcBH+znc//jqtWjez7pDirPgC1Oo+O/PIzBpdqWJ/6ay/KP8Ax1W/OtcPDnqJF15ezpOR64BgAAYArwkWv9m6xqliBhLe+mVB6Ix3r+jivdq8g8awtb/EC/U/duraC5X6jdGf/QVr0sdG9O/Y8vAStUt3Llgg2itFFwDVHT/urWljC15B6TM2Zj5hq5bHgVSuP9dirlp2pg9jQQcUko+U0+LpSSjg1qloY31KMS/vs1pL92qUa/Pk1cX7tJBLUq3dYF6dr5rfuvu1gX/Ws5G1PYmtXJApl/wlFrwoqS6GUxSK6nO3I4Oa6z4O2it/bWpYyXmW0Q/7Ma5P/jzn8q5HUT5ayOfuoCx/AZr074YWf2LwJpClcSTQi5k92kJc/wDoVduAjebl2OXHztTUe5n/ABds/N8P2d8o+awvYpSf9hj5bfo/6VyNudrAGvTfGtg+p+EdYs4v9bLayBP97aSv64ryPS737VYWtyOksaufqRVZhG0lIMuleDidfYH5MVbrHsLkbBzWrFIJBxXAdMlZlHVU/c5961/hbeI2n6jp+cS2d27bf9iT51P5lh+FUb5N8BFYfh68/sfxtYTsdsF8PsMx9zzGf++uP+BV04SfJVV+phiIc9F26ansFFFFe2eMFFFFABRRRQAUUUUAFFFFAHmPxJuvtPivT7AHKWls1ww/2nbav6K3507S49sYrH1+YXfj/WpQcrE0VsP+AoCf1Y10mmxjylrwsQ+etI9uiuShEe4O3FYl99oBYCNWX1BrpJkwKxtQwmcVjJWNKcrmBIhALMMH0rrfg5b/APEj1HUGX5r2+kIPqiYjH/oJ/OuRuWJzXoXwriMXgDRwerRtIf8AgTs39a7MvV5tmGYyappd2dXXl3xMUL400hx1ksZ1P/AXQj+Zr1GvKfilcxx+M9GWRtuyynY/8CdAP5Gu7F/wmefhXaqmybS/uitNulZOkSpIgMbq30Na3avEPXbvsZ065nq3bDGKYyZlzVmJeaaE3oXIhxQwzxSxttFLn5s1ujBkaxc08rhacDg9qQsM03YSuU7gZBrE1BOPxroJx1NZV5GGWsJKxvBlGHgCnzuNtMPyjFV53JqTUxtbO61ugO8Tj/x017D4LcS+ENEkXo1jAf8AyGteNancQqSruOQRgcmvU/hZMZvh7oLN1W2Ef/fJK/0r0MveskcGYNNKx1deBaXb/Y7nUtMJ4sryaBf90MSv/jpFe+14t4hhFt4+8QIvCyPDP+LRgH9VrbHxvTT7MjLpWqNd0S24lR8Rx7vfOK3bEPszIFDHsKyLB/mwa6G1UYWvJSPRqMSZcoRXHeJ7dns7jyyVlVd8ZHZl5U/mBXeSxjZXKa8nLDtinJcuoqT5nY9U0u7W/wBMtLxPuXEKSj6MAf61arlvhhcG48C6WGOXhRrdvbYxT+grqa+hi7pM8GS5ZNBRRRVEhRRRQAUUUUAFFFFAHiFmwuNf1iYdJL+c/lIV/pXbaavyLXBeGTuaZiclriYk+/mtXfWJworwL3qN+Z7s1aml5Inu+BWHqp4raujnFYmqVNTcVLYwLgfITXpfw6Xb4G0Mf9OqH8xXl2rS+TYzSf3UZvyBNeveFLb7H4X0i3PWK0iU/UIK7cuWsmYZi/dijVrxT4tNv8fRr/c06MD8ZH/wr2uvEfiypT4gBj0fToiPwkk/xrox38FnnU9zMtflAxwfatWC/uoQNk749GOR+tYtq/StBTkV4I7uL0NiDXJVb99Ejj1Xg1t6fqVrckKr7JD/AAvwa42pV4q4zaNFiZx31O7kbbVC6vlhBLNjFZ2kai0jrbXDFs8Ix/ka0bqzSdSrqDn2rbmvqjvozjUVyjHrcbvjdjPStGC48zkHIrNtdAhhl35ZsdAxJA+lXNQlXT7Teqjex2oPei7NJyjFXLdxcxQx5mkVPqetYGoa3bpnykaT3PArLnkaV2eRiznqTWbqDhYzWUptnnPFSb93Qnm1md2+QIg+maz7y8nlHzysR6DgVUjfJp0pzUXYnUnLdlSY8g+9e1fB9s/D7SvZph/5FevErjtXtnwfXHw90o9mMzD8ZXr0Mt+NkT+E7WvHfFy4+Ierf7UFuf8Ax1h/SvYq8l+IEJg8f+b/AA3NhGfxV2H/ALMK7sar0ma4B2rIgsuJK6a2PC1zVn/rK6O3PypXjx3PVqGhIP3VcxrqZDGumdv3dc5rf3GNXVMqG5sfCB8+Hr6L/nlqEw/MK3/s1dzXnvweP+j68ueBfA4+sSV6FXtYd3pR9DycSrVZeoUUUVsYhRRRQAUUUUAFFFFAHhXh1fLuriLP3Lmdfylau8tOFWuJsV8rxHrMPTy9QnH4Fy39a7W2+6K+flpUfqe9J3hF+RLcVh6qeTW3PWBqrZJqZbhSOY1xHurdbKP/AFl3Ilsv1dgv8ia96jRY41RBhVAUfQV494Vs/wC0PHmmxsN0doj3jj3A2J+rE/hXsdengIWg5dzhzCd5qPZBXkvxusjHqGiamoOxhJaSH0Jw6f8AoLV61XAfHO/isPhzfNIivLLJFHBntJvBB/AAmu2WHliV7GO70R5/Ooe89jy63kxitKGXgVymkatBfQho3w4HzKeqmtuGbNfNVaU6M3TqKzXRmt1Nc0djYVgakzWakpFTpNnvUEtF5DjkHBHINd1ARJDG56soY/iK88WTPA713FvMsUESE8qoH6VrTkdWEi7sv7QK5vxU/wC+gTsFJ/X/AOtWy12oHWuY8U3GZYXHTaVzV1JaaG2Ii/ZszJHAFY2pzZGAalubrAPNY1zIZH4rA4YxsWIj8tOY1ChAXk0POigksAAMkntStcsiu3CRO56KpP5V9B/D2xOneCdEtmGGS0RmHozDcf1Jr5Z13XYXgeCzbzHbguB8oH9a+mPhR4ik8T+CLC/uNv2td0E+0YBdDjOPcYP419Hg8sxGHo/WKsbJu2u/3HO8RTnL2cXdnX15x8WYhFf6Hef3jLbE/UBx/wCgH869HrkvilZfavBt3MilpbJlvEx/sHLf+O7hVV4c9NxNsPPkqxkcRZnLiumtv9Wlcpp7AhGBypHB9RXUWZzGteAj3KiL7n93WBrvERNbrfcrB1//AFNXMyo7ml8Hk/0LXJM/evsflFHXoFcL8HlP/COXsp/5a6hMQfXG1f8A2Wu6r28OrUo+h5GJd6svUKKKK2MQooooAKKKKACiiigDxvUofs/j3XY/71wko/4FGh/nmuotDlBWF41j8j4iTFePtFlDKfqGdf5AVs2J/divCrLlrSPbg+ajF+RYuThSa5zUW5reu2/dmuR1q6W3hmmkPyRqWP0AzWMjWkjqfhTaB7jWtUIzvkS0Q+yDJ/8AHnP5V6FXO/D7TW0vwhp0MwxcSR/aJv8AfkO9vyzj8K6Kveow5IKJ4lefPUcgrxf9p24K+H9Ftw2BJds5Geu1D/8AFV7RXzD+0PqjX/j8WW7MNhbpGB/tN8zH8io/CvYyim54qL7XZw4uXLSfmeaw7oyHjZkdejKcEVt2niS6hAE8Ymx/Ep2n8ulYqqwHynI9DUkahuDwfevpcZl+GxqtXgn+f3rU8unWnS+B2OvtPFVuSBIXjP8AtqcfmK2bXVobo4gZXP8AssDXnyJin+Wjn5kXPrXztfhHDS1pTcfXX/I7IZjJfGr/AIHrOnMI5FlmPI5Vf6mtf+0x1J/WvFopZ4f9Rc3EY9FkOKsf2lqQGBqFx+Y/wrglwlWXwVE/W6/zPTo51QhG3I/w/wCAevtqif3qo6lfwzwFHbnqD6GvLW1HUGGDfz/mB/SoJJZ5OZLq4b6yGiPCdd/FUX4/8Auee0WrKDOsvLkoTvwFH8RPFZcus2cZ5nDn0QbqwHiQn5gWPqxJprKADgAfpXbR4Ror+LUb9Fb/ADPLqZk38Ebeupo3PiJjkW9uf96Q/wBBWNeXlzdZ8+Viv9wcL+VIwyflBb6Co2Vu/Fe/hMoweDd6UFfu9X+P6HHUxNSr8TKzHBr6W/Zpnjk8C3cStmSO/csvplUxXzVKuBXr37MeqGDxPqmmu+EurYSqvq6H/Bj+VPNqbqYWVumpWEly1UfSVR3UEdzbSwTLuilQow9QRg1JRXxZ7J4VoaPawmyn/wBdZSvavnuUYqD+IAP411+ntkAVj+MYfsHjq9QLtS8iju19CfuP+qqfxq/pT5Ar5+rHkqOJ78Zc9NSNtj8lc7r5zHW8x+WuY8Sy+XBI3ZVJ/IVE2FFanZfCqLy/A2nt3maWY/8AApGP8sV1tYvgu3Fr4R0aFRjbZxZ+pUE/qa2q+hgrRSPCm7ybCiiiqJCiiigAooooAKKKKAPMfiTHs8ZaXN/z0spE/wC+XU/+zVasGzEKT4qrt1XQJB1xcIfyQ/0pulnMC14uLVqzPZw2tBE14SYm+lcbq0Bv7qx04cm9u44Dj+6Wy3/joau0vhi2Y1h+GbYXfjvSc8i2Wa5P4LsH6vWVKPNUijSU+WnKR62BgYHSiiivfPCAnAyelfFvjHUhrPjHWdQXOye6dkz/AHQcL+gFfW/jbU10fwjq9+zbTDbOVP8AtEYX9SK+LrfPc5Pc19HkNP46nov6/A87Hy2iW0Wp0TimRjip0HrX0J5wwxL24PtS7WHRvzqbFAFAiMF/QGnAMf4f1qYLTgvpSAg2v/dH4mhkfHVR+tTkU1hRYCt5b55kP4UeUoOSMn1NSNTTTsMYVqGRR1qwRmoZBxQgM+4FdH8J9SGlfEbQ7hm2o0/kOfZwV/qK56cHFQW8zWl1DcRnDwusi/UHP9KVSHtISg+qsOMuWSZ940VX065W80+2uk+7PEso+jAH+tWK/PWrOzPoTzr4uW/lz6DqIHCTvaufaRcj/wAeQfnVDSOcV03xVtvP8EX0g+/atHdL/wAAcE/pmuY0QhpAB0rx8dG1RPuevg5XotdjaJ+SuP8AGkmzS7w+kLfyrsZBha4bxrl7KeMfx7U/NgP61yW1SOiHVntlhGIrG3jHRI1UfgKnpFGAAOgpa+iPACiiigAooooAKKKKACiiigDz74rL+/0Ju4llH/jn/wBaqukn9yo9qt/FD57zQo8clp2/JVH9arWA2IorxcZ/GPZwv8BF27XdaP8ASs3wB/yO0+f4dPb9ZF/wrZI3wMPasjwiyW3j3y34+02Ukae7K6tj8sn8KMP/ABYsmq/3MkemUUCivaPIPLf2itS+x+AltVYh725SPHqq5c/+givmiEcV7n+1DcjyvD9oD82+aUj8FA/ma8MhPy19jk8OXCp923+n6Hj4x3qvyLUTY4qwD6VTQ81ZWvTschKDT1aohT1pgTgjFOD46VEDTjSsAM1MZqDUUhxTsA4nNJUQfkU/dTsA6opKeTUTsOaLAVZqpSDrmrsmM1Um60IZ9ffB7Uzqvw40SZ23SRw+Qx90JX+QFdnXlP7Nchf4eSITxHfSgewIU/1r1avg8bBQxE4ruz3aD5qcX5GJ43TzPBuup62M3/oBrgvCwLxxOepRT+ldz49uBa+DNbl7/ZJEX3LLtH6kVynhq38m0jB6qgU/gK8PHayietg3aEjQuOFNcR4pG8xqejTQg/8Afxa7a6PBrkPE6bY1kPRZY2Pth1rgXxr1O6Hwv0PahRSDv9aWvoTwAooooAKKKKACiiigAooooA4L4nL5V5oFy33PNltz9XUMP/RZqnbnCCtb4sQh/CYm6Nb3dvKp9D5gX+TGsCCU+UvrivHx0bVL9z18G70rdjatHyMGua8VR3NjNbapYKWu7CXz41/vgDDJ+Kkiti0lORVq9hW5gwetc8ZNardGrSTs9mdfpGo2+raZa39k4e2uIxIjex7H3HSrleZeBNR/4R/W30O6+SwvnMtk5+6kp5eL23feHvmvTQcivbo1FUipI8itTdKTizx344aRZ32vaBPf75IhFOpiU7c4KEHP49KyNG8N+Hp4MR6ZaP67lyw/Pmt74yS58Q6VF/ctZH/N1H/stcrpszwOHiYqw7iuDF4/ERn7OM2orom0XSVOGsoJ38tS1qHw20O8Qm2Sexk7NC5Zf++WzXDeIvA2r6JukhX7faD/AJaQqd6j3Tr+Wa9s0e6S+g3DAkH3l9P/AK1XJoMiu3BZ/jMPa8uZdnr+O5VfL8NXV4q3mj5fSQGplavXPGHgqy1NnngUWt4efNQcMf8AaHf69a8k1Gzu9Ku2tr+IxyDoequPVT3Ffb5bnFDMFaOkuz/TueBi8BVwur1j3HA0+q6PnoalDivWscIMcVXnfAp8jVVnegBVbJp/mBRzWj4Z8P32vXG2zULCpxJO/wBxP8T7CvZPCXg7StGZJUgFzdjn7ROAzA/7I6L+H5142Y55h8C+R+9Psv17fn5HoYXLquJXMtI93+h5n4f8Da5riLN5IsbQ/wDLW5BBI/2V6n9K7jTvhppFmN19JPfyjs7bE/If1Nek7SV55qjd4jRmcgKBkk9q+NxvEGMxHwy5F2X+e57uGyyhS1krvz/yOKuvD+i2qHbpdkqjqTGD+prmr/SdAucoNMiBPHmRZjI+mK39cvTdSELxEDwPX3NYJPzivFWYYmMuaNSV/VmlWVKS5YwVvRHrfwO0ZNH8BQbJfM+1zSXB4xtydoH5KK9ArkfhMwbwBpXt5q/lK4rc8Qavb6Jpc97dZKxjCRr96Vz91F9STXvyrSq/vaj1erOJU1F8kUcl8SL43l3ZaDCcglbq6I7KD8i/iwz9F96mtIxBbfhWJodrczzS32pv5l7cP5kp7A9lH+yowB9K27qTCYFeJVq+0m5dOh68Kfs4qH3laVtxNYOtwNePa2Mf+suriOFfbLAk/gAT+Fabyncaj0X9/wCOdIU8hBNIPqIyP/ZqypLmqJGtR8kG/I9RFFA6UV9AeEFFFFABRRRQAUUUUAFFFFAHKfFIZ8C6mQMlfKb8pUNchbZaMV2fxN48CawfSEH/AMeFchb4SBa8rMF7yPVwD9x+patshq0FkAGDVS2XzJzH3C5qvr10bHTpJtyoyAkM3QY9a4VodT1diXW9Ki1XTpYixST7yOvBRhyrD3Bwa67wZrB1rw9bXUwxdJmG4X0lQ7W/UZ+hFcXoGrQ6rpkd2h2qR8wPG0jqD9DV/wAA3ItPEus6cCfJulW/hyCOfuSY/JD+NduCqcs+TucmLp3hzdjnPjDn/hL7P0+wDH/fxq5i0PSum+MJP/CX2f8A14D/ANGNXLWZ5FcmN/jSOLojotLuHtZ0lTnHUeo9K7mCRJ4EljOUYZFcBbdBXT+GbjIltmPT51/r/SopPoVh6lpcj6l29hBBrifFGj22p2r212ny5yrDqh9RXfXQ+U1zerICPetY1JUpqcHZo9SMY1I8sldM8C1vTbrQ7ryrgh4mP7uVejfX0PtVNLnNeuazYxXkDRTxq6HqpHWuA1DwgUctZXBC/wByQZx+NfdZZxNSqQUMW+WXfo/u2/I+dxuS1IS5qGq7dUYElwMda0PDGiT+IL/aMpZxkebJ/Qe9LpPhmW+YNLOFiDFTtHPBxXqXh3TYrC0SC3QKg/Wnm/EdKlTcMJK8316L/giwGTznPmrq0V+JvaLZQ2drFbWsYjgiGFUdq6axSsezACjFbtiOK+CTcpXlq2fSTSjGy2LgHy1yniu7+b7LGfd/6CuonlWCCSV/uopNee30jSyySOcsxJNFZ2Vjgr1OVcq6mPeHg1mfx1pXnQ1mj79cphHY9u+Eox4A0z3Mx/8AIr1kavcHX/Fs6Mf+JfpJMUY/vzkfO34A7R/wKtPwJcR6R8LrG8n4jgtXuG9xlm/rXP8AhsNFpaG5Y/a5i1xNkEfO53N9eTXtYmpy0ow7m+GhecpdjYysfA6VBctleKwo9dS48RSWMbLtiUbh6sew+nGfqK35oz5TydlFebqd9rGW4NSeExu8dWn+xazt+qD+tKxBCE8bhmpfCSgeOo8D/lxmP/j8dbYX+LEnEP8AdSPSqKKK908MKKKKACiiigAooooAKKKKAMXxrYtqXhLV7SIFpZbWQIAOSwGR+oFeY2eppJaRlEMjtbrMo/56DuB7j+or2gnFeNeL7AaBr8iQqVt9/wBvt8DgIx2zRj6E7sf7Q9K8/HU+ZKa6HoYGok3B9TTs9QR721CgeVcwlopO+4c7T+HP4Gq/jQH+xpXxuEf7wg99pz/SsiCQ2ou4WBY2My3cXvGTk4+nzj8q6bWI1uLB14ZGGPqCK83bU9C2tiHVVTT/ABpcrCqra6jCl7Fjoz/dfH5Kf+BVEZEsNZ0zU13qlvcBJpCPlEcnyMCfqVP4VfttKuPEngLQbqzdBqunKUjLnAk25jdCe2QoOfUCsq5muGtLqwvNF1QvOrI0ItWbJIwdrDKke+a7KtOUaqqRWj1OWlOMqbpyeq0IfjKAPFGnt62TD8pP/r1yNj1FdN8Q7e9hsvCn9q4+3iykimOc/Mvlnk9zXM2I5rlxv8Zs4ehu2/QVoafOba9hlzwGw30PWs636CrPaueJzt2d0dtdfd46VzuqdCa3IX87ToJDyWQZ+tYepjg1tPue7Qd1c5+bnOax7zCs1bE425rF1X5YZWPZSf0qY7nU9jG8JHfaFvWVz/49XdW2FUfSuL8F20kFvJFOpV0kyVPuoYfoa7Jeoq6vxMzp/CjbsfmC10FpwBWFpoyFrdt+MUobmdUpeJpilksQ6yNz9B/kVx1z0NdH4ofddxJnhUz+Zrm7moqu7PFrSvUZkXh6is6Q7VdvQE1fvTyay787bG6I6iJsflWKV2XE9c1KQwfD/wAM6TGC0l7FAroByY1QO/8AID/gVUL+5jstMnlUN8ik4I5z6fWrWrQ32m6ra3E1ldXFpHp8VvbSW8TSiMgfOGCgkEnbzjkAUmiaRfa7qVrJc2dxa6XBKJ5GuU8t52ByqhDzjOCSccDHevVr051aqilojtozhSpuTfmUtU08abeeGdOwPtUNrNc3Ld2kkZMk/iG/KtTVLn7Lps8pUyFV+VP77HgD8SRUGtt9q8fag+ciCOG3HthS5/8AQ6g1yUG7s4CcRpuuZT6KowP1Of8AgNY4hr2rS6GtFP2cb9dSC81CKGUpKRmGHzZmHRB2H44NaXw/D3Xi25ughWOCwVGB/haRwQD74SuMEu61jurrKx3EjXs2eojQZRf/AED8q9X8BaZLpugrJeR7L68c3M691LfdX/gKhR9Qa0wdO9Tm7EYyajT5e50tFFFeweQFFFFABRRRQAUUUUAFFFFABWD4x8Pp4g01Yg4huoWLwSlchSRggjupBwR+Pat6ilKKkrMcZOLujw+JJbXUraG+VVuoGOn3aA5GCPlYZ6g4Ug/7Vbmis82nNaTMTLbHyGJHp90/iMGu41/wvpeuqzXsGLnbtS4iYpIvpyOuDzg5FcDfWOteH7tbi8s5btBiOS5s0LrNH2ZkHKsOvQjqAea8ithZQ1jqj1qWKjUVnoza+HF//Z93c+H7lssWe6tpCMbwzZdceoJz9D7V6BXlGpxTTGy1TRp4vtFu4nhkxlX4I2k/3WBwa9H0DVIdZ0m3vrcFRIMMh6xuDhlPuCCK7MHW548r3RyYulyy51szz/41r+98PtjrJOn5oD/7LXBWY+avSPjVFnSNHn/5536qT7NG4/wrze1OJK87MFat8jFfCjZg4Aqxniq0PQVZ7VxowkdVpR3aRB7A/wAzVHUFBVqu6L/yCYf+BfzNVdQ6NWz2R7eG+FHL3gwxrn9ez/Z9wB1ZCo+p4ro74Zyaw9ShM/2WFRlp7qGED/ekUUqavJI7Ju0GzV1q1Ww8Z6zaRjCoLc4/7YoP6VYg5xU3jtDH8TNQXGBPZwSj3xuX+lRWvStcSrVWjHDO9KLN3TBwtbcNY+ndBWxBWcdxVDm9ffdqkvsFH6ViXJrY13P9qXH1H8hWLcd6ynueHL436mLeH5qpyRGdUgHWaWOL/vp1H9auXY+bNS+HYftPifQoMZD30ZI9ly5/9Bp0lzVEvM2ifRwGAAOgqnrGoQaTplzfXbEQQIXbHU+gHuTgD3NXK878aag+uaqukWZH2OylSS6kxkSSDkRj2HBJ9cDsa+irVFSg5Mzo03Umomfoy3FzcXmp3gCT3kpmMKjIj4AC574AH41kanL9rhvJC+Ptcq2UJ/2BneR/4/8AlWnrN3JGi6fp0F3PcMMym1haRokP0HBPQZx3PatXQvA/28RXXiWLZHGu220+OQgRA9S7KRuYjjHQD1zXkU6NStK/c9WdaFJa/cZPhLQZvEOrrfzKi6FbOFi5yblkOcAf3A3U99oHrXrOKitoIraBIbeNI4Y1CoiKAqgdAB2qWvXo0lSjyo8qtVdWXMwooorUyCiiigAooooAKKKKACiiigAooooAKKKKAOK1fwxdWl3JPoio9nMS8llu2FHPVoyeOTyVOBnkEdK0PAel3mmabd/b4xDLc3LTiEMG8sEKoyRxk7cnHrXS0VjGhCM+dbmsq05Q5HscT8YYd/giaX/n3uIJvwEig/oTXk8fyzfjXtfxGtjd+BNdiAy32SRx9VG4fyrxGNw5Rx0ZQ3515mZr3oscPhNqHoKtj7tVIDlRVpfu158TGR1ejL/xKYfx/map6hwGrS0tdul24/2M/nzWZqfU1u/hR7OG+FHPXXOaqWEXneJ/DcP97UUcj2QM39KvXA4NSeEoRN8QdCUjPlJcT/TCBR/6FVYdXqxR0Yh2pSZe+KEITx7pM2P9fYSIT6lHB/8AZqzbUcmul+K8I/tbw3cd91xD+aA/+y1zluMPWmNVqxngneijb08cCtiDqKybHoK1YeorCJUzm/EQ26pN7gH9Kwbg9a6XxUm28jf++n8ia5i56Gs6nxHizVpsybrrWz8OIPP8faSMZEKTTn8E2j/0KsW4PJrr/g7b+Z4uvZyOILEKD7u//wBhWuDjetEvZHstec2/hfWbW5ureBYSsk8ki3jyfLh3LZKj5iwzjHAPrXo1Fe7Voxq2UjOnVlSvy9TN0LSIdHszDCzyyO3mTTScvK56k/yAHAAArSoorRJJWRDbbuwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAhvYFurOe3f7ssbRn6EYr5p0/ctnbo/wB+NfLb6qdp/lX05Xz14jsvsHifWLXGAl28ij/Zkw4/9CrzcyjeCka0+qLNm2YxWhbxtK6RryzEKPxrMsj8uK6jwva+ZcNcOPlj4X3avIgruwlDnkkdFtEcQReigAVi6hyTW7KPlNYl8OtdEz2KRg3hwK0/htH5vjieQjPkacQPYvIP/iKy7zlsVvfCld3iPxC//POG1i/PzG/rWuDV6yDGO1Fmj8W0C6folweseoov4Ojr/UVykS4eu0+LkO/wTNOOtrcQXH4LKuf0Jrk4gC1aZgrVE/IjL5fu2vM1LAcCtOPrWfYjArQj+9XJE1mUvEsHnWAkUZaI5/A9a4i54Br0mba0ZVhkEYIrzzWrdrS5eM/d6qfUVNVa3POr07PnRgTnL16V8FYP3Wt3WPvTRwA/7qZ/9nrzR+ZMV698G7cxeDBcN/y93U04+m7aP0UV05dG9W/ZGMvhO5ooor3DAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvE/ipbm28ctJztvLRJR/vISp/QrXtlecfGKxR10LUHX5Yro28hH92VcD/AMeVa5sZDnotGlJXly9zjtDtHvJVUZEY+8/p/wDXrvbKNLeFY4hhF6Vg6OQqBVAAHYVuoeBXhwVj1IUFT9SyxyDWRfLw1aoPy1nXw+Rq0k9DSGjOcuBl66b4TRD7V4lmxy11FH/3zEp/9mNc1OfnrsPhRHjStWlxzLqMnP0VF/pXRgF+9Ixz/dGv8Qrb7X4F16EDJNlKR9QpI/lXnemSedaW8n9+NW/MA167qEAurC5tyMiWJoyPqCK8X8KuW0TTy33hCqn6gY/pWuYr4WZZc9JI6mz4Aq9H1qlajgGrYOK4EdUiSU8VzviC3S6hKtw68q3pW87ZFYmqtjdQ9RKCkrM871AtaR3DOuHjQnHvjivoPwjp/wDZXhfSrHGGgtkVv97Az+ua8e+wpqWraTaMu7z72JW/3FO9h9MKa94r0Mup2UpHm4qn7J8oUUUV6ZyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxRtTdeBNW2DMkEYuU9jGwf8A9lrqqqaxbi70m9tmGRNA8Z/FSKUldNFRdmmeW6Udx3Do2GH41vx/dFcv4Vm83SrOQ/eMCZ+u0V00LZWvnNj3paku44qvdDKGp6jnGUNMlHMXa4k/Gu5+FiY8JJIf+W1zcSf+RWH9K4fVG8tt3vXb/CmTd4Oij/543FxH/wCRWP8AWuzL/jfoYY+/s16nX14jokZt/tVsf+Xe7uIf++ZWx+mK9urxW2cNrOtkd9SuT/5EI/pW+Yr3F6mGXfG15HSWh+UVaqnZn5Mk1cByOK8tHfLcD0rE1Yda2HkVThuKyNX6mhjjuReCoBP4204f8+8E9x+OFQf+hmvW68r+GqmTxreP2h05R+Ly/wD2FeqV7OCVqSPKxrvWYUUUV1nIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQeRRRQB4V4RcppsCHqm6P/AL5cj+lb+nXZOoSxHoADWBoa+U91H2S9uU/KZ6uGb7LrSseFkWvnJ6SfqfRRV4r0OuAJPFQ3TbIWPpUttdRmMGs/VbpfIkwe1DtYzV27HPanKLi1Mi9Ca7X4Qn/inr5f7uoTD8wp/rXCj/kGLnuxxXefCVceH75uz6hMR+G0f0rrwH8R+hjj/wCF8ztq8LspNuvayv8A1ELn/wBGtXuleEXSm08a69A3GL93H0cBx/6FXTmCvTXqc+XP9415G1pdw8+qyxE/JGM49a6RF9uK4q3uhZa++/hZFFdQNQXb0rykejUTvoR664i06Z84Kjg1hCZpdLgdzlinNN8R373SG3TIDdTRdL5NvFEOioBQyoqyRu/CdN2v+IJMfditox/5EP8AWvTK85+EYze+I37+bAv5RZ/rXo1e5hValE8TFu9aQUUUV0HOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4dZfLqOqL6aldf+jWqeWAXmorG3QDg+lQRf8AIY1n/sJ3P/ow1rW1u4mWaMZI6ivnavxv1PoabtBehZSxnhUKshOOM1latHMFCOxwxxXUJJuj3MCvqDWPqSNcTKVU7VOeahji9dTH1ArD5cXARBz9BXovwviMfgfTZGUq1wHuSD/00dmH6EV5br8T3Rmt422vJE6KfQkECvYPA93Fe+EdIngXahtY12/3So2kfgQRXo5elzNnFmDfJFG5XjXxItxY+PWmUfLe20c3/AkJQ/psr2WvI/irILzxbaRIQRY2hLkf3pWGAfwTP411Y1L2TucuBbVZWM+6toria1mkyFcAZHY10FvpsUYyWZgR3NZ2jwLc6eIpe3Q+lbFrHLCFjdt6joa8VHrSZma5bxR26JDGAxbr3qhqI5Cn0ropbbzZhJJ0XoKwtXXEpNJjg+h0HwkGJfEX/X1EP/IKV6FXn3wm/wBb4i/6+o//AESleg172G/hR9DxMT/FkFFFFbmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHh0Rzq2sN3Op3P/oZrptM5rmI+NW1b/sJ3X/ow11OmDABr5+p8b9T3o/w16GmseQeKqXKARtxWlH92qV8MI1ElZERlqcTdx7tS9xXYfCm/IXVtKf8A5dp/PiH/AEzlG79HD/nXOGHffMaf4LuDZePrQZwt5by2ze7LiRf/AGetMHPlqrzHi489J+R7EeleFz3B1a81PU8ki8uXeP8A65r8ifoufxr1rxpfnTPCWr3qHEkVrIUP+1tIX9SK8o0y3FvZQ2w6RRKn5DFdeYT0UTly+Ormbfh4fuRW9Gm4GsLQeFIrorcfKa82CudlV2K7DHFc3rX+sIrppfvVzusLmQ0pFU9zZ+Ex/wBJ8Rj/AKeYj/5BWvQq88+E/F94kH/TeA/+QhXode7hv4UfQ8bFfxZBRRRW5gFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4Yn/IX1UHtql1/6MNddYcRiuTf5db1oemqXH/oWf611lgcxL9K+fq/xH6nvR/hx9DXh5SqWofcNXrYfIaqX65RqqXwmMX7xzAP+mOR0xWWsn2bxDo9yDjytRhBPs5KH/wBCrScFJ5c9hWDfEvJAAfma8tgPr5yVnSdpo6aivB+h6b8WJNvg9oP+fm6t4fqDKpP6A1xFocyt75rs/iyP+Kesn7JqNuT+LY/rXF2YxNXXj/4i9DlwH8N+pqaH99hXTQDCVzOif65vrXTx/crlpm1YrTfern9W+8a35vvVhalyzVEiqRp/Cj/kIeJP+u0H/ooV6HXnvwpH+n+Jj2+0Qj/yCv8AjXoVe7hv4UfQ8fFfxZBRRRW5gFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4nrURtfF/iCD/p8WcfSSNT/MGuj0o5txVH4jW32bxrFOBhL6yHPq8T8/+OyD8qt6Owa3GK8LER5aske5RlzUYs37Q5Qiq90Oalszzim3anNJ6wM1pM5XUPlnl9xWBbx+drmjQnpJqUGfoG3f+y10WrIRO5x1FZfhuAy+N9AjI6XEkx+ixN/VhU0Feol5nRUdqUn5Hf8AxVTPga+k7wyQzD/gMyH+Wa4mGPE3HrXo3j21N54J1yBRlms5Sv1Ckj9RXm+nTedHE4/jRW/MZrrzBe9FnHgH7kkaekLiVvrXSJ/q65/TRid/rXQrxFXJTOituU5j8xrBvzmRq3Jjw1c7qUq26zTynCRKXY+wGazka0zpfhNHnTNYuiP+PjUpcH1VFWP+aGu5rnPh3Yvp/grSYZRiV4fPkB67pCXP6tXR19BSjywSPCqy5pthRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBx3xN09bjTbK/wD4rG4DE/7DjY3/AKED+FZGjQFDtP0r0DULSO+sp7WcZimQo341xOlxyoAkw/fRkxyf7y8E/j1/GuDFUryUjuw1W0HA17aLa1PuoM1NGh4OKmdMrWSp+7Ypz1ucvq1mGGcc4qp4M0/PjKKY9Le0lYfV2UfyBrpr2DdH0pPCtp5Wo30pHPlxoPzY1VCjaomOrWvTaOiuIlnglhk5SRSh+hGK8k8Pac6afaxt96JPKP1U7f6V6/XI2tl5dxcgDjz5CPxYn+tb4qnzpGGFqcjZnWNkyyucd612hIjxV2G2AJ4qyYRt6VzRw9jede7Oclt22k4rmtZ09r4xWGD/AKdOlucDohPzn/vkNXoM1uNvSoNLsFfV/tDL8tspVP8AfbqfwHH40oYW80N4m0Wb6qFUKoAUDAA7UtFFeqeaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZN5ZKL9pVGPNAJ/3h/9bH5VrVHMoZfdTkVMo8ysVF2dypHF8oqQxgipVFOxUKCG5MqSwgr0pdOh8qWc/wB7b/WrLLSwjBb8KqMUncHLSxJWesIEsp9XJrQqEr8zfWnJXFF2I1jp5WngUEUrBcrygAEnoOalso/Lt17M3zH6mkkTdhexOKsU4rqDfQKKKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCM0UUARrxx+FL+dB++aUUhiGlTqaQilTqaAHVGep+tSUzHJpiAUGlxQRSGNXmT6CpKagxk06mIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIBNGKKKADFGKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A glucagon shot can be given in the side of the lower belly or upper leg (as shown by the shaded areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28624=[""].join("\n");
var outline_f27_61_28624=null;
var title_f27_61_28625="External ventricular device";
var content_f27_61_28625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    External ventricular drain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An external ventricular drain (EVD) is a small catheter inserted through the skull usually into the lateral ventricle, which is typically connected to a closed collecting device to allow for drainage of cerebrospinal fluid. The EVD can also be connected to a transducer that records intracranial pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28625=[""].join("\n");
var outline_f27_61_28625=null;
var title_f27_61_28626="Patient information: Sertoli-Leydig cell tumor (The Basics)";
var content_f27_61_28626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83539\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"          Types of abdominal hysterectomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/56/9090\">",
"         Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/41/3731\">",
"         Patient information: Hysterectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/12/29891\">",
"         Patient information: Absent or irregular periods (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/40/20099\">",
"         Patient information: Acne (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/24/13698\">",
"         Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sertoli-Leydig cell tumor (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sertoli-leydig-cell-tumor-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H279462828\">",
"      <span class=\"h1\">",
"       What is a Sertoli-Leydig cell tumor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Sertoli-Leydig cell tumor is a very rare tumor that grows from cells in a woman&rsquo;s ovary (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). This tumor can be cancerous or not.",
"     </p>",
"     <p>",
"      A Sertoli-Leydig cell tumor sometimes makes male hormones, which doctors call &ldquo;androgens.&rdquo; These hormones can cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H279462860\">",
"      <span class=\"h1\">",
"       What are the symptoms of a Sertoli-Leydig cell tumor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Sertoli-Leydig cell tumor causes symptoms in different ways. Some women have symptoms from the male hormones the tumor makes. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having fewer monthly periods or no periods at all",
"       </li>",
"       <li>",
"        Loss of breast tissue, which can make the breasts smaller",
"       </li>",
"       <li>",
"        Hair growth in places where only men tend to grow hair, such as the face, chest, and back",
"       </li>",
"       <li>",
"        Voice changes, making the voice sound deeper",
"       </li>",
"       <li>",
"        Losing hair from the head (like men)",
"       </li>",
"       <li>",
"        Acne",
"       </li>",
"       <li>",
"        An increase in the size of the clitoris (a part of the genitals)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other women have symptoms as the tumor grows bigger. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        An increase in belly size",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H279462875\">",
"      <span class=\"h1\">",
"       Is there a test for a Sertoli-Leydig cell tumor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor suspects you have a tumor in your ovary, he or she will probably order:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests to measure hormone levels",
"       </li>",
"       <li>",
"        A pelvic ultrasound, which is an imaging test that creates pictures of the ovaries and uterus",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But the only way to know for sure that you have a Sertoli-Leydig cell tumor is for a doctor to remove the tumor and then look at it under a microscope. This will happen during treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H279462890\">",
"      <span class=\"h1\">",
"       How is a Sertoli-Leydig cell tumor treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment is surgery to remove the tumor. The type of surgery done depends partly on your age and whether you plan to have more children.",
"     </p>",
"     <p>",
"      Women who are older or done having children usually have surgery to remove their ovaries, uterus, and the tubes connecting the ovaries to the uterus (fallopian tubes). This surgery is called a &ldquo;hysterectomy&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef57901 \" href=\"UTD.htm?37/40/38534\">",
"       figure 2",
"      </a>",
"      ). It&rsquo;s important to know that after a woman&rsquo;s uterus is removed, she cannot get pregnant. Also, women who have both ovaries removed sometimes need to take hormone pills.",
"     </p>",
"     <p>",
"      Women who might want more children or who don&rsquo;t want to take hormone pills usually have surgery to remove only the ovary with the tumor.",
"     </p>",
"     <p>",
"      Other treatment depends on the type of tumor you have and whether the tumor cells spread to another part of your body. If the cells did not spread, you probably won&rsquo;t need any other treatment.",
"     </p>",
"     <p>",
"      But if the tumor cells spread to another part of your body, you will need treatment with chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H279462922\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for a Sertoli-Leydig cell tumor can involve making choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H279462937\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=see_link\">",
"       Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=see_link\">",
"       Patient information: Hysterectomy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"       Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"       Patient information: Absent or irregular periods (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"       Patient information: Acne (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/61/28626?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83539 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28626=[""].join("\n");
var outline_f27_61_28626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462828\">",
"      What is a Sertoli-Leydig cell tumor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462860\">",
"      What are the symptoms of a Sertoli-Leydig cell tumor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462875\">",
"      Is there a test for a Sertoli-Leydig cell tumor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462890\">",
"      How is a Sertoli-Leydig cell tumor treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462922\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279462937\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"       Types of abdominal hysterectomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=related_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28627="Tolnaftate: Drug information";
var content_f27_61_28627=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolnaftate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/62/39907?source=see_link\">",
"    see \"Tolnaftate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43826?source=see_link\">",
"    see \"Tolnaftate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Blis-To-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      Mycocide&reg; NS [OTC];",
"     </li>",
"     <li>",
"      Podactin Powder [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal Deodorant [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal Jock Itch [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Tinaderm [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Cream [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Spray Liquid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pitrex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea infection:",
"     </b>",
"     Topical: Wash and dry affected area; spray aerosol or apply 1-3 drops of solution  or a small amount of cream, or powder and rub into the affected areas 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May use for up to 4 weeks for tinea pedis or tinea corporis, and up to 2 weeks for tinea cruris.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F229142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43826?source=see_link\">",
"      see \"Tolnaftate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Deodorant: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Jock Itch: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (150 g) [contains ethanol 29% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ting&reg; Spray Liquid: 1% (128 g) [contains ethanol 41% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1% (15 g, 30 g, 114 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Jock Itch: 1% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ting&reg; Cream: 1% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blis-To-Sol&reg;: 1% (30 mL, 55 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (59 mL) [contains ethanol 70% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical: 1% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Podactin Powder: 1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (108 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycocide&reg; NS: 1% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinaderm: 1% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Cream, powder, solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tinea pedis, tinea cruris, tinea corporis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tinactin&reg; may be confused with Talacen",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolnaftate or any component of the formulation; nail and scalp infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for self-medication (OTC use) in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes. Apply to clean, dry skin. When used for self-medication (OTC use), contact health care provider if condition does not improve within 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (LamISIL AF Defense External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (133 g): $5.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Tolnaftate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (130 g): $6.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fungoid-D External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (113 g): $27.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Medi-First Anti-Fungal External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (1): $0.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tinactin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $5.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tinactin Jock Itch External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $5.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tolnaftate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $6.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Tinactin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (108 g): $5.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Tolnaftate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (45 g): $3.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tolnaftate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $3.05",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F229123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Athlete's Foot (AR, HU);",
"     </li>",
"     <li>",
"      Athletes Foot Powder (IL);",
"     </li>",
"     <li>",
"      Chinofungin (HU, PL);",
"     </li>",
"     <li>",
"      Ezon-T (JP);",
"     </li>",
"     <li>",
"      Focusan (AT, CH, CZ, NL);",
"     </li>",
"     <li>",
"      Hi-Alarzin (JP);",
"     </li>",
"     <li>",
"      Mycil Healthy Feet (AU);",
"     </li>",
"     <li>",
"      Pitrex (IL);",
"     </li>",
"     <li>",
"      Ringworm Ointment (AU);",
"     </li>",
"     <li>",
"      Separin (JP);",
"     </li>",
"     <li>",
"      Sorgoa (LU);",
"     </li>",
"     <li>",
"      Sporiline (FR);",
"     </li>",
"     <li>",
"      Tinaderm (AR, AU, CN, CR, DO, EC, ES, GR, GT, HN, IE, IN, IT, MX, NI, NZ, PA, PE, PY, SV, VE, ZA);",
"     </li>",
"     <li>",
"      Tinaderm M (CO);",
"     </li>",
"     <li>",
"      Tinaderme (PT);",
"     </li>",
"     <li>",
"      Tinatox (DE);",
"     </li>",
"     <li>",
"      Tineafax (AU);",
"     </li>",
"     <li>",
"      Tolnadem (IN);",
"     </li>",
"     <li>",
"      Tolnaderm (MY, PH, SG);",
"     </li>",
"     <li>",
"      Tolsol (IN);",
"     </li>",
"     <li>",
"      Tonaf (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distorts the hyphae and stunts mycelial growth in susceptible fungi",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 24-72 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10005 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28627=[""].join("\n");
var outline_f27_61_28627=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229126\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229127\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229155\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229129\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229142\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229130\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229119\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229153\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229122\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229110\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300155\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229114\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324003\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229123\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229109\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229121\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/62/39907?source=related_link\">",
"      Tolnaftate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43826?source=related_link\">",
"      Tolnaftate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28628="Refractive errors in children";
var content_f27_61_28628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Refractive errors in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28628/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28628/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/61/28628/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review refractive errors in children. Vision assessment, strabismus, cataracts, and amblyopia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link\">",
"     \"Evaluation and management of strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link\">",
"     \"Overview of amblyopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Refractive errors in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=see_link\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL REFRACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refraction is the bending of light rays as they pass from one transparent medium to another medium with a different density. During vision, light that is reflected from an object is refracted by the cornea and lens and focused on the retina.",
"   </p>",
"   <p>",
"    In emmetropia (an eye with normal refractive error), parallel light rays from a distant object are brought into focus precisely on the retina, and a clear image is perceived (",
"    <a class=\"graphic graphic_movie graphicRef79812 \" href=\"UTD.htm?24/19/24894\">",
"     movie 1",
"    </a>",
"    ). Perfect emmetropia rarely exists. The majority of individuals have some degree of refractive error, although most do not require correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REFRACTIVE ERRORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractive errors are present when the optical image does not accurately focus on the retina. There are three types: myopia (",
"    <a class=\"graphic graphic_movie graphicRef69617 \" href=\"UTD.htm?23/20/23886\">",
"     movie 2",
"    </a>",
"    ), hyperopia (",
"    <a class=\"graphic graphic_movie graphicRef72862 \" href=\"UTD.htm?30/37/31326\">",
"     movie 3",
"    </a>",
"    ), and astigmatism (",
"    <a class=\"graphic graphic_movie graphicRef61074 \" href=\"UTD.htm?8/36/8783\">",
"     movie 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Refractive errors requiring correction are uncommon in preschool children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/1\">",
"     1",
"    </a>",
"    ]. However, nearly 20 percent of children develop refractive errors that require the use of eyeglasses before late adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/2\">",
"     2",
"    </a>",
"    ]. Risk factors for refractive error include retinopathy of prematurity and family history of high refractive error [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H31#H31\">",
"     \"Retinopathy of prematurity\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopia (nearsightedness) occurs when the refracting power of the eye is too strong. It commonly occurs when the anterior-posterior diameter of the eye is too long relative to the refracting power of the cornea and lens. The focal point of the image is anterior to the retina and the image that reaches the retina is blurred (",
"    <a class=\"graphic graphic_movie graphicRef69617 \" href=\"UTD.htm?23/20/23886\">",
"     movie 2",
"    </a>",
"    ). Patients with myopia have better near vision than distance vision when they are uncorrected.",
"   </p>",
"   <p>",
"    The prevalence of myopia increases during and after puberty, when the eye undergoes its adolescent growth phase (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    ). The prevalence of myopia among children and adolescents in the United States is approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of myopia varies with ethnicity and is particularly high among Asians; one study reported a prevalence of 84 percent among 16- to 18-year-olds in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/5\">",
"     5",
"    </a>",
"    ]. In the United States, Asian children have the highest prevalence of myopia (18.5 percent), followed by Hispanic children (13.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/6\">",
"     6",
"    </a>",
"    ]. The rates of myopia in Caucasians (4.4 percent) and African-Americans (6.6 percent) were not significantly different.",
"   </p>",
"   <p>",
"    Myopia is corrected with a concave spherical lens to focus the light rays on the retina (",
"    <a class=\"graphic graphic_movie graphicRef80691 \" href=\"UTD.htm?40/2/41006\">",
"     movie 5",
"    </a>",
"    ). Mild myopia does not require correction. However, myopia of any magnitude should be corrected if it alters a child's education or social function. Severe myopia (approximately &gt;5 diopters) should be corrected, even in an apparently asymptomatic child, because of the risk of developing refractive amblyopia. The absolute threshold for when a child should be corrected varies by the caretaker's preference, age of the child, and other factors. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Corrective lenses'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several randomized trials have demonstrated the potential for topical anticholinergic agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    , pirenzepine) to slow the progression of myopia in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Additional studies are necessary before such treatments can be routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hyperopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperopia (farsightedness) is the opposite of myopia. Hyperopia occurs when the refracting power of the eye is too weak. Most commonly, the hyperopic eye is too short relative to the refracting power of the cornea and lens. The focal point of the image is posterior to the retina, and the image that reaches the retina is blurred (",
"    <a class=\"graphic graphic_movie graphicRef72862 \" href=\"UTD.htm?30/37/31326\">",
"     movie 3",
"    </a>",
"    ). High degrees of hyperopia are associated with amblyopia and accommodative esotropia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41800?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of horizontal strabismus in children\", section on 'Accommodative'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild hyperopia is the normal refractive state for infants and children. Children have the ability to \"accommodate\" or focus by contracting the ciliary body, which changes the shape and power of the lens and focuses the image appropriately on the retina. Without the ability to accommodate (eg, after cycloplegic drops), patients with hyperopia have better distance vision than near vision.",
"   </p>",
"   <p>",
"    Hyperopia is corrected with a convex spherical lens to focus the light rays on the retina (",
"    <a class=\"graphic graphic_movie graphicRef51690 \" href=\"UTD.htm?39/1/39966\">",
"     movie 6",
"    </a>",
"    ). Mild hyperopia generally does not require optical correction in children. Higher degrees of hyperopia (ie, &gt;4 diopters) should be corrected in asymptomatic children because of the risk of developing refractive amblyopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accommodative esotropia. Any degree of hyperopia may warrant correction if the child is symptomatic. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Corrective lenses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Astigmatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Astigmatism (from Greek: \"a\" = lack of, \"stigma\" = point) occurs when the optical system of the eye, particularly the cornea, is not perfectly spherical. The refractive power of the eye is different in different meridians, and the light rays cannot be brought to a single point (",
"    <a class=\"graphic graphic_movie graphicRef61074 \" href=\"UTD.htm?8/36/8783\">",
"     movie 4",
"    </a>",
"    ). Astigmatism may occur with myopia or hyperopia. Children with moderate or more severe astigmatism have difficulty performing visual tasks at both distance and near fixation.",
"   </p>",
"   <p>",
"    Astigmatism is corrected with a cylindrical lens (",
"    <a class=\"graphic graphic_movie graphicRef68083 \" href=\"UTD.htm?13/28/13775\">",
"     movie 7",
"    </a>",
"    ). Astigmatism should be corrected in symptomatic children and in asymptomatic children with large degrees of astigmatism (ie, approximately &gt;1.75 to 2 diopters) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/12\">",
"     12",
"    </a>",
"    ]. The threshold for correcting astigmatism is lowered as the child gets older and visual demands increase. &nbsp;(See",
"    <a class=\"local\" href=\"#H7\">",
"     'Corrective lenses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CORRECTIVE LENSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractive errors are treated with corrective lenses. Myopia and hyperopia are corrected with spherical lenses (concave and convex lenses, respectively). Concave lenses are minus or divergent; convex lenses are plus or convergent. Astigmatism is neutralized with cylindrical lenses. Spectacle prescriptions reflect the spherical and cylindrical components necessary for correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REFRACTIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractive error can be reduced with extraocular surgical procedures and intraocular surgical procedures. The extraocular procedures include excimer laser procedures (photorefractive keratectomy [PRK], laser in situ keratomileusis [LASIK], and laser-assisted subepithelial keratectomy [LASEK]) and intrastromal corneal rings (INTACS). The excimer laser emits an ultraviolet beam that has sufficient energy to break intermolecular bonds within the cornea (\"photoablation\"), which results of changing the shape and thus refracting power of the cornea.",
"   </p>",
"   <p>",
"    The intraocular procedures include phakic intraocular lens implantation and refractive lensectomy or lens exchange. Phakic intraocular lens implantation is a procedure in which an artificial lens is inserted into the eye (anterior chamber or posterior chamber) while preserving the natural crystalline lens. Refractive lensectomy is a procedure that is essentially the same as cataract surgery except that the crystalline lens is being replaced because of high refractive error rather than lens opacity.",
"   </p>",
"   <p>",
"    Refractive surgical procedures are typically performed in adults (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=see_link\">",
"     \"Laser refractive surgery\"",
"    </a>",
"    ). However, in select conditions, refractive surgery may be performed in children to prevent amblyopia or as a component of the treatment of amblyopia (eg, severe anisometropia and bilateral severe abnormal refraction [isoametropia] with amblyopia in children who cannot or will not wear refractive correction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28628/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of amblyopia\", section on 'Refractive surgery for amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refractive errors are present when the optical image does not accurately focus on the retina. Risk factors for refractive error include retinopathy of prematurity and family history of high refractive error. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Refractive errors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myopia (nearsightedness) occurs when the refracting power of the eye is too strong, most commonly when the anterior-posterior diameter of the eye is too long relative to the refracting power of the cornea and lens (",
"      <a class=\"graphic graphic_movie graphicRef69617 \" href=\"UTD.htm?23/20/23886\">",
"       movie 2",
"      </a>",
"      ). The prevalence of myopia increases during and after puberty. Myopia is corrected with a concave spherical lens (",
"      <a class=\"graphic graphic_movie graphicRef80691 \" href=\"UTD.htm?40/2/41006\">",
"       movie 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Myopia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperopia occurs when the refracting power of the eye is too weak, most commonly when the eye is too short relative to the refracting power of the cornea and lens (",
"      <a class=\"graphic graphic_movie graphicRef72862 \" href=\"UTD.htm?30/37/31326\">",
"       movie 3",
"      </a>",
"      ). High degrees of hyperopia are associated with amblyopia and accommodative esotropia. Hyperopia is corrected with a convex spherical lens (",
"      <a class=\"graphic graphic_movie graphicRef51690 \" href=\"UTD.htm?39/1/39966\">",
"       movie 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hyperopia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Astigmatism occurs when the optical system of the eye, particularly the cornea, is not perfectly spherical (",
"      <a class=\"graphic graphic_movie graphicRef61074 \" href=\"UTD.htm?8/36/8783\">",
"       movie 4",
"      </a>",
"      ). Astigmatism is corrected with a cylindrical lens (",
"      <a class=\"graphic graphic_movie graphicRef68083 \" href=\"UTD.htm?13/28/13775\">",
"       movie 7",
"      </a>",
"      ). Astigmatism should be corrected in symptomatic children and in asymptomatic children when it is &ge;1.75 to 2 diopters, and sometimes even lower. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Astigmatism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/1\">",
"      Giordano L, Friedman DS, Repka MX, et al. Prevalence of refractive error among preschool children in an urban population: the Baltimore Pediatric Eye Disease Study. Ophthalmology 2009; 116:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/2\">",
"      Eye examination and vision screening in infants, children, and young adults. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine, Section on Ophthalmology. Pediatrics 1996; 98:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/3\">",
"      Maly E. Frequency and natural history of retinopathy of prematurity (ROP). A prospective study in a Swedish city 1986-1990. Acta Ophthalmol Suppl 1993; :52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/4\">",
"      Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009; 127:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/5\">",
"      Lin LL, Shih YF, Tsai CB, et al. Epidemiologic study of ocular refraction among schoolchildren in Taiwan in 1995. Optom Vis Sci 1999; 76:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/6\">",
"      Kleinstein RN, Jones LA, Hullett S, et al. Refractive error and ethnicity in children. Arch Ophthalmol 2003; 121:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/7\">",
"      Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006; 113:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/8\">",
"      Siatkowski RM, Cotter SA, Crockett RS, et al. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS 2008; 12:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/9\">",
"      Tan DT, Lam DS, Chua WH, et al. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology 2005; 112:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/10\">",
"      Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012; 119:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/11\">",
"      Saw SM, Shih-Yen EC, Koh A, Tan D. Interventions to retard myopia progression in children: an evidence-based update. Ophthalmology 2002; 109:415.",
"     </a>",
"    </li>",
"    <li>",
"     The Ophthalmic News &amp; Education (O.N.E.) Network. Preferred Practice Pattern&reg; guidelines. American Academy of Ophthalmology. file://one.aao.org/CE/PracticeGuidelines/PPP.aspx (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28628/abstract/13\">",
"      Daoud YJ, Hutchinson A, Wallace DK, et al. Refractive surgery in children: treatment options, outcomes, and controversies. Am J Ophthalmol 2009; 147:573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6260 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28628=[""].join("\n");
var outline_f27_61_28628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL REFRACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REFRACTIVE ERRORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hyperopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Astigmatism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CORRECTIVE LENSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REFRACTIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6260|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/19/24894\" title=\"movie 1\">",
"      Emmetropia normal refraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/20/23886\" title=\"movie 2\">",
"      Myopia nearsightedness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/37/31326\" title=\"movie 3\">",
"      Hyperopia farsightedness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/36/8783\" title=\"movie 4\">",
"      Astigmatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/2/41006\" title=\"movie 5\">",
"      Correction of myopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?39/1/39966\" title=\"movie 6\">",
"      Correction of hyperopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?13/28/13775\" title=\"movie 7\">",
"      Correction of astigmatism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41800?source=related_link\">",
"      Causes of horizontal strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=related_link\">",
"      Laser refractive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28629="Nylon flock worker's lung";
var content_f27_61_28629=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nylon flock worker's lung",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28629/contributors\">",
"     David G Kern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Robert S Crausman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28629/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/61/28629/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An outbreak of work-related interstitial lung disease among employees at a Rhode Island textile plant specializing in the manufacture and application of nylon flock was described in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1\">",
"     1",
"    </a>",
"    ]. Based on a case definition of persistent respiratory symptoms, previous work in the flocking industry, and histologic evidence of otherwise unexplained interstitial lung disease, a cluster of eight cases of flock worker's lung was recognized among fewer than 200 at-risk workers at a single production facility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, additional cases have been recognized in Rhode Island, Massachusetts, North Carolina, and Ontario [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and natural history of flock worker's lung are described here. General issues related to the diagnosis of interstitial lung disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NYLON FLOCK EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the nylon flocking industry, short fibers (flock) are cut from cables of synthetic monofilaments and applied to adhesive coated fabric surfaces to produce velvet-like materials often used to produce upholstery, blankets, and clothing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Exposures common to the industry include nylon, tannic acid, acrylic adhesive, nonfibrous zeolite, heat transfer oil, thermal degradation products, and ammonium ether of potato starch [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most manufacturers worldwide use guillotines to cut flock, two large North American companies use rotary cutters. The rotary cutters apparently generate substantial quantities of respirable-sized nylon particles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Inhalation of these fibers resulted in pulmonary toxicity in one animal model; however, these findings were not replicated in a separate industry-sponsored experiment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. All affected workers described thus far have had occupational exposure to rotary-cut nylon flock [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrotic interstitial lung disease is an uncommon, if not rare, disease. At a Rhode Island textile plant, seven of the eight identified cases of flock worker's interstitial lung disease (together with three additional cases of other forms of interstitial lung disease) occurred among a cohort of 165 workers. This yields a gender-adjusted standardized incidence ratio for all interstitial lung diseases of 48 (95 percent CI: 23 to 88). The age- and gender-adjusted standardized incidence ratio for idiopathic pulmonary fibrosis (used as a surrogate for flock worker's lung) was 258 (95 percent CI: 104 to 530) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unknown whether this greatly increased risk of interstitial lung disease applies only to workers exposed to rotary-cut nylon flock, or is shared among all flock workers. Case reports have also identified evidence of interstitial lung disease in flock workers exposed to polyethylene, guillotine cut polypropylene, and rayon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with flock worker's lung have presented in a variety of ways. In the Rhode Island outbreak, those initially referred were previously healthy young male textile workers who developed respiratory symptoms. The first patient described the rapid onset of pleuritic chest pain and dyspnea, which progressed over one year to chronic interstitial lung disease initially believed to be hypersensitivity pneumonitis. The second patient described a chronic cough, intermittent pleuritic chest pain, and dyspnea over an eighteen-month period. Most of those initially diagnosed presented with subacute or chronic symptoms. However, in the Canadian outbreak, 5 of 88 exposed workers developed severe disease reportedly over a five to seven day time frame following several months of mildly progressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/10\">",
"     10",
"    </a>",
"    ]. Two patients in Canada and one in Rhode Island required long-term oxygen therapy.",
"   </p>",
"   <p>",
"    In the Rhode Island outbreak, patients included seven men and one woman, with ages ranging from 28 to 58. All manifested cough and dyspnea, and in six, symptoms were chronic and progressive. Three patients reported intermittent atypical chest pain. On average, affected employees had a six-year latency period from hire to symptom onset. Only two reported work-related symptoms, and no high-risk job categories were identified. Additional case finding on the basis of symptoms alone was confounded by the high prevalence of respiratory symptoms temporally related to work [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/11\">",
"     11",
"    </a>",
"    ]. On physical examination, crackles were auscultated in all but one of the first eight cases identified in Rhode Island, but in only one of the five subsequently diagnosed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine chest radiography appears to have low sensitivity as a diagnostic test. When abnormal, chest radiographs most often show diffuse reticulonodular or patchy opacities. High resolution chest computed tomography (HRCT) has been abnormal in every case, although the changes are often subtle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62150 graphicRef73820 graphicRef52916 graphicRef60591 graphicRef72339 \" href=\"UTD.htm?19/32/19978\">",
"     image 1A-E",
"    </a>",
"    ). Diffuse micronodular opacities, patchy ground glass opacities, patchy consolidation, and peripheral honeycombing have been described most frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1,3,12\">",
"     1,3,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High resolution chest computed tomography may be abnormal even in patients without pulmonary symptoms. This was illustrated in a study in which HRCT scans were performed in 87 individuals, including 11 with flock worker's lung and 32 flock-exposed workers not meeting criteria for the disease; the studies were blindly reviewed by three pulmonary radiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/12\">",
"     12",
"    </a>",
"    ]. Diffuse abnormalities were noted in all 11 previously diagnosed individuals and in 19 of the 32 asymptomatic flock-exposed individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests are generally abnormal. In the Rhode Island outbreak, only one of eight patients had normal pulmonary function. A restrictive pulmonary defect with reduced diffusing capacity for carbon monoxide was most frequently observed, although an obstructive defect also was seen in some individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consistent abnormality on routine blood testing, including antinuclear antibodies, serum precipitins, and cellular differential, has been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage is almost always abnormal, with eosinophilia (&gt;25 percent), lymphocytosis (&gt;30 percent), or neutrophilia commonly observed. In most patients, lung histopathology is that of nonspecific interstitial",
"    <span class=\"nowrap\">",
"     pneumonia/fibrosis,",
"    </span>",
"    with nodular peribronchovascular interstitial lymphoid infiltrates with or without germinal centers, and a lymphocytic bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Co-existing diffuse alveolar damage has been observed twice. Organizing pneumonia (previously called bronchiolitis obliterans organizing pneumonia) and desquamative interstitial pneumonia have each been observed once, but even in these cases sentinel nodular peribronchovascular interstitial lymphoid infiltrates were present. Notably, granulomas (suggestive of hypersensitivity pneumonitis) have never been observed. A pulmonary pathologist consensus group concluded that, while not always present, a characteristic and distinctive pattern of lymphocytic bronchiolitis and peribronchiolitis with lymphoid hyperplasia was common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals in the initial Rhode Island cohort displayed clinical, radiographic, and functional improvement within weeks to months of leaving work, and similar regression has occurred in subsequently reported patients. Treatment with immunosuppressive therapy has been instituted in several cases, but there is no evidence that it provides benefit.",
"   </p>",
"   <p>",
"    It is not known if patients can ever safely return to work within this industry once they have developed flock worker's lung. There is, however, evidence to the contrary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/2\">",
"     2",
"    </a>",
"    ]. It is sensible to recommend respirator use aimed at primary prevention in populations at risk. However, in the absence of a clearly defined inciting agent, the efficacy of this approach is uncertain. It is also unclear whether respirator use offers adequate protection to those with established disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term occupational exposure to nylon flock may be associated with an increased risk of lung cancer. In a retrospective cohort study of lung cancer incidence in nylon flock workers, the Rhode Island Cancer Registry detected five cases versus 1.61 cases expected on the basis of age-gender-era specific rates of lung cancer incidence in Rhode Island for a standardized incidence ratio of 3.1 (95% CI, 1.01-7.23). The observed threefold increase in lung cancer incidence could not be readily ascribed to chance, study bias, or uncontrolled confounding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28629/abstract/14\">",
"     14",
"    </a>",
"    ]. Two of the case-patients had clinical evidence of flock worker's lung, but three did not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flock worker's lung occurs in textile workers in the nylon flocking industry and most likely results from inhalation of respirable-sized fragments of rotary-cut nylon monofilament. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Workers exposed to flock made of polyethylene, polypropylene, and rayon fibers may also be at risk. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Affected patients usually present with chronic respiratory symptoms, restrictive pulmonary function abnormalities, and abnormal high resolution CT scans. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage is almost always abnormal with eosinophilia (&gt;25 percent), lymphocytosis (&gt;30 percent), or neutrophilia commonly observed. Lung biopsy usually reveals the histologic findings of nonspecific interstitial",
"      <span class=\"nowrap\">",
"       pneumonia/fibrosis,",
"      </span>",
"      together with bronchiolocentric lymphoid nodules and a lymphocytic bronchiolitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Removal from exposure is the only effective therapy and is associated with stabilization or improvement in respiratory symptoms. There is no clear therapeutic role for immunosuppressive agents. It is not known if respirator use is protective or if previously affected individuals can be safely rechallenged. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term occupational exposure to nylon flock may be associated with an increased risk of lung cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected flock worker's lung should be reported to the National Institute for Occupational Safety and Health (1-800-35-NIOSH or",
"      <a class=\"external\" href=\"file://www.cdc.gov/niosh/homepage.html\">",
"       www.cdc.gov/niosh/homepage.html",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"       \"Information and educational resources for occupational and environmental health issues in the United States\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/1\">",
"      Kern DG, Crausman RS, Durand KT, et al. Flock worker's lung: chronic interstitial lung disease in the nylon flocking industry. Ann Intern Med 1998; 129:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/2\">",
"      Eschenbacher WL, Kreiss K, Lougheed MD, et al. Nylon flock-associated interstitial lung disease. Am J Respir Crit Care Med 1999; 159:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/3\">",
"      Kern DG, Kuhn C 3rd, Ely EW, et al. Flock worker's lung: broadening the spectrum of clinicopathology, narrowing the spectrum of suspected etiologies. Chest 2000; 117:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/4\">",
"      Burkhart J, Piacitelli C, Schwegler-Berry D, Jones W. Environmental study of nylon flocking process. J Toxicol Environ Health A 1999; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/5\">",
"      Porter DW, Castranova V, Robinson VA, et al. Acute inflammatory reaction in rats after intratracheal instillation of material collected from a nylon flocking plant. J Toxicol Environ Health A 1999; 57:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/6\">",
"      Warheit DB, Webb TR, Reed KL, et al. Four-week inhalation toxicity study in rats with nylon respirable fibers: rapid lung clearance. Toxicology 2003; 192:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/7\">",
"      Barroso E, Iba&ntilde;ez MD, Aranda FI, Romero S. Polyethylene flock-associated interstitial lung disease in a Spanish female. Eur Respir J 2002; 20:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/8\">",
"      Atis S, Tutluoglu B, Levent E, et al. The respiratory effects of occupational polypropylene flock exposure. Eur Respir J 2005; 25:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/9\">",
"      Antao VC, Piacitelli CA, Miller WE, et al. Rayon flock: a new cause of respiratory morbidity in a card processing plant. Am J Ind Med 2007; 50:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/10\">",
"      Lougheed MD, Roos JO, Waddell WR, Munt PW. Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers. Potential role of mycotoxins. Chest 1995; 108:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/11\">",
"      Washko RM, Day B, Parker JE, et al. Epidemiologic investigation of respiratory morbidity at a nylon flock plant. Am J Ind Med 2000; 38:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/12\">",
"      Weiland DA, Lynch DA, Jensen SP, et al. Thin-section CT findings in flock worker's lung, a work-related interstitial lung disease. Radiology 2003; 227:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/13\">",
"      Boag AH, Colby TV, Fraire AE, et al. The pathology of interstitial lung disease in nylon flock workers. Am J Surg Pathol 1999; 23:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28629/abstract/14\">",
"      Kern DG, Kern E, Crausman RS, Clapp RW. A retrospective cohort study of lung cancer incidence in nylon flock workers, 1998-2008. Int J Occup Environ Health 2011; 17:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4314 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28629=[""].join("\n");
var outline_f27_61_28629=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NYLON FLOCK EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4314|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/11/34993\" title=\"diagnostic image 1A\">",
"      Flock workers lung CT - Mild",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/51/16176\" title=\"diagnostic image 1B\">",
"      Flock workers lung CT - Ground glass opacities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/37/4689\" title=\"diagnostic image 1C\">",
"      Flock workers lung CT - Nodular consolidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/51/22335\" title=\"diagnostic image 1D\">",
"      Flock workers lung CT - Micronodular pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/24/25999\" title=\"diagnostic image 1E\">",
"      Flock workers lung CT - Honeycombing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=related_link\">",
"      Information and educational resources for occupational and environmental health issues in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28630="Identification of the abnormal pupil";
var content_f27_61_28630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Figures depicting the identification of the abnormal pupil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A)  Normal pupillary reactions. Both pupils are symmetric in the light and dark. B)  The small pupil is abnormal. The right pupil does not dilate well in the dark. C)  The large pupil is abnormal. The right pupil does not react well to light. D) Physiologic anisocoria. The amount of anisocoria is the same in light and dark.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28630=[""].join("\n");
var outline_f27_61_28630=null;
var title_f27_61_28631="Dietary history and recommended dietary intake in children";
var content_f27_61_28631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dietary history and recommended dietary intake in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Sarah M Phillips, MS, RD, LD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Craig Jensen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28631/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/61/28631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of nutritional assessment in childhood is to identify and prevent nutritional disorders such as malnutrition and overweight, as well as the increased morbidity and mortality that accompany them. To meet this goal, pediatric clinicians must know the normal and abnormal patterns of growth and the changes in body composition that occur during childhood and adolescence, and must understand the risk factors for overweight and malnutrition. In addition, they must be able to accurately perform and interpret the results of the nutritional evaluation.",
"   </p>",
"   <p>",
"    Nutritional assessment is the quantitative evaluation of nutritional status. A comprehensive nutritional assessment has six components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary history, with comparison to recommended intakes",
"     </li>",
"     <li>",
"      Medical and medication history",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Growth and anthropometric measurements",
"     </li>",
"     <li>",
"      Laboratory tests",
"     </li>",
"     <li>",
"      Intervention and monitoring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dietary history and the recommended dietary intake are reviewed here. The indications for nutritional assessment, clinical features of nutrition disorders, measurements of growth, and laboratory evaluation of nutritional status are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36487?source=see_link\">",
"     \"Indications for nutritional assessment in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22391?source=see_link\">",
"     \"Laboratory and radiologic evaluation of nutritional status in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIETARY HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dietary history should determine the quantity and quality of the food that is consumed by the infant or child and the eating behaviors and beliefs of the family. Nutrient intake then is compared with the age-specific recommended intake to assess the likelihood of undernutrition or overeating.",
"   </p>",
"   <p>",
"    The initial dietary history reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The type of food provided to the infant or child",
"     </li>",
"     <li>",
"      The number of meals and snacks provided per day",
"     </li>",
"     <li>",
"      The use of a special diet or formula",
"     </li>",
"     <li>",
"      The use of herbal or other alternative supplements",
"     </li>",
"     <li>",
"      The consistency with which vitamin and mineral supplements are given",
"     </li>",
"     <li>",
"      The presence of food allergies, intolerances, or avoidances",
"     </li>",
"     <li>",
"      Unusual feeding behaviors or difficulty feeding",
"     </li>",
"     <li>",
"      Chewing or swallowing difficulties",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk is the recommended primary source of nutrients for healthy term infants during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/1\">",
"     1",
"    </a>",
"    ]. Iron-fortified infant formulas are acceptable substitutes when mother's milk is not available. Solid foods are added between four and six months of age; most infants in this age group have sufficient neuromuscular development and coordination to swallow pureed foods without complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link\">",
"     \"Introducing solid foods and vitamin and mineral supplementation during infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Breastfed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of the adequacy of the dietary intake of the breastfed infant is based upon the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link\">",
"     \"Initiation of breastfeeding\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequency and duration of breastfeeding &mdash; The breastfed infant should be allowed to nurse within an hour after birth. The exclusively breastfed infant typically nurses every two to three hours while awake, or 8 to 12 times per day. After suckling at one breast, the infant should be repositioned at the second breast. The average duration of each nursing is 5 to 20 minutes per breast. \"Appetite spurts\" or periods of increased feeding frequency may occur at or near 10 days, four weeks, and three months of life. Vitamin D supplementation is recommended for all infants who are exclusively or primarily breastfed, beginning within days of birth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Frequency of urination and stooling &mdash; The breastfed infant usually has at least six wet diapers per day after the first week of life and an average of four bowel movements per day when consuming an adequate amount of milk. However, stooling patterns in healthy breastfed infants varies markedly, ranging from less than one per day to one after each feeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rate of weight gain &mdash; Breastfed infants usually gain 15 to 30",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      during the first six months, when the average weight is approximately 3.5 to 7.5 kg [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/5\">",
"       5",
"      </a>",
"      ]. It is normal and appropriate for breastfed infants to gain weight more slowly than formula-fed infants after three months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/6-10\">",
"       6-10",
"      </a>",
"      ]. However, by 12 to 23 months of age, the weights of breast- and formula-fed infants do not differ [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. Use of growth charts based on World Health Organization standards provides the most accurate assessment of a breastfed infant&rsquo;s growth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H3#H3\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Normal patterns'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H31542395#H31542395\">",
"       \"Measurement of growth in children\", section on 'Recommended growth charts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Formula-fed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of the adequacy of the dietary intake of the formula-fed infant is based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formula preparation &mdash; Infant formulas are available in three forms: ready-to-feed liquid, concentrated liquid, and powder. Concentrated liquid formula should be mixed with an equal volume of potable water, whereas powdered formulas should be prepared according to directions, usually as one scoop per 2 ounces of water; the water should be measured first and the powder added to it. All three types of formula preparations are nearly identical in nutrient composition, although small differences may exist for technical reasons.",
"     </li>",
"     <li>",
"      Frequency and volume of feedings &mdash; The frequency with which the formula-fed infant feeds is highly variable because of the variability in gastric emptying time (one to four hours). Ideally, the feeding schedule should be regulated \"on demand\" by the infant. After the first week of life, most infants will demand six to nine feedings per 24 hours. Some infants will be satisfied with feedings every three to four hours, whereas others will require feedings every two to three hours. Most infants rapidly increase their intake from 30 to 90 mL (one to three ounces) every three to four hours by the end of the first week of life. Most infants require feedings throughout the day and night, although some infants will not awaken for the middle-of-the-night feed.",
"     </li>",
"     <li>",
"      Dietary energy intake &mdash; Standard infant formulas contain 0.67",
"      <span class=\"nowrap\">",
"       kcal/mL",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       kcal/oz)",
"      </span>",
"      when properly prepared. Therefore, the daily energy intake of the formula-fed infant can be determined from the product of the caloric density of the formula and the volume of formula consumed. Average energy requirements in healthy infants are approximately 110",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      at one month of age, 95",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      at three months of age, and 80",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      between 6 and 12 months of age (",
"      <a class=\"graphic graphic_figure graphicRef87702 \" href=\"UTD.htm?39/15/40190\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/11\">",
"       11",
"      </a>",
"      ]. This intake results in weight gain of 15 to 30",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      during the first six months of life, and 6 to 15",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      between 6 and 12 months. Actual energy requirements for an infant vary depending on individual characteristics including medical needs and catch-up growth. Energy requirements for breastfed infants are up to 15 percent less than for formula-fed infants. These estimates are 10 to 20 percent lower than those used in the past [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/12\">",
"       12",
"      </a>",
"      ]. However, undernourished infants with acute or chronic illness may require increased energy intakes in the range of 150 to 180",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day and higher weight gains of 50 to 60 g per day to maintain good nutritional health.",
"     </li>",
"     <li>",
"      Type of formula &mdash; The primary distinction among infant formulas is their protein source, which classifies them into the following categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conventional cow&rsquo;s milk formulas",
"     </li>",
"     <li>",
"      Partial whey hydrolysate formulas",
"     </li>",
"     <li>",
"      Extensively hydrolyzed whey or casein-based formulas",
"     </li>",
"     <li>",
"      Soy protein-based formulas",
"     </li>",
"     <li>",
"      Amino acid-based formulas",
"      <br/>",
"      <br/>",
"      All infant formulas are designed to be nutritionally complete, and have ratios of macronutrients (protein, fat and carbohydrate) that are similar to breast milk. A few formulas used for infants with specific metabolic disorders may be nutritionally incomplete, but these are highly unusual. The primary indication for use of an extensively hydrolyzed or amino acid-based formula is an infant with established food allergy or protein intolerance, or at high risk of developing allergy. These considerations are discussed in separate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=see_link\">",
"       \"Introducing formula and solid foods to infants at risk for allergic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"      </a>",
"      .) Formulas are sometimes changed empirically for nonspecific symptoms such as reflux or irritability, but a favorable response may or may not be causally related. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;No standard approach exists for estimating the dietary intake in children. Several methods that differ in ease of use and reliability are available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/13\">",
"     13",
"    </a>",
"    ]. Once a history has been obtained, food servings should be converted into nutrient content to allow comparison with the Dietary Reference Intakes for specific nutrients. Consultation with a dietitian is helpful in calculating the nutrient content of the child's diet. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Dietary Reference Intakes (DRIs)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dietary recall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dietary history of the child can be assessed with a 24-hour dietary recall or a food frequency questionnaire. In both of these approaches, the child or the parents are asked to provide a quantitative or qualitative estimate, respectively, of habitual food consumption patterns in the recent past. These methods of dietary analysis can be misleading because individual family members must rely on memory to describe typical eating patterns. However, one study found that sixth- and seventh-grade inner city students could provide valid estimates of intake of calories, carbohydrates, calcium, phosphorus, iron and vitamin C, although fourth- and fifth-grade students could not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dietary diary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dietary diary, a three-day written food record that lists all foods consumed during a period of two weekdays and one weekend day performed while the child is at home, is a more valid tool than is dietary recall to quantify actual dietary intake. Parents record the types of food served to the child, the manner in which the food was prepared, the use of additional condiments, and the amount of food consumed using common household measurements. Even in this setting, dietary intake can be doubtful because anxious parents tend to over- or underestimate the child's food consumption depending on the nature of the nutritional problem. Despite these difficulties, every effort should be made to document the possibility that altered dietary intakes contribute to the nutritional problem of the child. Unusual meal patterns such as excessive fruit juice consumption may become apparent from the written document and serve as an explanation for failure to thrive in the young child [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Food servings are converted into nutrient content using a computerized nutrient database available from a variety of sources including commercial software packages; a variety of sources are listed at the",
"    <a class=\"external\" href=\"file://www.nutrientdataconf.org/indd/\">",
"     International Nutrient Database Directory",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Alternatively, Atwater conversion factors can be used to estimate the energy content of the diet based on the reported intake of each macronutrient. The following conversion factors are used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protein &ndash; 4",
"      <span class=\"nowrap\">",
"       kcal/g",
"      </span>",
"     </li>",
"     <li>",
"      Carbohydrate &ndash; 4",
"      <span class=\"nowrap\">",
"       kcal/g",
"      </span>",
"     </li>",
"     <li>",
"      Fat &ndash; 9",
"      <span class=\"nowrap\">",
"       kcal/g",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDED DIETARY INTAKES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two sets of standards have been developed to describe optimal nutritional intake:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily Values (DVs) are determined by the US Food and Drug Administration for the purpose of food labeling. They are comprised of daily reference values (DRV) and Reference Daily Intakes (RDI). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Daily Values (DVs)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Dietary Reference Intakes (DRI) are determined by the National Academy of Sciences [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/16\">",
"       16",
"      </a>",
"      ]. They are comprised of four standards each of which describes a different aspect of optimal nutritional intake: the Estimated Average Requirement (EAR), Recommended Dietary Allowance (RDA), Adequate Intake (AI) and Upper Tolerable Level (UL). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dietary Reference Intakes (DRIs)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Daily Values (DVs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Recommended Dietary Allowances (USRDA) were established in 1968 by the Food and Drug Administration (FDA) for the purpose of food labeling. In 1990, the USRDAs were revised to &ldquo;Daily Values&rdquo; (comprised of DRVs and RDIs). The 33 nutrients for which DVs were established reflect the common health problems for the people of the United States, including obesity, hyperlipidemia, hypertension, and osteoporosis (",
"    <a class=\"graphic graphic_table graphicRef70427 \" href=\"UTD.htm?41/21/42333\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The reference values are listed on food labels as a percentage of DVs (%DV), based on a 2000 calorie daily energy intake. A 2000 kcal energy intake was used as the reference because it approximates the energy requirement for postmenopausal women, the group of individuals who have the highest risk for excessive dietary energy and fat intakes. However, it is important to note that these values should be adjusted for individuals whose energy intake is significantly above or below this level, including most children.",
"   </p>",
"   <p>",
"    The term Daily Value (DV) is used on a food label, to provide the consumer with information about the nutritional value of various food products. However, the DV actually reports either the DRV or RDI, depending on the nutrient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DRVs are provided for total fat, saturated fat, cholesterol, total carbohydrate, dietary fiber, sodium, potassium, and protein.",
"     </li>",
"     <li>",
"      RDIs are provided for vitamins and minerals. These were formerly known as United States Recommended Dietary Allowances [USRDAs]. The name change was necessary to avoid confusion with the Recommended Dietary Allowance (RDA), which is determined by the Institute of Medicine, as described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Target DVs for energy-producing nutrients are based on the amount of dietary energy consumed per day. This permits calculation of target values for individuals whose energy intake is substantially more or less than the reference 2000 calorie diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total fat &ndash; varies by age group:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children one to three years &ndash; 30 to 40 percent of total daily calories",
"     </li>",
"     <li>",
"      Older children and adolescents &ndash; 25 to 35 percent of total daily calories",
"     </li>",
"     <li>",
"      Adults &ndash; 20 to 35 percent of total daily calories &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saturated fat &ndash; less than 10 percent of total daily calories (and minimize intake of trans fats as much as possible)",
"     </li>",
"     <li>",
"      Carbohydrate &ndash; approximately 45 to 65 percent of total daily calories",
"     </li>",
"     <li>",
"      Protein &ndash; approximately 15 to 20 percent of total daily calories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Target intake for dietary fiber is at least 25 g per 2000 kcal. For children, an age-based target fiber intake has been suggested, with targets of 30 or more grams daily for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. A more modest target can be estimated by recommending daily intake of fiber in grams equal to the child&rsquo;s age plus 5, and this provides a goal that is more realistic for some children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/21\">",
"     21",
"    </a>",
"    ]. One serving of most fruits or vegetables (eg, one whole apple or pear, or &frac12; cup of vegetables) equals approximately 3 grams of fiber. Fiber intake is encouraged because high intake is associated with lower visceral fat mass and markers of inflammation in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/22\">",
"     22",
"    </a>",
"    ], as well as decreased risk for cardiovascular events, diabetes mellitus and all-cause mortality in adults (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link&amp;anchor=H949890#H949890\">",
"     \"Healthy diet in adults\", section on 'Fiber'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Food labels may be confusing for consumers because the DVs for fat, cholesterol, and sodium are presented as the uppermost limit that is considered desirable to consume, whereas the DVs for some vitamins and minerals are presented as the smallest desirable daily intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dietary Reference Intakes (DRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary Reference Intakes (DRIs) were developed by the Food and Nutrition Board of the Institute of Medicine to provide quantitative estimates of optimal nutrient intake in a variety of populations. They expand the previously-used RDAs by more carefully identifying optimal nutrient requirements for a population rather than intakes designed to avoid deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Moreover, the DRIs include upper limits (UL) to avoid adverse effects of excessive intake.",
"   </p>",
"   <p>",
"    The DRIs are a set of four nutrient-based reference values that can be used to plan and assess the diets of healthy individuals or populations. The components of the DRIs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated Average Requirement (EAR) &mdash; The EAR is the daily intake value for individual nutrients that is estimated to meet the requirement in 50 percent of the individuals within a given life stage group.",
"     </li>",
"     <li>",
"      Recommended Dietary Allowance (RDA) &mdash; The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group. It is determined by the National Academy of Sciences based on the best available research data. Consumption of nutrients below the RDA does not necessarily constitute a deficiency because absolute nutrient requirements for individuals usually are not known with certainty. However, the further the intake is below the RDA, the more likely that a deficiency will develop. The average intake of most nutrients by children in the United States exceeds 100 percent of the RDA, with the exception of iron, calcium, and zinc [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adequate Intake (AI) &mdash; The AI represents an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population. This value is used when scientific data are insufficient to calculate an EAR.",
"     </li>",
"     <li>",
"      Upper Tolerable Level (UL) &mdash; The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DRIs are identified for the following life stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infancy (zero to six months and 6 to 12 months)",
"     </li>",
"     <li>",
"      Early childhood (1 to 3 years)",
"     </li>",
"     <li>",
"      Late childhood (4 to 8 years)",
"     </li>",
"     <li>",
"      Early adolescence (9 to 13 years)",
"     </li>",
"     <li>",
"      Late adolescence (14 to 18 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DRIs (RDA, AI, and UL) have been provided for macronutrients (carbohydrates, fiber, fat, protein, and amino acids) and various vitamins and minerals (",
"    <a class=\"graphic graphic_table graphicRef62525 graphicRef78274 \" href=\"UTD.htm?37/20/38221\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/16,23,26,27\">",
"     16,23,26,27",
"    </a>",
"    ]. The estimate of the nutrient content of an individual&rsquo;s diet should be compared with the age- and gender-specific DRI, with the caveat that these standards meet or exceed the nutrient needs of nearly all healthy children but do not take into account the nutrient needs of children with acute or chronic illness (",
"    <a class=\"graphic graphic_table graphicRef51044 \" href=\"UTD.htm?1/37/1629\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/28\">",
"     28",
"    </a>",
"    ]. More detailed information is available at the website of the",
"    <a class=\"external\" href=\"file://fnic.nal.usda.gov/nal_display/index.php?info_center=4&amp;tax_level=3&amp;tax_subject=256&amp;topic_id=1342&amp;level3_id=5140\">",
"     Food and Nutrition Information Center",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dietary composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The daily composition of a recommended diet is based upon the 2010 Dietary guidelines for Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/29\">",
"     29",
"    </a>",
"    ], which are taught by the USDA &ldquo;",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/\">",
"     Choose my plate",
"    </a>",
"    &rdquo; tool. &ldquo;Choose my plate&rdquo; replaced the Food Guide Pyramid in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/30\">",
"     30",
"    </a>",
"    ]. The revised guide divides foods into five major groups: grains, vegetables, fruits, dairy and protein. It emphasizes moderation, variety, and proportionality in food consumption and notes the importance of physical activity.",
"   </p>",
"   <p>",
"    The revised &rdquo;choose my plate&rdquo; plan assigns individuals to a calorie level based upon their gender, age, and activity level, using a",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/myplate/index.aspx\">",
"     calculator",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/31\">",
"     31",
"    </a>",
"    ]. Similar information about recommended energy intake is shown in this table (",
"    <a class=\"graphic graphic_table graphicRef80428 \" href=\"UTD.htm?8/20/8525\">",
"     table 4",
"    </a>",
"    ). The plan then suggests amounts of food that individuals should consume from the five major groups to meet their recommended nutrient intakes at different calorie levels. Nutrient and energy contributions from each group are calculated according to the nutrient-dense forms of foods in each group. Examples of dietary composition recommendations from the 1200 to 3000 calorie levels are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef68420 \" href=\"UTD.htm?35/26/36268\">",
"     table 5",
"    </a>",
"    ). Recommendations for special populations and educational materials are available on the &ldquo;Choose my plate&rdquo; website:",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/\">",
"     ChooseMyPlate.gov",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28631/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23397939\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For breastfed infants, assessment of the adequacy of the dietary intake is based upon the frequency and duration of breastfeeding, frequency of urination and stooling, and rate of weight gain. Breastfed infants usually gain 15 to 30",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      during the first six months of life, and typically gain more slowly than formula-fed infants between 3 and 12 months of age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Breastfed infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The formula-fed infant normally consumes an average of 110",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day during the first month of life, falling to about 80",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      by six months of age (",
"      <a class=\"graphic graphic_figure graphicRef87702 \" href=\"UTD.htm?39/15/40190\">",
"       figure 1",
"      </a>",
"      ), resulting in a weight gain of 15 to 30",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      However, undernourished infants with acute or chronic illness may require increased energy intakes in the range of 150 to 180",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day and higher weight gains of 50 to 60 g per day to maintain good nutritional health. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Formula-fed infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No standard approach exists for estimating the dietary intake in children. Methods include dietary recall, a dietary diary, or various survey instruments. Once a history has been obtained, food servings should be converted into nutrient content to allow comparison with the Dietary Reference Intakes for specific nutrients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food labels in the United States report Daily Values (DV), which suggest appropriate intake of a number of key nutrients, based on a reference 2000 calorie diet (",
"      <a class=\"graphic graphic_table graphicRef70427 \" href=\"UTD.htm?41/21/42333\">",
"       table 1",
"      </a>",
"      ). It is important to note that these values should be adjusted for individuals whose energy intake is significantly above or below this level, including most children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Daily Values (DVs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximate energy requirements range from 1000 calories daily in a healthy two-year-old child to 3000 calories daily in an active adolescent boy (",
"      <a class=\"graphic graphic_table graphicRef80428 \" href=\"UTD.htm?8/20/8525\">",
"       table 4",
"      </a>",
"      ). Actual requirements vary considerably among individuals, and are affected by chronic illness (",
"      <a class=\"graphic graphic_table graphicRef51044 \" href=\"UTD.htm?1/37/1629\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dietary composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary Reference Intakes (DRIs) consist of the Estimated Average Requirement (EAR), Recommended Dietary Allowance (RDA), Adequate Intake (AI), and Upper Limit (UL). DRIs are provided for macronutrients (carbohydrates, fiber, fat, protein, and amino acids) and most vitamins and minerals, and vary by age group (",
"      <a class=\"graphic graphic_table graphicRef62525 graphicRef78274 \" href=\"UTD.htm?37/20/38221\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dietary Reference Intakes (DRIs)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Formula feeding of term infants. In: Pediatric Nutrition Handbook, 6, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village 2009. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/2\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/3\">",
"      Choe YH, Lee JE, Moon KB, et al. The infrequent bowel movements in young infants who are exclusively breast-fed. Eur J Pediatr 2004; 163:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/4\">",
"      Weaver CM, Rothwell AP, Wood KV. Measuring calcium absorption and utilization in humans. Curr Opin Clin Nutr Metab Care 2006; 9:568.",
"     </a>",
"    </li>",
"    <li>",
"     Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance data from vital and health statistics. Number 314. National Center for Health Statistics; Centers for Disease Control and Prevention, Hyattsville, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/6\">",
"      Dewey KG, Heinig MJ, Nommsen LA, et al. Growth of breast-fed and formula-fed infants from 0 to 18 months: the DARLING Study. Pediatrics 1992; 89:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/7\">",
"      Dewey KG, Heinig MJ, Nommsen LA, L&ouml;nnerdal B. Adequacy of energy intake among breast-fed infants in the DARLING study: relationships to growth velocity, morbidity, and activity levels. Davis Area Research on Lactation, Infant Nutrition and Growth. J Pediatr 1991; 119:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/8\">",
"      Hediger ML, Overpeck MD, Ruan WJ, Troendle JF. Early infant feeding and growth status of US-born infants and children aged 4-71 mo: analyses from the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2000; 72:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/9\">",
"      Dewey KG, Peerson JM, Brown KH, et al. Growth of breast-fed infants deviates from current reference data: a pooled analysis of US, Canadian, and European data sets. World Health Organization Working Group on Infant Growth. Pediatrics 1995; 96:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/10\">",
"      Dewey KG. Growth patterns of breastfed infants and the current status of growth charts for infants. J Hum Lact 1998; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO) and United Nations University (UNU): Human Energy Requirements. Chapter 2: Energy requirements of infants from birth to 12 months. Available at: file://www.fao.org/docrep/007/y5686e/y5686e05.htm (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     Energy and protein requirements: Report of a joint FAO/WHO/UNU expert consultation. World Health Organization; Geneva, 1985.",
"    </li>",
"    <li>",
"     A Reference Case: The RENO Diet-Heart Study. In: Obesity Assessment Tools, Methods, Interpretations, St. Jeor ST (Ed), Chapman and Hall, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/14\">",
"      Field AE, Peterson KE, Gortmaker SL, et al. Reproducibility and validity of a food frequency questionnaire among fourth to seventh grade inner-city school children: implications of age and day-to-day variation in dietary intake. Public Health Nutr 1999; 2:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/15\">",
"      Smith MM, Lifshitz F. Excess fruit juice consumption as a contributing factor in nonorganic failure to thrive. Pediatrics 1994; 93:438.",
"     </a>",
"    </li>",
"    <li>",
"     Food and nutrition information center, Dietary Reference Intake Reports. Available at: file://fnic.nal.usda.gov/nal_display/index.php?info_center=4&amp;tax_level=3&amp;tax_subject=256&amp;topic_id=1342&amp;level3_id=5141&amp;level4_id=0&amp;level5_id=0&amp;placement_default=0 (Accessed on March 02, 2011).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration, labeling and nutrition information. How to understand and use the Nutrition Facts Label. Available at: file://www.fda.gov/Food/LabelingNutrition/ConsumerInformation/ucm078889.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/18\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     USDA Dietary Guidelines for Americans 2010. Available at: usda.gov/publications/dietaryguidelines/2010/policydoc/chapter2.pdf (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     American Heart Association website, available at: file://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/Fiber-and-Childrens-Diets_UCM_305981_Article.jsp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/21\">",
"      Dwyer JT. Dietary fiber for children: how much? Pediatrics 1995; 96:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/22\">",
"      Parikh S, Pollock NK, Bhagatwala J, et al. Adolescent fiber consumption is associated with visceral fat and inflammatory markers. J Clin Endocrinol Metab 2012; 97:E1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/23\">",
"      Yates AA, Schlicker SA, Suitor CW. Dietary Reference Intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998; 98:699.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary Reference Intakes: Applications in Dietary Assessment. Food and Nutrition Board of the Institute of Medicine. National Academies Press, 2000. Available at: file://www.nap.edu/openbook.php?record_id=9956&amp;page=R1 (Accessed on March 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/25\">",
"      Kennedy E, Goldberg J. What are American children eating? Implications for public policy. Nutr Rev 1995; 53:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/26\">",
"      Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999; 281:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28631/abstract/27\">",
"      Bailey LB. Dietary reference intakes for folate: the debut of dietary folate equivalents. Nutr Rev 1998; 56:294.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board. Recommended Dietary Allowances, 10, National Academy Press, Washington DC 1989.",
"    </li>",
"    <li>",
"     United States Department of Agriculture, Center for Nutrition Policy and Promotion: Dietary guidelines for Americans, 2010. Available at: file://www.cnpp.usda.gov/dietaryguidelines.htm (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     United States Department of Agriculture, \"Choose my plate.\" Available at: file://www.choosemyplate.gov/ (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     United States Department of Agriculture, Daily food plan. Available at: file://www.choosemyplate.gov/myplate/index.aspx (Accessed on June 07, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5357 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28631=[""].join("\n");
var outline_f27_61_28631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23397939\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIETARY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Breastfed infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Formula-fed infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dietary recall",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dietary diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDED DIETARY INTAKES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Daily Values (DVs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dietary Reference Intakes (DRIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dietary composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23397939\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5357|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/15/40190\" title=\"figure 1\">",
"      Energy requirements of infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/21/42333\" title=\"table 1\">",
"      FDA Daily Values for Food Labels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/6/3180\" title=\"table 2A\">",
"      DRI infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/46/4845\" title=\"table 2B\">",
"      DRI selected nutrients children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/37/1629\" title=\"table 3\">",
"      Nutrition risk chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/20/8525\" title=\"table 4\">",
"      Energy requirements children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/26/36268\" title=\"table 5\">",
"      Dietary composition children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36487?source=related_link\">",
"      Indications for nutritional assessment in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=related_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=related_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22391?source=related_link\">",
"      Laboratory and radiologic evaluation of nutritional status in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28632="Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children";
var content_f27_61_28632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Vance G Fowler, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28632/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/61/28632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    is a leading cause of both community-associated and hospital-acquired bacteremia.",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) is associated with increased morbidity and mortality, even with appropriate therapy.",
"   </p>",
"   <p>",
"    Several underlying conditions predispose patients to the development of SAB. The presence of individual risk factors substantially affects clinical management. Thus, clinicians need to inquire specifically as to the presence or absence of these risk factors before making clinical decisions regarding treatment.",
"   </p>",
"   <p>",
"    The epidemiology of and risk factors for SAB in children will be reviewed here. The treatment of SAB in children and the epidemiology, risk factors for, and treatment of SAB in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    can be divided into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hospital-onset healthcare-acquired (previously known as hospital-acquired or nosocomial)",
"     </li>",
"     <li>",
"      Community-associated",
"     </li>",
"     <li>",
"      Community-onset healthcare-associated (previously called non-nosocomial healthcare-associated infection) (eg, related to outpatient intravascular therapy or acquired in chronic-care facilities)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately one-half of episodes of",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) in children are healthcare associated, and one-half are community associated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, the expanding role of outpatient intravenous (IV) therapies is increasing the rate of community-onset healthcare-associated SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intravascular catheters'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SAB has increased since the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. In a Danish surveillance study, for example, the overall incidence of SAB in children increased from 4.6 to 8.4 cases per 100,000 population between 1971-1974 and 1996-2000, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. The incidence was 10- to 17-fold greater in infants (&lt;1 year) than in other age groups. The male:female ratio was 1.75:1. A similar pattern of increased incidence among infants was noted in a retrospective review of 164 episodes of SAB among 151 children from a single tertiary-care children's hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3\">",
"     3",
"    </a>",
"    ] and a review of hospital discharge data from seven states in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/8\">",
"     8",
"    </a>",
"    ]. Among 33 children&rsquo;s hospitals in the United States, the incidence of SAB increased from 2.9 to 3.4 per 1000 admissions between 2002 and 2007; the increase was related primarily to methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hospital-onset healthcare-acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAB has become a leading cause of nosocomial bloodstream infections (BSIs) in children in the United States, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/8,10-12\">",
"     8,10-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the National Nosocomial Infections Surveillance System (NNIS) indicate that",
"      <em>",
"       S. aureus",
"      </em>",
"      is the third-most common cause of nosocomial bacteremia in pediatric intensive care units (9.3 percent of bacteremias) and the second-most common cause in the neonatal intensive care unit (12.3 percent of bacteremias) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective analysis of nosocomial BSIs at 49 hospitals in the United States between 1995 and 2002, 3432 episodes occurred in patients &le;16 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/12\">",
"       12",
"      </a>",
"      ]. The most frequently isolated organisms were coagulase-negative staphylococci (43 percent),",
"      <em>",
"       S. aureus",
"      </em>",
"      (9 percent), enterococci (9 percent), and",
"      <em>",
"       Candida",
"      </em>",
"      spp (9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospital-onset healthcare-acquired SAB is more frequent in infants (&lt;1 year) than in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3,7,13\">",
"     3,7,13",
"    </a>",
"    ], and particularly in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/14\">",
"     14",
"    </a>",
"    ]. In a seven-year Danish surveillance study, 74 to 91 percent of SAB in infants was hospital acquired, compared to 39 to 50 percent of SAB in the older age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. In a 10-year review from a single institution in the United States, all episodes of SAB in neonates were hospital acquired, compared to 20 percent in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/13\">",
"     13",
"    </a>",
"    ]. In another children's hospital, 41 percent of 242 episodes of nosocomial",
"    <em>",
"     S. aureus",
"    </em>",
"    infection were bacteremias primarily related to catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/15\">",
"     15",
"    </a>",
"    ]. However, other centers have reported community-associated SAB in otherwise normal neonates, particularly related to community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for nosocomial SAB in infants and children are similar to those described in adults and relate mainly to intravascular devices, respiratory illness, and surgical wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1,3,17\">",
"     1,3,17",
"    </a>",
"    ]. Premature infants are especially likely to suffer from SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospital-onset healthcare-acquired SAB is a serious infection with a mortality of approximately 4 percent in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. Hospital-onset SAB also may be associated with metastatic complications, including infective endocarditis (IE) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/17\">",
"     17",
"    </a>",
"    ]. In a prospective observational cohort at a tertiary-care children's hospital, 51 children were identified with SAB over a three-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/17\">",
"     17",
"    </a>",
"    ]. Ten children developed IE (nine with congenital heart disease); in nine of these patients, the SAB was nosocomial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Nosocomial and healthcare-associated endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Community-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;In otherwise normal children, community-associated SAB is typically related to a focus of infection, especially musculoskeletal infections, while IE is unusual. In one 10-year review of 58 children with",
"    <em>",
"     S. aureus",
"    </em>",
"    sepsis who were admitted to a pediatric intensive care unit (55 of which were community associated), 79 percent had musculoskeletal symptoms, and 10 percent had pneumonia; 95 percent had normal cardiac valves [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonetheless,",
"    <em>",
"     S. aureus",
"    </em>",
"    remains the predominant organism causing IE in children without congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CA-MRSA infection is discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'CA-MRSA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Community-onset healthcare-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-nosocomial healthcare-associated infection differs from hospital-onset (nosocomial) and community-associated infections, and its incidence is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The following definition has been proposed: infection diagnosed at the time of admission or within 48 hours of admission in an outpatient with extensive healthcare contact, as defined by [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous therapy, wound care, or specialized nursing care at home, or intravenous chemotherapy within the prior 30 days",
"     </li>",
"     <li>",
"      Hospitalization in an acute-care hospital for two or more days within the prior 90 days",
"     </li>",
"     <li>",
"      Dialysis or receipt of intravenous therapy within the prior 30 days",
"     </li>",
"     <li>",
"      Residence in a nursing home or other long-term care facility (least common in children)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Community-onset healthcare-associated SAB typically affects chronically ill children (eg, those with asthma, eczema, neurologic disorders, diabetes, malignancy etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3\">",
"     3",
"    </a>",
"    ]. Prospective surveillance at Texas Children's Hospital identified 899 episodes of community-onset healthcare-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    infection between 2001 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared to community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    infection, community-onset healthcare-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    infection is more often associated with invasive disease (9 versus 5 percent for MRSA and 24 versus 9 percent for methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    [MSSA]).",
"   </p>",
"   <p>",
"    Intravascular catheters play an increasingly important role in non-nosocomial healthcare-associated SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In the Texas Children's surveillance study described above, intravenous catheters were present in 74 of 899 episodes of",
"    <em>",
"     S. aureus",
"    </em>",
"    infection (8.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intravascular catheters'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Methicillin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a significant rise in the rate of methicillin resistance since 1990 for all types of",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1,3,12,22\">",
"     1,3,12,22",
"    </a>",
"    ]. In several large series of bloodstream infections (BSIs) in children, 13 to 19 percent of",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates were resistant to methicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1,3,12,22\">",
"     1,3,12,22",
"    </a>",
"    ]. Widespread antibiotic use and poor adherence to infection control precautions have contributed to the increase in methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CA-MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) is genetically distinct from traditional strains of hospital-acquired MRSA. USA300 is the predominant clone of CA-MRSA associated with",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) in most studies from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/15,23,24\">",
"     15,23,24",
"    </a>",
"    ]. However, in one study, USA300 was also the predominant clone for nosocomial MRSA isolates, accounting for 73 percent of such isolates since 2003, and several reports have emphasized the growing frequency of the USA300 clone as a cause of nosocomial SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although CA-MRSA typically causes skin and soft-tissue infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], it can cause invasive disease at any site, including hematogenous osteomyelitis, septic arthritis, pneumonia, myositis and pyomyositis, and fasciitis; hematogenous osteomyelitis is the most common invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/27\">",
"     27",
"    </a>",
"    ]. Septic thrombophlebitis, often of the lower extremities or pelvis, is an increasingly recognized clinical manifestation of pediatric community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia due to CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare contact (particularly prior hospitalization) is an important risk factor for MRSA, but there are numerous reports of patients with no identifiable healthcare contacts or other risk factors; infections in these patients are referred to as \"community-associated\" MRSA and are illustrated by the following reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prospective surveillance at a tertiary-care children's hospital where 60 to 67 percent of community-associated",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates are methicillin resistant found that the presence of known risk factors for methicillin resistance did not differentiate children with CA-MRSA from those with community-associated methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      (CA-MSSA) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Retrospective chart review at another tertiary-care children's hospital found a marked increase in the number of children without an identifiable risk factor who were hospitalized for community-associated MRSA infection in the period of 1993 to 1995 compared to 1988 to 1990 (259 versus 10 per 100,000 admissions) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/29\">",
"       29",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vancomycin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates with intermediate susceptibility or resistance to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    are much less common than MRSA. Bacteremia has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/33\">",
"     33",
"    </a>",
"    ]. These infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical conditions predispose patients to develop",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravascular catheters",
"     </li>",
"     <li>",
"      Indwelling foreign body or prosthesis",
"     </li>",
"     <li>",
"      Underlying medical conditions",
"     </li>",
"     <li>",
"      Nasal colonization",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intravascular catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular catheters serve as a direct conduit into the intravascular space, allowing easy access for pathogens, such as",
"    <em>",
"     S. aureus",
"    </em>",
"    , into the bloodstream.",
"   </p>",
"   <p>",
"    Intravascular catheters are both the most common predisposing cause for SAB in hospitalized patients and an increasingly important cause of community-onset healthcare-associated SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1,3-6,10,15,34\">",
"     1,3-6,10,15,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a seven-year prospective review of bloodstream infections (BSIs) in children, 49 percent of infections were associated with intravascular catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More than 90 percent of episodes of nosocomial bacteremia reported to the National Nosocomial Infections Surveillance System (NNIS) from pediatric intensive care units occurred in patients with central venous lines [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/10\">",
"       10",
"      </a>",
"      ]. In 144 pediatric ICUs reporting data to the Centers for Disease Control and Prevention (CDC) from 1997 through 2007, methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (MRSA) and methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      (MSSA) accounted for 2.6 and 5.3 percent of all central line associated blood stream infections [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In single-institution studies, approximately 75 percent of nosocomial SAB episodes were related to catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3,15\">",
"       3,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increasing proportion of intravenous catheter-related SAB is caused by USA300 MRSA. In one tertiary-care children's hospital, MRSA caused 26 percent of intravenous catheter-related SAB; 41 percent of the MRSA isolates were USA300 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increasing role of outpatient intravenous therapies in the pathogenesis of SAB is illustrated by an investigation that found that 22 percent of community-onset SAB cases were related to intravascular catheters in 1990-1993 compared with no cases in 1980-1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/4\">",
"     4",
"    </a>",
"    ]. In prospective surveillance, 5.7 percent of 279 peripherally inserted central venous catheters in 271 children were removed for BSI, and another 5.4 percent were removed for presumed BSI (fever in the absence of an identified focus of infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/36\">",
"     36",
"    </a>",
"    ]. These findings are consistent with those of a retrospective review in which 11 percent of 75 children who received &ge;2 weeks of intravenous therapy via a central venous catheter for the treatment of osteomyelitis developed a catheter-related BSI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tunneled venous catheters (eg, Hickman and perm catheters) and central venous catheters account for a significant percentage of cases of catheter-associated SAB. Peripheral venous and midline catheters have much lower risk of infection, and peripherally inserted central catheters have an intermediate risk of causing SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Implanted foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any implanted foreign body that becomes infected is a potential source for SAB. Implanted devices include vascular, urologic, neurologic, and orthopedic prostheses and devices.",
"   </p>",
"   <p>",
"    A classic experiment demonstrated that subcutaneous injection of up to one million colony-forming units of",
"    <em>",
"     S. aureus",
"    </em>",
"    did not produce clinically apparent infection in normal human volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/39\">",
"     39",
"    </a>",
"    ]. However, in the presence of a subcutaneous suture, subcutaneous injection of 300 colony-forming units of",
"    <em>",
"     S. aureus",
"    </em>",
"    invariably led to infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Underlying medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying medical conditions are associated with an increased risk of SAB in children. In a retrospective review of 164 episodes of SAB in 151 children, 74 percent of patients had an underlying medical condition, including heart disease (24 percent), malignancy (18 percent), premature birth (12 percent), gastrointestinal disorder (7 percent), transplant recipient (7 percent), and end-stage renal disease (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately one-half of cases had onset in hospital.",
"   </p>",
"   <p>",
"    Hemodialysis-dependent and diabetic patients have high rates of nasal and skin colonization with",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Such patients are more prone to",
"    <em>",
"     S. aureus",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/40,42\">",
"     40,42",
"    </a>",
"    ], including SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inherited defects in white-blood-cell function or immune responses such as Job syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and Wiskott-Aldrich syndrome also predispose patients to recurrent staphylococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/44\">",
"     44",
"    </a>",
"    ]. However, these conditions are extremely uncommon. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nasal colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of nasal colonization in the development of SAB was prospectively evaluated in a study in which more than 14,000 nonbacteremic, nonsurgical adults were screened for nasal",
"    <em>",
"     S. aureus",
"    </em>",
"    carriage on hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/45\">",
"     45",
"    </a>",
"    ]. Nosocomial SAB occurred significantly more often in the 24 percent of patients who were nasal carriers (1.2 versus 0.4 percent in noncarriers). Genotyping demonstrated that 80 percent of strains causing SAB in nasal carriers were endogenous. On the other hand, nasal carriers had significantly lower rates of SAB-related mortality (3 of 40 versus 13 of 41 (8 versus 32 percent)), a difference that could not be explained by differences in age or comorbidities.",
"   </p>",
"   <p>",
"    Differences in the immune response of",
"    <em>",
"     S. aureus",
"    </em>",
"    carriers and noncarriers may help to explain the lower mortality among carriers. Support for this hypothesis comes from an observational study in which nasal swabs and serum samples were obtained from healthy blood donors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/46\">",
"     46",
"    </a>",
"    ]. Carriers of",
"    <em>",
"     S. aureus",
"    </em>",
"    demonstrated effective antibody response against the colonizing strain, whereas the antibody response against other strains was similar to that of noncarriers. This strain-specific immunity may contribute to the improved mortality outcome for nasal carriers compared to noncarriers. How these findings relate to children is unknown.",
"   </p>",
"   <p>",
"    A more marked increase in the risk of infection has been described in patients who are colonized with methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) at hospital admission. What role nasal carriage of",
"    <em>",
"     S. aureus",
"    </em>",
"    plays in the pathogenesis of SAB with onset in the community as opposed to the hospital is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Colonized individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of injection drug use in SAB is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\", section on 'Injection drug use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overwhelming",
"    <em>",
"     S. aureus",
"    </em>",
"    sepsis may occur in previously healthy children, particularly adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA) and methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) have been associated with a meningococcemia-like clinical presentation and course that is rapidly fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality of",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) in the preantibiotic era exceeded 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/49\">",
"     49",
"    </a>",
"    ]. With the advent of antibiotics, the mortality of SAB in children has decreased to less than 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Data from 30 years of surveillance for SAB in Denmark indicate that the overall mortality of SAB in children decreased from 19.6 to 2.5 percent between 1971-1974 and 1996-2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. The 1996-2000 mortality was 3.7 percent for children &lt;1 year of age, 1.5 percent for those 1 to 10 years, and 2.4 percent for those 11 to 20 years. Similarly, 1995 hospital discharge data from seven states in the United States indicate a case fatality rate of 5.7 percent for children &lt;1 year of age, 0 percent for those 1 to 10 years, and 3.8 percent for those 11 to 19 years with severe",
"    <em>",
"     S. aureus",
"    </em>",
"    sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multivariate analysis of the Danish study, the risk of mortality was increased in children of any age with pulmonary infection and endocarditis, in children older than one year with a comorbid condition, and in children aged 11 to 20 years with hospital-acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"     7",
"    </a>",
"    ]. In another study of children with SAB, the mortality for children with IE was 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/17\">",
"     17",
"    </a>",
"    ]. Mortality among children with SAB in association with osteomyelitis is unusual.",
"   </p>",
"   <p>",
"    In a retrospective study of 22 children with MRSA bacteremia who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    for &gt;5 days, the 30-day mortality was 13.6 percent and all deaths occurred in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28632/abstract/50\">",
"     50",
"    </a>",
"    ]. Nine children (41 percent) had persistent bacteremia (&gt;7 days) while receiving vancomycin and two (9 percent) had a recurrence of bacteremia within 30 days of completing vancomycin therapy. Thus, treatment failure occurred in one-half of patients despite catheter removal from all patients with catheters at the time of onset of infection and surgical drainage of all identified abscesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      bacteremia (SAB) is a leading cause of nosocomial bloodstream infections. Risk factors for nosocomial SAB in infants and children relate mainly to intravascular devices, respiratory illness, and surgical wounds. Premature infants are at particular risk. Hospital-acquired SAB is also associated with metastatic complications, including infective endocarditis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hospital-onset healthcare-acquired'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In otherwise normal children, community-associated SAB is typically related to a focus of infection, especially musculoskeletal infections. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Community-associated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community-onset healthcare-associated infection typically affects chronically ill children; intravascular catheters play an important role. Community-onset healthcare-associated",
"      <em>",
"       S. aureus",
"      </em>",
"      infection is more often associated with invasive disease than community-associated",
"      <em>",
"       S. aureus",
"      </em>",
"      infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Community-onset healthcare-associated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of methicillin resistance has significantly increased since 1990 for all types of SAB. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antimicrobial resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for SAB include intravascular catheters, indwelling foreign body or prosthesis, underlying medical conditions, nasal colonization, and injection drug use. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality of SAB in children is less than 3 percent. The risk of mortality is increased in children with pulmonary infection and endocarditis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/1\">",
"      Gray JW. A 7-year study of bloodstream infections in an English children's hospital. Eur J Pediatr 2004; 163:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/2\">",
"      Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/3\">",
"      Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol 2009; 30:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/4\">",
"      Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/5\">",
"      Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/6\">",
"      Ruebner R, Keren R, Coffin S, et al. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics 2006; 117:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/7\">",
"      Frederiksen MS, Espersen F, Frimodt-M&oslash;ller N, et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J 2007; 26:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/8\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/9\">",
"      Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009; 49:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/10\">",
"      Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/11\">",
"      Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996; 98:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/12\">",
"      Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/13\">",
"      Denniston S, Riordan FA. Staphylococcus aureus bacteraemia in children and neonates: a 10 year retrospective review. J Infect 2006; 53:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/14\">",
"      Hakim H, Mylotte JM, Faden H. Morbidity and mortality of Staphylococcal bacteremia in children. Am J Infect Control 2007; 35:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/15\">",
"      Hult&eacute;n KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol 2010; 31:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/16\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/17\">",
"      Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/18\">",
"      Miles F, Voss L, Segedin E, Anderson BJ. Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Arch Dis Child 2005; 90:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/19\">",
"      Martin JM, Neches WH, Wald ER. Infective endocarditis: 35 years of experience at a children's hospital. Clin Infect Dis 1997; 24:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/20\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/21\">",
"      Hult&eacute;n KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/22\">",
"      Khairulddin N, Bishop L, Lamagni TL, et al. Emergence of methicillin resistant Staphylococcus aureus (MRSA) bacteraemia among children in England and Wales, 1990-2001. Arch Dis Child 2004; 89:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/23\">",
"      Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr Infect Dis J 2004; 23:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/24\">",
"      Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/25\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/26\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/27\">",
"      Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/28\">",
"      Gonzalez BE, Teruya J, Mahoney DH Jr, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics 2006; 117:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/29\">",
"      Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus &mdash; Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/31\">",
"      Collignon P, Gosbell I, Vickery A, et al. Community-acquired meticillin-resistant Staphylococcus aureus in Australia. Australian Group on Antimicrobial Resistance. Lancet 1998; 352:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/32\">",
"      Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/34\">",
"      Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J 2010; 29:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/35\">",
"      Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/36\">",
"      Levy I, Bendet M, Samra Z, et al. Infectious complications of peripherally inserted central venous catheters in children. Pediatr Infect Dis J 2010; 29:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/37\">",
"      Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/38\">",
"      Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995; 155:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/39\">",
"      ELEK SD, CONEN PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol 1957; 38:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/40\">",
"      Kirmani N, Tuazon CU, Murray HW, et al. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/41\">",
"      Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA 1975; 231:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/42\">",
"      Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/43\">",
"      Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39:6.",
"     </a>",
"    </li>",
"    <li>",
"     Waldvogel, FA. Staphylococcus aureus (including toxic shock). In: Principles and Practice of Infectious Diseases, 4th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Churchill Livingstone, New York 1995. p.1754.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/45\">",
"      Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/46\">",
"      Holtfreter S, Roschack K, Eichler P, et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis 2006; 193:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/47\">",
"      Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/48\">",
"      Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/49\">",
"      Skinner, D, Keefer, CS. Significance of bacteremia caused by Staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28632/abstract/50\">",
"      Welsh KJ, Abbott AN, Lewis EM, et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol 2010; 48:894.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6056 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0869272E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28632=[""].join("\n");
var outline_f27_61_28632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hospital-onset healthcare-acquired",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Community-associated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Community-onset healthcare-associated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIMICROBIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Methicillin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CA-MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vancomycin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intravascular catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Implanted foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Underlying medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nasal colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28633="Squamous cell carcinoma - tongue";
var content_f27_61_28633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81810%7EDERM%2F59057%7EDERM%2F74239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81810%7EDERM%2F59057%7EDERM%2F74239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma of the tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nodule on the ventral surface of the tongue is a squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma on the lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This erythematous, crusted nodule on the lip represents a squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma on the gingiva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ulcerated nodule involving the gingiva represents a squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28633=[""].join("\n");
var outline_f27_61_28633=null;
var title_f27_61_28634="Surveillance after colorectal cancer resection";
var content_f27_61_28634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surveillance after colorectal cancer resection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Brian C Jacobson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Beverly Moy, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Francis A Farraye, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/61/28634/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/61/28634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is the third most common cause of cancer death in the United States; an estimated 142,820 new cases are diagnosed each year, of which 102,480 are colon and the remainder rectal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/1\">",
"     1",
"    </a>",
"    ]. Global, country-specific data on incidence and mortality are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Surgical resection is the primary treatment for the 80 percent of CRC that present with nonmetastatic disease, and the most powerful tool for assessing prognosis is pathologic analysis of the resected specimen. Despite potentially curative surgery and the use of modern adjuvant chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT), more than 40 percent of patients who present with stage II or III disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) will have a disease recurrence following primary therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been considerable variability among physicians in the use of follow-up studies after potentially curative resection of CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/2-6\">",
"     2-6",
"    </a>",
"    ] and in the guidelines from major societies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Multiple surveillance strategies have been published at costs ranging from a few hundred to several thousand dollars per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intensive postoperative surveillance programs have been justified in the hope that early detection of asymptomatic recurrences will increase the proportion of patients who are potentially eligible for curative therapy. A survival benefit from such an approach has in fact been shown in three separate meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Furthermore, data that point to the value of periodic imaging to detect early potentially resectable recurrences led the American Society of Clinical Oncology (ASCO) to reverse its previous recommendation against including CT scans as a component of the posttreatment surveillance strategy in 2005 (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, consensus is now emerging as to the best strategy for surveillance of patients with resected stage II and III CRC. Whether patients with stage I disease benefit from posttreatment surveillance is unclear. Although these patients have such a favorable prognosis that posttreatment surveillance has generally not been recommended, newer data are challenging this viewpoint. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Surveillance for treated stage I disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Here we will discuss the rationale for intensive posttreatment surveillance, the benefit of surgery for recurrent disease, the randomized trials that have studied the effectiveness of various surveillance strategies, and current recommendations for posttreatment surveillance in patients with resected CRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR INTENSIVE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of surveillance after definitive therapy of colon and rectal cancer is early identification of those patients who might potentially be cured by further surgical intervention and to screen for second primary cancers and polyps. Increasing amounts of data support the view that early diagnosis of recurrent disease results in a more favorable outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Does early detection of recurrent disease improve survival?",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important clinical question that arises when considering the debate over appropriate surveillance after treatment of primary CRC is whether early detection of recurrent disease improves survival. Reresection can cure some patients who have a limited localized recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\", section on 'Locally recurrent rectal cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of the management of primary colon cancer\", section on 'Management of locally recurrent disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125360754#H125360754\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Surgery for locally recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery also has curative potential for patients with limited sites of metastatic disease, particularly involving the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Five year survival rates approaching 40 percent have been reported in patients undergoing partial hepatectomy for limited hepatic metastases (",
"    <a class=\"graphic graphic_table graphicRef74509 \" href=\"UTD.htm?23/60/24524\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although isolated lung metastases are less common than liver involvement, metastasectomy has also been used to treat carefully selected patients with lung metastases, with five-year survival rates of 35 to 45 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies show that patients with asymptomatic rather than symptomatic recurrences are more likely to be eligible for potentially curative resection, they are more likely to have completely resected disease at reexploration, and they have significantly better progression-free and overall survival rates after such surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. This was shown in a meta-analysis that included 3283 patients enrolled in seven studies comparing intensive follow-up (history and physical examination with serum, radiologic, and endoscopic tests, the intensive group) with",
"    <span class=\"nowrap\">",
"     minimal/no",
"    </span>",
"    follow-up (the control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/26\">",
"     26",
"    </a>",
"    ]. Asymptomatic recurrences were detected in significantly more patients who had intensive posttreatment surveillance (45 versus 8 percent), and they also had a higher incidence of resectable recurrent disease (35 versus 21 percent).",
"   </p>",
"   <p>",
"    However, it must be emphasized that symptomatic recurrences are not necessarily beyond the potential for curative treatment. In a review of the Eastern Cooperative Oncology Group's experience with recurrent colon cancer, 25 percent of ultimately resectable recurrences were symptomatic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intensive versus less intense surveillance strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest data to support better outcomes in patients who undergo routine posttreatment surveillance come from randomized trials and three separate meta-analyses that have examined intensive versus nonintensive surveillance strategies following potentially curative resection of CRC. The surveillance testing used in these studies include history and physical examination (H&amp;P), fecal occult blood testing (FOBT), CEA, LFTs, CBC, CXR, abdominal CT, colonoscopy, and proctosigmoidoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seven [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]of nine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28-36\">",
"     28-36",
"    </a>",
"    ] randomized trials comparing an intense surveillance strategy to a less intensive surveillance program have failed to show a survival benefit from more intensive follow-up. However, none of the trials was optimally designed, each had methodologic flaws limiting the ability to derive firm conclusions, and many were underpowered to detect survival differences with different surveillance strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/37\">",
"     37",
"    </a>",
"    ]. The control groups in several of the trials underwent fairly intense testing, making the detection of small differences in outcomes endpoints less apparent. Furthermore, many studies included patients with stage I disease whose outcome is extremely favorable, further limiting the ability to detect a difference in outcome between the more and less intensively followed groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three separate meta-analyses of the available randomized controlled trials have shown a modest but significant survival benefit from intensive versus nonintensive surveillance after potentially curative treatment of CRC (",
"    <a class=\"graphic graphic_table graphicRef77401 \" href=\"UTD.htm?13/15/13563\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/16,17,38\">",
"     16,17,38",
"    </a>",
"    ]. However, because of the wide variation in follow-up programs, it was not possible to infer the best combination and frequency of evaluations. In a later cost-effectiveness analysis based upon an earlier 2002 Cochrane meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/15\">",
"     15",
"    </a>",
"    ], the adjusted cost per year of life saved for intensive surveillance was US $5884 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/39\">",
"     39",
"    </a>",
"    ]. Interventions that yield a cost-effectiveness ratio of less than $50,000 to $100,000 per quality-adjusted life year gained have been considered to have an acceptable cost-effectiveness ratio in the United States and several other countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surveillance for treated stage I disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emerging consensus as to the best surveillance strategy for patients with resected CRC focuses mainly on stage II and III disease. In general, aggressive surveillance other than colonoscopy has generally not been recommended in patients with resected stage I tumors since over 95 percent are cured by surgery alone. However, newer data are challenging this viewpoint.",
"   </p>",
"   <p>",
"    A secondary analysis of data from the Clinical Outcomes of Surgical Therapy (COST) trial (laparoscopic versus open colectomy for colon cancer) included 527 patients with stages I (n = 265) or IIA disease, and 254 patients with stage IIB or III disease (as defined by the 2002 AJCC staging criteria) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/40\">",
"     40",
"    </a>",
"    ]. The posttreatment surveillance strategy consisted of CEA testing every three months for the first year, and then every six months for five years; chest x-ray every six months for two years then annually, and colonoscopy at one year, and then every three years if the colon was free of neoplasia; CT scans were performed for symptoms, physical findings, or an increased CEA.",
"   </p>",
"   <p>",
"    Five-year recurrence rates were higher in patients with later stage disease (36 versus 10 percent). However, patients with earlier stage disease experienced similar benefits from postoperative surveillance as did those with later stage disease (salvage rate 36 and 37 percent), and the method of first detection of recurrence was not significantly different: CEA, 29 versus 37 percent; chest x-ray, 7 versus 12 percent; colonoscopy, 13 versus 9 percent.",
"   </p>",
"   <p>",
"    The authors concluded that implementation of surveillance guidelines for patients with stage I disease was appropriate. However, the number of patients who can be cured as a result of CEA and imaging surveillance is very small, less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although individual randomized trials do not demonstrate a survival benefit, meta-analyses suggest a modest but significant survival benefit from intensive surveillance after resection of CRC. However, there is insufficient evidence from either randomized trials or meta-analyses to choose the specific tests that should be included in postoperative testing.",
"   </p>",
"   <p>",
"    The remainder of this discussion will review individual components of the surveillance strategy following resection in patients with treated CRC, focusing on ASCO recommendations. The use of these tests for staging and diagnosis of CRC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF INDIVIDUAL TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appropriate surveillance strategy should consider the temporal pattern and location of recurrent disease. The overwhelming majority of tumor recurrences develop within the first five years, most within the first two to three years after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the management of primary colon cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, liver metastases predominate overall, while lung metastases occur more commonly in patients with distal rectal cancers since the venous and lymphatic drainage of the distal rectum bypass the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection rates for recurrent disease based strictly upon the H&amp;P are between 15 and 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/11,23,29,42\">",
"     11,23,29,42",
"    </a>",
"    ]. Although the available data are limited, routine periodic H&amp;Ps do not appear to influence the detection of resectable recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/27,42\">",
"     27,42",
"    </a>",
"    ]. One reason may be that a significant number of recurrences are heralded by symptoms that occur between physician visits and are thus not affected by the performance of the H&amp;P [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Additionally, liver and lung metastases are unlikely to be symptomatic early in their natural history.",
"   </p>",
"   <p>",
"    The lack of contribution of routine physical examination to the outcome of surveillance was shown in a series of 1356 patients with stage II or III colon cancer who were followed according to a prescribed set of protocol guidelines after treatment on the multicenter adjuvant chemotherapy protocol Intergroup 0089 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/27\">",
"     27",
"    </a>",
"    ]. Of the 421 patients who developed recurrent disease, 96 underwent surgical resection with curative intent. In this group, the first indication of recurrent disease was elevated CEA, CXR, colonoscopy, or symptoms in 31, 12.5, 15, and 25 percent, respectively. Routine physical examination failed to identify a single resectable recurrence.",
"   </p>",
"   <p>",
"    Despite the lack of impact of H&amp;P on outcome, routine clinician visits maintain the doctor-patient relationship, and facilitate the arranging of diagnostic testing and discussions about test results and risk assessment. Thus, updated ASCO guidelines recommend an H&amp;P every three to six months for the first three years, every six months during years four and five, then annually thereafter (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ]. The same schedule is recommended by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    . Although most recurrences develop within five years, failure beyond five years is not uncommon, particularly in patients treated for locally advanced rectal cancer. As an example, in the German Rectal Cancer Study of preoperative versus postoperative chemoradiotherapy, 12 percent of local recurrences (7 of 60) and 7.5 percent of distant metastases (17 of 226) occurred beyond five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H13#H13\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'German Rectal Cancer Study'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Based upon the frequency of symptomatic recurrences, patients should be encouraged to report symptoms that might relate to recurrent cancer (eg, abdominal pain or distension, hematochezia, change in bowel habits, fatigue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only laboratory test routinely recommended for CRC surveillance is serum CEA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Carcinoembryonic antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEA is an oncofetal protein that is elevated in the serum of patients with a variety of cancers, including CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/44\">",
"     44",
"    </a>",
"    ]. Because it lacks both sensitivity and specificity, serum CEA is not a useful screening tool for CRC. However, in patients with established disease, the absolute level of the serum CEA correlates with disease burden and is of prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Furthermore, elevated preoperative levels of CEA should return to baseline after complete resection; residual disease should be suspected if they do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of CEA testing as a component of posttreatment surveillance in patients with resected primary CRC has been extensively evaluated. The estimated sensitivity of CEA to detect disease relapse in patients with completely resected CRC ranges from 58 to 89 percent (ie, between 60 and 90 percent of patients with a disease relapse have an elevated CEA level) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/37,48\">",
"     37,48",
"    </a>",
"    ]. Serial measurement of CEA can detect disease recurrence even among patients with an initially normal CEA level, although the sensitivity is lower (between 27 and 50 percent in four separate studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]). Thus, a postoperative CEA elevation indicates recurrence with high probability, but a normal postoperative CEA level (even if it was initially elevated) is not useful for excluding a disease recurrence.",
"   </p>",
"   <p>",
"    Despite its widespread use in follow-up strategies, the utility of serial CEA testing has been questioned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23113171\">",
"    <span class=\"h4\">",
"     Arguments in favor of CEA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest argument put forth by advocates of serial CEA testing is that resection of limited metastases, particularly involving the liver, leads to long-term relapse-free survival in as many as 40 percent of patients who undergo an attempted resection. By comparison, chemotherapy is not associated with long-term survival in patients with metastatic disease. As noted previously, the detection of asymptomatic recurrences, particularly by CEA testing, increases the likelihood of a complete resection, which in turn is associated with better long-term outcome.",
"   </p>",
"   <p>",
"    Studies have demonstrated a lead time of 1.5 to 6 months between elevation of serum CEA levels and detection of recurrent disease by other means [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Whether this lead time actually improves overall survival remains a point of controversy. However, as noted previously, at least one meta-analyses supports a significantly increased survival among patients who undergo intensive as compared to routine surveillance, as long as CEA testing is a component of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Intensive versus less intense surveillance strategies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Finally, although systemic chemotherapy for metastatic disease has not significantly improved five-year survival rates, it has produced meaningful improvements in median survival and progression-free survival. These benefits are most pronounced with regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in combination with 5-FU; median overall survival durations consistently approach 20 months, in some studies, as high as 24 months. In contrast, among patients receiving supportive care alone for metastatic disease, median survival durations are five to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23113186\">",
"    <span class=\"h4\">",
"     Arguments against serial CEA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opponents of serial CEA testing make the following arguments:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      30 to 40 percent of all CRC recurrences are not associated with measurable elevations in serum CEA [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The benefit of CEA monitoring is limited to a small number of patients with recurrent CRC and is not cost-effective.",
"     </li>",
"     <li>",
"      There are no data showing that CEA testing improves survival [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/38\">",
"       38",
"      </a>",
"      ] or quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One cost-effectiveness study examined the benefit of CEA monitoring on the life expectancy of patients with colon cancer using decision analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/56\">",
"     56",
"    </a>",
"    ]. The influence of CEA monitoring on quality adjusted life expectancy varied from an average increase of seven days (+0.3 percent) to an average decrease of five days (-0.09 percent). Cost-effectiveness of CEA testing ranged from $22,963 to $4,888,208 per quality adjusted life year (QALY) saved.",
"   </p>",
"   <p>",
"    These results contrast with a simple cost analysis from the Eastern Cooperative Oncology Group database, in which the cost per resectable recurrence was only $5696 based upon 1995 Medicare reimbursement guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/27\">",
"     27",
"    </a>",
"    ]. CEA measurement was the most cost-effective test for detecting potentially curable recurrent disease. The contrast with the quality of life study exemplifies the tremendous difference between the cost per quality of life gained by treating a recurrence and the cost for simply finding the recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=see_link\">",
"     \"Decision analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23113201\">",
"    <span class=\"h4\">",
"     Frequency of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of CEA measurements is unclear. Although one study suggests better disease-free survival in patients who have a CEA level checked every one or two months compared to less frequent intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/52\">",
"     52",
"    </a>",
"    ], these results have not been confirmed by others, and no study has shown a survival benefit for any CEA testing frequency. Most published guidelines, including those from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    and an expert panel on tumor markers convened by ASCO, recommend testing every three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/7,8,18,57,58\">",
"     7,8,18,57,58",
"    </a>",
"    ]. Adjuvant therapy with a 5-fluorouracil-based regimen may falsely elevate the serum CEA level, possibly because of treatment-related changes in liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, waiting until adjuvant treatment is completed to initiate CEA surveillance is advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18,58\">",
"     18,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If CEA monitoring is undertaken, an elevated CEA should be confirmed by retesting. If still increased, further evaluation is necessary to identify the site of",
"    <span class=\"nowrap\">",
"     metastatic/recurrent",
"    </span>",
"    disease. Testing may include abdominal and pelvic CT, chest CT, and in some cases, colonoscopy. PET scanning may be considered in selected patients. Surgical exploration in the setting of an elevated CEA level without a radiographic or endoscopic study localizing the area of disease recurrence is not warranted. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'PET scanning'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of serial serum CEA monitoring in CRC surveillance remains controversial. Nevertheless, because of its potential to identify patients who may be resectable for cure, ASCO guidelines suggest that postoperative serum CEA testing be performed every three months for at least three years after initial therapy in patients with stage II or III disease, if the patient is a potential candidate for surgery or systemic therapy (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18,58\">",
"     18,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    differ slightly, suggesting postoperative CEA testing every three to six months for two years, then every six months for a total of five years. They suggest that serial testing be limited to patients who have T2 or higher stage and who would be considered potential candidates for resection of isolated metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18887065\">",
"    <span class=\"h3\">",
"     Other tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of other tumor markers, including CA 19-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/60-62\">",
"     60-62",
"    </a>",
"    ], DR-70 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], and soluble CD26 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] is unclear. Although one of these assays (the DR-70 (FDP) ELISA test [Onko-Sure&reg;]) is approved in the US in conjunction with other clinical modalities for serial monitoring after treatment of CRC and in other countries (Europe, India, Taiwan, Korea and Vietnam) as a blood test for cancer detection, it is not clear that detection accuracy is improved over CEA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In one study of 112 individuals with previously treated CRC, rates of sensitivity and specificity for the DR-70 assay in detecting clinical disease progression were 65 and 67 percent, respectively, and not better than CEA alone (sensitivity and specificity 65 and 73 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/64\">",
"     64",
"    </a>",
"    ]. Among patients with disease progression, there was a suggestion that DR-70 was more effective at monitoring patients whose CEA values were &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but the specific data were not provided. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Thus, use of the Onko-Sure assay could be considered for patients with initially low CEA levels. One of the advantages of the DR-70 assay, which measures fibrin and fibrinogen degradation products (collectively referred to as FDP) in the serum, is that the antigen is freely diffusible in the blood compared to CEA, which is normally attached to cancer cells due to its role as an adhesion molecule.",
"   </p>",
"   <p>",
"    However, as with CEA, an elevated DR-70 assay value should not be interpreted as absolute evidence for the presence of disease recurrence, since a small percentage of healthy individuals as well as those with non-malignant conditions (pancreatic disease, heart disease, coagulation disorders, acute infection, or trauma) and malignancy at other sites have elevations in DR-70.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Liver function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence does not support routine assay of LFTs for surveillance after treatment of CRC, since they lack sensitivity to detect early recurrences. In one retrospective cohort study, for example, only 2 of 109 patients (2 percent) undergoing curative-intent salvage surgery for recurrence first presented with non-CEA related laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/23\">",
"     23",
"    </a>",
"    ]. ASCO guidelines do not recommend the use of follow-up LFTs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to suggest that any portion of the CBC can accurately predict recurrence of CRC, and routine monitoring of the CBC is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18,68,69\">",
"     18,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fecal occult blood testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies support the use of FOBT as a screening tool to detect primary CRC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data regarding use of this test to detect disease recurrence are not as strong. The goal of FOBT after initial treatment is to detect anastomotic recurrences, new polyps, or metachronous cancers. However, FOBT is inferior to colonoscopy for this purpose since it has a low sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. In one study, for example, FOBT was performed before 1244 colonoscopies in patients with previous cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/70\">",
"     70",
"    </a>",
"    ]. FOBT was positive in only 3 of 9 patients with local recurrence, and 2 of 13 with a metachronous cancer.",
"   </p>",
"   <p>",
"    Based upon these data and the recommendation that patients who have CRC undergo surveillance colonoscopy (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Postoperative endoscopic surveillance'",
"    </a>",
"    below), routine FOBT was considered to add little to the surveillance strategy and not recommended in the year 2000 ASCO guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/12\">",
"     12",
"    </a>",
"    ]. It was not addressed in the 2005 guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ] and is not mentioned in the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, the role of radiographic imaging in the routine posttreatment surveillance of CRC has evolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray (CXR) is a noninvasive, relatively inexpensive test that may be used to detect pulmonary metastases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial comparing intense follow-up (which included CXR every three months for two years and then every six months for the next two years) with no follow-up, CXR was the test first heralding recurrence in 2 out of 17 follow-up patients, and 1 out of 18 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28\">",
"       28",
"      </a>",
"      ]. No long-term outcome for these specific patients was provided.",
"     </li>",
"     <li>",
"      Another randomized trial compared annual CXR with CXR obtained only when indicated by other abnormal findings [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/31\">",
"       31",
"      </a>",
"      ]. Of the seven patients found to have isolated pulmonary metastases, all three found in the patients undergoing surveillance CXR were amenable to surgical resection, while only one of the four control patients underwent resection. Nevertheless, only one patient (from the intense arm) remained alive after four years. Overall, only 0.6 percent of recurrences in the group undergoing intense surveillance underwent a potentially curative operation based upon an annual CXR finding.",
"     </li>",
"     <li>",
"      Similar results were noted in an observational report of 1045 patients followed after CRC resection, in whom annual CXR detected 15 isolated pulmonary metastases in a total of 350 recurrences [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/72\">",
"       72",
"      </a>",
"      ]. Seven lesions were resected, but only two patients were free of disease at the time of reporting. This 0.5 percent cure rate for recurrences detected by an annual CXR is similar to that noted in the randomized trial above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Updated guidelines from ASCO and the NCCN that recommend annual surveillance chest CT for at least three years, and the greater sensitivity of chest CT for the detection of intrathoracic metastases renders the discussion of CXR irrelevant. Annual CXR is not recommended as a component of posttreatment surveillance in either the 2005 ASCO guidelines or in",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     CT scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of routine postoperative follow-up CT scans has evolved over the past few years. As noted previously, systematic reviews and meta-analyses support a survival advantage for patients undergoing intensive as compared to non-intensive follow-up. However, the tests that were considered part of intensive follow-up differed in the five randomized trials included in these meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28-31,35\">",
"     28-31,35",
"    </a>",
"    ], particularly with regard to CT scanning. In some cases, CT was performed of liver only, or pelvis only, and all studies used chest radiography alone to evaluate for pulmonary metastases. Furthermore, patients with any stage disease were included, and adjuvant chemotherapy was not always administered.",
"   </p>",
"   <p>",
"    Nevertheless, in one meta-analysis, the survival benefit from intensive surveillance was most pronounced in trials that used both CT imaging (every 3 to 12 months) and frequent measurement of CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/16\">",
"     16",
"    </a>",
"    ]. Two other meta-analyses reported a survival benefit specifically with liver imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. The increasingly aggressive surgical approaches to metastatic disease, as well as the availability of newer more active chemotherapeutic agents that have the potential to improve survival, have brought this issue again to the forefront. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Intensive versus less intense surveillance strategies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other data to support the utility of CT scanning come from studies evaluating surveillance policies in patients participating in adjuvant chemotherapy trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/23,27,72-74\">",
"     23,27,72-74",
"    </a>",
"    ]. In both United States Intergroup studies for colon cancer, CT was not mandated in the follow-up policy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/23,27\">",
"     23,27",
"    </a>",
"    ], while two European trials did include routine postoperative CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/72,74\">",
"     72,74",
"    </a>",
"    ]. In the European studies, 32 and 44 percent of relapses were detected by imaging, respectively, and 38 and 46 percent of these patients proceeded to potentially curative resection, respectively. Only between 20 and 22 percent of all relapsed patients in both Unites States trials underwent potentially curative resection. Thus, routine rather than directed (ie, for evaluation of symptoms) postoperative CT scans are more likely to detect patients with isolated potentially resectable hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less evidence for chest surveillance than for liver imaging, and none of the meta-analyses addressed thoracic imaging specifically. However, in one of the European trials, all seven patients with CT-detected pulmonary relapses who underwent potentially curable resection were asymptomatic with normal CEA levels and would otherwise have been undetected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/74\">",
"     74",
"    </a>",
"    ]. The CT-detected group had a significantly longer median survival from the time of relapse as compared to the symptomatic group (26.4 versus 12.6 months), but not the CEA-detected group (19.2 months). While the greatest number of recurrences was found with abdominal CT scanning, the largest proportion of resectable recurrences was found using thoracic CT scan.",
"   </p>",
"   <p>",
"    In light of these data, the most recent 2005 ASCO guidelines and guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend that routine CT scanning of the chest and abdomen be carried out annually for three years after primary therapy in high-risk patients with colon or rectal cancer if they could be candidates for curative intent surgery (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ]. CT scan of the pelvis was recommended for rectal cancer surveillance, particularly for patients not treated with radiation therapy.",
"   </p>",
"   <p>",
"    Recommendations from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    do not distinguish between colon and rectal cancers, recommending that clinicians \"consider\" an annual CT of the chest, abdomen and pelvis for three years in patients at high risk of recurrence (those with lymphatic or venous invasion, poorly differentiated tumors).",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of unnecessary CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of PET in the detection of recurrence after potentially curative surgery is uncertain. Although early recurrences (and unexpected second primary tumors) may be found in some patients, these benefits are counterbalanced by false positive and false negative results, and uncertainty as to the survival impact of adding PET to the postoperative surveillance strategy.",
"   </p>",
"   <p>",
"    These issues were illustrated in a trial that randomly assigned 130 patients undergoing potentially curative resection of colon or rectum cancer to conventional surveillance (periodic serum tumor markers, ultrasound, chest x-ray and CT at 9 and 15 months) with or without a PET scan at 9 and 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/76\">",
"     76",
"    </a>",
"    ]. Because of missing data, primary analyses were performed with 125 patients (60 in the PET group versus 65 in the conventional group). The number of patients with a suspected recurrence was 44 (23 in the PET group and 21 in the conventional group), and recurrence was confirmed by biopsy or surgery in 15 patients in the PET group versus 12 in the conventional group (25 versus 18.5 percent), a difference that was not statistically significant. The PET group had a significantly shorter time to recurrence (12 versus 15 months), and recurrences were also more frequently cured by surgery in this group (ten versus two). PET also detected three unsuspected second primary tumors (one gastric GIST and two primary lung cancers); three patients had a false positive result, and two of 25 patients with a recurrence had a false negative result.",
"   </p>",
"   <p>",
"    Until further data are available, PET scans have no role in routine surveillance.",
"   </p>",
"   <p>",
"    On the other hand, for patients with a persistently elevated serum CEA and unrevealing conventional diagnostic studies, PET scanning may reveal occult metastatic disease and potentially alter patient management. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Clinical staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosing second cancers and polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is the only means to directly visualize intraluminal CRC and is the mainstay of surveillance techniques to diagnose a metachronous CRC or polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Perioperative colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synchronous colon cancers, defined as two or more distinct primary tumors separated by normal bowel and not due to direct extension or metastasis, occur in 2 to 5 percent of patients with colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. All patients treated for a primary CRC should undergo colonoscopy to exclude synchronous malignancy and nonmalignant polyps. CT colography or double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema can be performed preoperatively in patients with obstructing tumors. If colonoscopy cannot be performed preoperatively (for example in a patient with an obstructing cancer), it should be done following recovery from surgery (usually within six months postoperatively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Postoperative endoscopic surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the question of a survival benefit is unsettled [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28,31,80,81\">",
"     28,31,80,81",
"    </a>",
"    ], periodic posttreatment endoscopic surveillance is endorsed by major groups, including the American Society of Clinical Oncology (ASCO), American Cancer Society (ACS) and the US Multi-Society Task Force on Colorectal Cancer. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Guidelines from major groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The goals of surveillance colonoscopy are to detect metachronous CRCs and polyps (nonanastomotic new tumors developing at least six months after the initial diagnosis) and anastomotic recurrences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metachronous lesions develop in 1.5 to 3 percent of patients in the first three to five years postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/26,31,77,82-86\">",
"       26,31,77,82-86",
"      </a>",
"      ]; risk remains elevated for up to ten years in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/77\">",
"       77",
"      </a>",
"      ]. Over one-half of these \"metachronous\" lesions arise within 24 months of the initial resection and may represent synchronous cancers that were missed initially [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/31,83,85\">",
"       31,83,85",
"      </a>",
"      ]. There are no data to suggest that metachronous cancers are more aggressive than standard malignancies.",
"     </li>",
"     <li>",
"      The risk of a metachronous cancer is indirectly related to age at diagnosis of the first CRC [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. In one report of 6579 subjects followed for an average of 4.3 years after CRC resection, the standardized incidence ratio (SIR) for a second cancer was 1.5 overall (95 percent confidence interval [CI], 1.2 to 1.8) and was significantly greater in younger patients (38.3, 7.6, 2.2, and 1.2 for patents age 30 to 39, 40 to 49, 50 to 59, and over 60 years old, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anastomotic recurrences occur in 5 to 10 percent of patients, and at least 80 percent are detected within 2.5 years of the primary resection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. The majority (over 70 percent) are recurrent rectal rather than colon cancers. In one study, the only anastomotic recurrences occurred after low anterior resections (LARs); all were within reach of a sigmoidoscope, and none were resectable for cure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of postoperative colonoscopic surveillance has been debated. Two randomized trials failed to show improved survival or increased resectability of recurrent cancer in patients who underwent frequent colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, these studies were underpowered for detecting a significant difference between patients undergoing intense follow-up versus those undergoing less frequent or no monitoring.",
"   </p>",
"   <p>",
"    A larger study randomly assigned 325 patients to either standard or intense follow-up after surgical resection of CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/31\">",
"     31",
"    </a>",
"    ]. The standard arm consisted of CBC, LFTs, CEA, and FOBT every three months for two years and then every six months for five years. The intense surveillance arm added annual CXR, liver CT, and colonoscopy, while the standard group had these tests performed at five years or sooner if abnormalities were discovered during standard surveillance.",
"   </p>",
"   <p>",
"    Colonoscopy detected eight invasive carcinomas, only one of which was asymptomatic and not associated with laboratory abnormalities, and only one of which was curable. Furthermore, patients undergoing standard surveillance did not have an increased incidence of unsuspected cancer uncovered at their fifth-year colonoscopy. The authors concluded that routine follow-up was nearly as effective as intensive follow-up in preventing death from recurrent CRC and that colonoscopy only needs to be performed five years after the primary resection unless abnormalities are detected during standard surveillance.",
"   </p>",
"   <p>",
"    All patients with a history of CRC are also at risk for developing adenomatous polyps, the precursor of most invasive cancers. The National Polyp Study revealed a 76 to 90 percent reduction in the incidence of CRC when surveillance colonoscopy was used in the setting of polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/89\">",
"     89",
"    </a>",
"    ]. Performing colonoscopy at three-year intervals is as effective as one-year intervals for detecting new polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Guidelines from major groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent 2005 surveillance guidelines from the American Society of Clinical Oncology (ASCO) recommend preoperative or perioperative colonoscopy or all patients with colon or rectal cancer (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ]. For those presenting with an obstructing cancer, full colonoscopy is recommended within six months of surgery. Subsequent colonoscopies are suggested after three years, and then, if normal, every five years. These guidelines are consistent with past recommendations from the American Gastroenterological Association.",
"   </p>",
"   <p>",
"    However, updated 2006 joint guidelines from the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer (which included the American Gastroenterological Association) suggest an additional screening colonoscopy be carried out one year after clearing for synchronous lesions, because of the high incidence of apparently metachronous second cancers in the first two years after resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/79\">",
"     79",
"    </a>",
"    ]. If this examination is normal, then the next colonoscopy is recommended at three years; if normal, subsequent studies are recommended at five-year intervals. Similar recommendations have been made by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    with one exception. The",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    provide a consensus-based opinion about the frequency of additional surveillance colonoscopies in a patient with an abnormal study at one year, recommending a repeat colonoscopy in one year for those with an &ldquo;advanced&rdquo; adenoma (villous adenoma, &gt;1 cm polyp, high-grade dysplasia) and at three years for nonadvanced adenomas. &nbsp;",
"   </p>",
"   <p>",
"    American Gastroenterological Association (AGA) guidelines for colonoscopy surveillance after cancer resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/79\">",
"     79",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/\">",
"     www.gastro.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Proctosigmoidoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proctosigmoidoscopy is less expensive, less time consuming, and safer than colonoscopy. It has a role in patients with rectal cancer since anastomotic recurrence is more likely in this setting than in cancer of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/84\">",
"     84",
"    </a>",
"    ]. However, the effectiveness of proctosigmoidoscopy is no better established than colonoscopy for the detection of curable anastomotic recurrences.",
"   </p>",
"   <p>",
"    Patients with rectal cancer who have undergone pelvic RT are substantially less likely to develop cancer recurrence than those who did not receive it [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/78\">",
"     78",
"    </a>",
"    ]. Thus, ASCO guidelines recommend flexible proctosigmoidoscopy every six months for five years only for patients who have not received pelvic radiotherapy (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ]. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    also suggest flexible proctosigmoidoscopy at six month intervals for five years, but do not distinguish between patients who have or have not received pelvic radiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Transrectal endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following therapy of rectal cancer, transrectal endoscopic ultrasound may be more accurate than other radiographic imaging modalities for early detection of local recurrence. The optimal selection criteria for patients who would benefit from this more aggressive posttreatment surveillance strategy are unclear, as is the optimal timing and frequency of study. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28967?source=see_link&amp;anchor=H9#H9\">",
"     \"Endoscopic ultrasound in rectal cancer\", section on 'Follow-up after resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary and recommendations from major groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several organizations, including the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    have published guidelines for posttherapy surveillance of patients with resected CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/7-10,18,57\">",
"     7-10,18,57",
"    </a>",
"    ]. ASCO guidelines for surveillance after primary treatment of CRC were updated in 2005 (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ), and the major difference from 1999 was the added recommendation of annual surveillance CT scans of the chest and abdomen for patients with high risk disease (those with node-positive cancer, and some patients with stage II disease and several poor risk factors) who would be considered to be candidates for curative intent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    are similar but differ slightly from those of ASCO, as illustrated in the following table (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ASCO guidelines do not specifically address the management of patients with potentially curatively resected metastatic (stage IV) disease;",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    suggest that these patients undergo a similar schedule of history and physical examination and CEA testing, but also recommend CT of the chest, abdomen and pelvis every three to six months for two years, then every 6 to 12 months up to a total of five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Preventive care for long-term survivors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the appropriate primary and preventive care of survivors as they transition from treatment into the period of active surveillance and then to long-term survivorship, or who should be responsible for providing that care. In the setting of breast cancer, randomized trial data provide evidence that primary care providers are able to monitor survivors for recurrence-related clinical events as well as cancer specialists, as long as they are advised of the appropriate surveillance and management strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link&amp;anchor=H12070561#H12070561\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Coordination of care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data that address the utility of generalist versus specialist care in CRC survivors. However, in general, CRC survivors who are followed by generalists tend to receive more preventive care than do patients who are seen primarily by oncologists, while on the other hand, cancer-related screening may decrease as oncologists become less involved in survivor care. In addition, because many CRC survivors are elderly, primary care providers may be better equipped to address comorbidities that are often neglected among cancer survivors. These results suggest a need for a shared survivorship care plan in which the roles of the primary care physician and oncology specialist are explicitly outlined. These data are addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28202?source=see_link&amp;anchor=H617978533#H617978533\">",
"     \"Approach to the long-term survivor of colorectal cancer\", section on 'Coordination of care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SCREENING OF FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history, particularly in first degree relatives, increases the risk of developing CRC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .) Thus, when caring for a patient with CRC, the clinician should recommend screening of family members when appropriate.",
"   </p>",
"   <p>",
"    Both the American Gastroenterological Association (AGA) and the American Cancer Society recommend that first-degree relatives of patients with CRC be offered average-risk screening methods beginning at age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Assessing genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nonpolyposis colorectal cancer (HNPCC) is a heritable disorder associated with CRC. Its prevalence among patients with CRC is between 1 and 5 percent. Although the minimum diagnostic criteria to suspect this syndrome are controversial, the possibility of HNPCC should be considered in patients fulfilling the revised Bethesda guidelines for testing colorectal tumors for microsatellite instability (MSI) (",
"    <a class=\"graphic graphic_table graphicRef72965 \" href=\"UTD.htm?41/48/42763\">",
"     table 5",
"    </a>",
"    ). MSI is the biologic footprint of cells that have deficient DNA repair capacity due to inherited (HNPCC) or acquired (through hypermethylation of the promoter region preventing protein transcription) silencing of genes governing mismatch repair. Deficient mismatch repair is the genetic abnormality underlying HNPCC, and is present in both the tumor and in germline DNA.",
"   </p>",
"   <p>",
"    The identification of an MSI-high (MSI-H) colorectal cancer requires that lymphocytes from a blood sample be examined. If the lymphocytes are also MSI-H, this confirms the diagnosis of HNPCC. If the lymphocytes show normal MSI status, then the tumor MSI-H status is an acquired defect that is not likely to be inherited (ie, a sporadic CRC). Hypermethylation is more common in older patients as a cause of MSI-H tumors while HNPCC is more common as a cause of MSI-H tumors in younger individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link&amp;anchor=H17#H17\">",
"     \"Molecular genetics of colorectal cancer\", section on 'Mismatch repair genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other major inherited colorectal cancer syndrome is familial adenomatous polyposis (FAP). This disorder is much less common than HNPCC and characterized by multiple polyps throughout the colon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing for the responsible gene (the APC gene) in FAP and for mismatch repair genes in HNPCC is available, and patients with CRC who meet these diagnostic criteria should undergo genetic counseling to discuss genetic testing. The demonstration of a mutated gene can then be used to screen the remainder of the family and identify those members who need intensive monitoring. The topic of screening for HNPCC and FAP is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of surveillance after definitive therapy of colon and rectal cancer is early identification of those patients who might potentially be cured by further surgical intervention and to screen for second primary cancers and polyps. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Does early detection of recurrent disease improve survival?'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Diagnosing second cancers and polyps'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Early diagnosis of an asymptomatic recurrence increases the likelihood of a complete surgical resection if potentially resectable recurrent disease is identified. Furthermore, at least three meta-analyses support a modest but significant survival benefit from an intensive surveillance strategy after resection of CRC (",
"    <a class=\"graphic graphic_table graphicRef77401 \" href=\"UTD.htm?13/15/13563\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Intensive versus less intense surveillance strategies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend intensive postoperative surveillance for patients with resected stage II or III (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) colon or rectal cancer (CRC) who would be considered candidates for curative intent surgery (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). Aggressive surveillance other than colonoscopy may be warranted in patients with stage I CRC but the data are inconclusive. It is important to remember that over 95 percent of patients with stage I tumors are cured of their disease surgically.",
"   </p>",
"   <p>",
"    The following recommendations for posttreatment follow-up of patients with resected stage II or III (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) colorectal cancer are consistent with updated 2005 surveillance guidelines from the American Society of Clinical Oncology (ASCO) (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients have a clinical encounter with a physician every three to six months for the first three years, every six months during years four and five, and yearly thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although most recurrences develop within five years, failure beyond five years is not uncommon, particularly in patients treated for locally advanced rectal cancer.",
"      <br/>",
"      <br/>",
"      A history should be obtained at each visit, aimed at highlighting symptoms that could suggest cancer recurrence. The physical examination should include a rectal examination for those patients who have undergone low anterior resection for rectal cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest obtaining serum carcinoembryonic antigen (CEA) levels at each follow-up visit in patients with colon or rectal cancer for at least the first three years after primary resection, even if preoperative CEA levels were normal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is reasonable to eliminate CEA testing from the surveillance strategy in patients who would not be potentially eligible for resection if an early recurrence were documented. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The available data are too preliminary to make any firm recommendations about the use of the OnkoSure assay during routine posttreatment followup. (See",
"      <a class=\"local\" href=\"#H18887065\">",
"       'Other tumor markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with colon or rectal cancer undergo a complete colonoscopy either before surgical resection or within a few months after resection to exclude synchronous polyps and cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosing second cancers and polyps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In keeping with updated guidelines from the American Gastroenterologic Association, as well as ASCO [",
"      <a class=\"abstract\" href=\"UTD.htm?27/61/28634/abstract/18,79\">",
"       18,79",
"      </a>",
"      ], we recommend that colonoscopy be repeated one year after primary resection of colon or rectal cancer to exclude new lesions, if normal, three years later, and if normal, at subsequent five-year intervals (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Symptoms or laboratory values that suggest recurrence should prompt colonoscopy prior to the third postoperative year. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Guidelines from major groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, we suggest that patients who have undergone low anterior resection for rectal cancer and not received radiation therapy undergo flexible proctosigmoidoscopy every six months for five years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with colon or rectal cancer, we suggest that annual surveillance CT scans of the chest and abdomen be performed for at least three years, if would otherwise be eligible for curative intent surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with rectal cancer, we suggest an annual pelvic CT if pelvic radiation therapy was not administered. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT obtaining the following tests for routine surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fecal occult blood testing",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"     <li>",
"      PET scanning",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/2\">",
"      Johnson FE, Longo WE, Vernava AM, et al. How tumor stage affects surgeons' surveillance strategies after colon cancer surgery. Cancer 1995; 76:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/3\">",
"      Johnson FE, McKirgan LW, Coplin MA, et al. Geographic variation in patient surveillance after colon cancer surgery. J Clin Oncol 1996; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/4\">",
"      Johnson FE, Novell LA, Coplin MA, et al. How practice patterns in colon cancer patient follow-up are affected by surgeon age. Surg Oncol 1996; 5:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/5\">",
"      Vernava AM 3rd, Longo WE, Virgo KS, et al. Current follow-up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1994; 37:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/6\">",
"      Virgo KS, Wade TP, Longo WE, et al. Surveillance after curative colon cancer resection: practice patterns of surgical subspecialists. Ann Surg Oncol 1995; 2:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/7\">",
"      Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/8\">",
"      Anthony T, Simmang C, Hyman N, et al. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum 2004; 47:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/9\">",
"      Richard CS, McLeod RS. Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons. Can J Surg 1997; 40:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/10\">",
"      Tveit KM, Kataja VV, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer. Ann Oncol 2005; 16 Suppl 1:i20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/11\">",
"      T&ouml;rnqvist A, Ekelund G, Leandoer L. The value of intensive follow-up after curative resection for colorectal carcinoma. Br J Surg 1982; 69:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/12\">",
"      Benson AB 3rd, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000; 18:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/13\">",
"      Richert-Boe KE. Heterogeneity of cancer surveillance practices among medical oncologists in Washington and Oregon. Cancer 1995; 75:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/14\">",
"      Virgo KS, Vernava AM, Longo WE, et al. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995; 273:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/15\">",
"      Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002; :CD002200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/16\">",
"      Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/17\">",
"      Figueredo A, Rumble RB, Maroun J, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 3:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/18\">",
"      Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23:8512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/19\">",
"      McAfee MK, Allen MS, Trastek VF, et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/20\">",
"      Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/21\">",
"      Ike H, Shimada H, Ohki S, et al. Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/22\">",
"      Rizk NP, Downey RJ. Resection of pulmonary metastases from colorectal cancer. Semin Thorac Cardiovasc Surg 2002; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/23\">",
"      Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998; 129:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/24\">",
"      Quentmeier A, Schlag P, Smok M, Herfarth C. Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 1990; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/25\">",
"      Ovaska J, J&auml;rvinen H, Kujari H, et al. Follow-up of patients operated on for colorectal carcinoma. Am J Surg 1990; 159:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/26\">",
"      Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/27\">",
"      Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998; 228:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/28\">",
"      Ohlsson B, Breland U, Ekberg H, et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/29\">",
"      M&auml;kel&auml; JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995; 130:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/30\">",
"      Kjeldsen BJ, Kronborg O, Fenger C, J&oslash;rgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/31\">",
"      Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/32\">",
"      Rodr&iacute;guez-Moranta F, Sal&oacute; J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/33\">",
"      Grossmann EM, Johnson FE, Virgo KS, et al. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surg Oncol 2004; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/34\">",
"      Wang T, Cui Y, Huang WS, et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc 2009; 69:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/35\">",
"      Pietra N, Sarli L, Costi R, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998; 41:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/36\">",
"      Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/37\">",
"      Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol 2003; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/38\">",
"      Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; :CD002200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/39\">",
"      Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ 2004; 328:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/40\">",
"      Tsikitis VL, Malireddy K, Green EA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/41\">",
"      Chao M, Gibbs P. Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol 2009; 27:e279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/42\">",
"      Castells A, Bessa X, Daniels M, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum 1998; 41:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/43\">",
"      Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/44\">",
"      Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/45\">",
"      Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 1980; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/46\">",
"      Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/47\">",
"      Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/48\">",
"      Hara M, Kanemitsu Y, Hirai T, et al. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum 2008; 51:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/49\">",
"      Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/50\">",
"      Bhattacharjya S, Aggarwal R, Davidson BR. Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study. Br J Cancer 2006; 95:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/51\">",
"      Park IJ, Choi GS, Lim KH, et al. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009; 16:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/52\">",
"      Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/53\">",
"      McCall JL, Black RB, Rich CA, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/54\">",
"      Hine KR, Dykes PW. Serum CEA testing in the post-operative surveillance of colorectal carcinoma. Br J Cancer 1984; 49:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/55\">",
"      Martin EW Jr, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res 1980; 28:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/56\">",
"      Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 1990; 65:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/57\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/58\">",
"      Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/59\">",
"      Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/60\">",
"      Guadagni F, Roselli M, Cosimelli M, et al. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993; 72:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/61\">",
"      von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996; 16:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/62\">",
"      Carpelan-Holmstr&ouml;m M, Louhimo J, Stenman UH, et al. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004; 66:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/63\">",
"      Kerber A, Trojan J, Herrlinger K, et al. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther 2004; 20:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/64\">",
"      Small-Howard AL, Harris H. Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J Immunoassay Immunochem 2010; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/65\">",
"      Shimwell NJ, Wei W, Wilson S, et al. Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark 2010; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/66\">",
"      Cordero OJ, Imbernon M, Chiara LD, et al. Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol 2011; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/67\">",
"      Ayude D, Fern&aacute;ndez-Rodr&iacute;guez J, Rodr&iacute;guez-Berrocal FJ, et al. Value of the serum alpha-L-fucosidase activity in the diagnosis of colorectal cancer. Oncology 2000; 59:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/68\">",
"      Graffner H, Hultberg B, Johansson B, et al. Detection of recurrent cancer of the colon and rectum. J Surg Oncol 1985; 28:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/69\">",
"      Peethambaram P, Weiss M, Loprinzi CL, et al. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure. Oncology 1997; 54:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/70\">",
"      Jahn H, Joergensen OD, Kronborg O, Fenger C. Can Hemoccult-II replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy? Dis Colon Rectum 1992; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/71\">",
"      Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993; 269:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/72\">",
"      Bleeker WA, Mulder NH, Hermans J, et al. Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg 2001; 88:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/73\">",
"      Tepper JE, O'Connell M, Hollis D, et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003; 21:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/74\">",
"      Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/75\">",
"      Mortazavi A, Shaukat A, Othman E, et al. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? Am J Clin Oncol 2005; 28:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/76\">",
"      Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/77\">",
"      Ringland CL, Arkenau HT, O'Connell DL, Ward RL. Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. Ann Oncol 2010; 21:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/78\">",
"      Passman MA, Pommier RF, Vetto JT. Synchronous colon primaries have the same prognosis as solitary colon cancers. Dis Colon Rectum 1996; 39:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/79\">",
"      Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/80\">",
"      Ramsey SD, Howlader N, Etzioni R, et al. Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. Cancer 2007; 109:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/81\">",
"      Fisher DA, Jeffreys A, Grambow SC, Provenzale D. Mortality and follow-up colonoscopy after colorectal cancer. Am J Gastroenterol 2003; 98:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/82\">",
"      Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev 1993; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/83\">",
"      Barillari P, Ramacciato G, Manetti G, et al. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Dis Colon Rectum 1996; 39:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/84\">",
"      Juhl G, Larson GM, Mullins R, et al. Six-year results of annual colonoscopy after resection of colorectal cancer. World J Surg 1990; 14:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/85\">",
"      Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/86\">",
"      Mulder SA, Kranse R, Damhuis RA, et al. The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. Dis Colon Rectum 2012; 55:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/87\">",
"      Shureiqi I, Cooksley CD, Morris J, et al. Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst 2001; 93:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/88\">",
"      Levi F, Randimbison L, Te VC, La Vecchia C. Re: Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst 2002; 94:529; author reply 529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/89\">",
"      Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/61/28634/abstract/90\">",
"      Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328:901.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2493 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28634=[""].join("\n");
var outline_f27_61_28634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR INTENSIVE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Does early detection of recurrent disease improve survival?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intensive versus less intense surveillance strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surveillance for treated stage I disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFECTIVENESS OF INDIVIDUAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Carcinoembryonic antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23113171\">",
"      Arguments in favor of CEA testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23113186\">",
"      Arguments against serial CEA testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23113201\">",
"      Frequency of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18887065\">",
"      - Other tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Liver function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fecal occult blood testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - CT scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - PET scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosing second cancers and polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Perioperative colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Postoperative endoscopic surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Guidelines from major groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Proctosigmoidoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Transrectal endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary and recommendations from major groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Preventive care for long-term survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SCREENING OF FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Assessing genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/53/21341\" title=\"table 2\">",
"      Postop surv ASCO NCCN rec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24524\" title=\"table 3\">",
"      Hepatic resection for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/15/13563\" title=\"table 4\">",
"      Meta anal surveillance CRC surg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42763\" title=\"table 5\">",
"      Revised Bethesda criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=related_link\">",
"      Decision analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28967?source=related_link\">",
"      Endoscopic ultrasound in rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_61_28635="Causes of low HDL-C levels";
var content_f27_61_28635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary disorders causing low HDL levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipid levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmatory studies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial primary hypoalphalipoproteinemia",
"       </td>",
"       <td>",
"        HDL &lt;10th percentile in patient and in one first- degree or two second-degree relatives; TC and TG &lt;90th percentile; no secondary cause of low HDL",
"       </td>",
"       <td>",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td>",
"        Cataracts; corneal arcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonfamilial hypoalphalipoproteinemia",
"       </td>",
"       <td>",
"        Same as above except no relatives with HDL &lt;10th percentile",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypoalphalipoproteinemia with hypertriglyceridemia",
"       </td>",
"       <td>",
"        HDL &lt;10th percentile, TC &lt;90th percentile, and TG &gt;90th percentile in patient and in one first-degree or two second-degree relatives; no secondary cause of low HDL",
"       </td>",
"       <td>",
"        Reduced LPL activity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of diagnostic criteria for the different metabolic disorders responsible for low HDL levels.",
"    <div class=\"footnotes\">",
"     TC: total cholesterol; TG: total triglycerides; LPL: lipoprotein lipase.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rosenson RS, Frauenheim WA, Tangney CC. Disease-A-Month 1994; XL:369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28635=[""].join("\n");
var outline_f27_61_28635=null;
var title_f27_61_28636="Feminizing effects in male-to-female transsexual persons";
var content_f27_61_28636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Feminizing effects in male-to-female transsexual persons",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Redistribution of body fat",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        2-3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in muscle mass and strength",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        1-2 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Softening of skin/decreased oiliness",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased libido",
"       </td>",
"       <td>",
"        1-3 months",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased spontaneous erections",
"       </td>",
"       <td>",
"        1-3 months",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male sexual dysfunction",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast growth",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        2-3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased testicular volume",
"       </td>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        2-3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased sperm production",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        &gt;3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased terminal hair growth",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"       <td>",
"        &gt;3 yr",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scalp hair",
"       </td>",
"       <td>",
"        No regrowth",
"       </td>",
"       <td>",
"        &Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voice changes",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Estimates represent clinical observations.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Complete removal of male sexual hair requires electrolysis, or laser treatment, or both.",
"     <br/>",
"     &Delta; Familial scalp hair loss may occur if estrogens are stopped.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Treatment by speech pathologists for voice training is most effective.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28636=[""].join("\n");
var outline_f27_61_28636=null;
var title_f27_61_28637="Contents: Critical care calculators";
var content_f27_61_28637=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Critical care calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Critical care calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2706\">",
"           Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1123\">",
"           Calculator: Right to Left Shunt Fraction Qs/Qt",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F7C002C2E3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_61_28637=[""].join("\n");
var outline_f27_61_28637=null;
var title_f27_61_28638="FEC plus docetaxel for MBC";
var content_f27_61_28638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by docetaxel for metastatic breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"        <br/>",
"        Duration of therapy: 6 cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cycles 1 through 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluorouracil",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as slow IV push over five minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epirubicin",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer as an IV push into a free flowing IV solution with normal saline (NS) or 5 percent dextrose (D5W), generally over 3 to 20 minutes. May dilute in NS or D5W and infuse over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS or D5W and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cycles 4 through 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docetaxel",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS or D5W to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days after) and void frequently to reduce the risk of hemorrhagic cystitis",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cystitis in patients with cancer\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        The emesis risk with FEC is HIGH (&gt;90 percent frequency of emesis). The emesis risk with docetaxel monotherapy is LOW (10 to 30 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Epirubicin is a vesicant; avoid extravasation",
"        <sup>",
"         [4]",
"        </sup>",
"        . Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation",
"        <sup>",
"         [3]",
"        </sup>",
"        . Fluorouracil and cyclophosphamide are irritants. Refer to UpToDate topic on \"Chemotherapy extravasation injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not indicated (incidence of neutropenic fever is 11 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of fluorouracil may be needed for patients with liver impairment, known dihydropyrimidine dehydrogenase (DPD) deficiency, or renal impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. A lower starting dose of epirubicin may be needed in patients with renal or hepatic impairment. Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations greater than 1.5 times the ULN in conjunction with alkaline phosphatase greater than 2.5 times the ULN",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess liver and renal function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential prior to and during each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment with docetaxel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative epirubicin dose. Reassess LVEF during therapy as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        If ANC &le;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &le;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1 of each cycle, delay therapy until counts recover",
"        <sup>",
"         [1]",
"        </sup>",
"        . Dose reductions are suggested for ANC &le;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        for &gt;5 days, ANC &lt;100 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        for &gt;3 days, a platelet count &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or febrile neutropenia. Reduce dose as follows upon recovery of counts to &le;grade 1: fluorouracil (375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), epirubicin (75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), cyclophosphamide (375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), and docetaxel (75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        Grade 3 diarrhea or mucositis, reduce doses as follows upon recovery: fluorouracil (375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), epirubicin (75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), cyclophosphamide (375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ), and docetaxel(75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"        <sup>",
"         [1]",
"        </sup>",
"        . For grade 4 diarrhea, hold treatment",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesia:",
"        </strong>",
"        Hold fluorouracil for grade 2 or greater palmar plantar erythrodysesthesia, and reduce subsequent dose by 20 percent",
"        <sup>",
"         [5]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     ANC: absolute neutrophil count; CBC: complete blood count; G-CSF: granulocyte-colony stimulating factor; IV: intravenous.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Wildiers H, et al. Breast Cancer Res Treat 2009; 114:103.",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"      <li>",
"       Taxotere (docetaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"      <li>",
"       Ellence (epirubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"      <li>",
"       Fluorouracil injection FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28638=[""].join("\n");
var outline_f27_61_28638=null;
var title_f27_61_28639="Form for documentation POP-Q";
var content_f27_61_28639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Form for clinical documentation of pelvic organ prolapse quantitative",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 600px; background-image: url(data:image/gif;base64,R0lGODlh8AFYAsQAAP///4CAgMDAwEBAQAAAAPDw8ODg4DAwMNDQ0KCgoGBgYCAgIHBwcFBQULCwsJCQkBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADwAVgCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKzVwYCtwIpBg8BDwYvAwwxDAO0xrABBMoEKAkECwMQzC4BCQACBAEiA9Mn3MfgrdjFKMoFItoCDQMDDyIFCgMBAbnVAAoE8gIL2QIG8cHOfQtHENW4FPwWKEhwLoCCANysHSDAAJ+2fAAmQksgbUACAfLwKQAwsKDJUQdR/yDgpuxAgQIPGkykR2AktovFbm7rliAexpIng3pKeeJcAQf8BByA8OBBv2zXoGLUSXIaA4oHgQrdimkXgQP1COQaAYGBAAcQIBR4JuBqgLUL2krNSaCBg6oOVhJw4KyYVq6AJyVbBiDZWBEK+NVFAMBZPqgcH+PcCQEAWgIPEHT82S2wZ1Yf1e39TBowvmfaSqtezbq169ewK+H69Y7xiwTWaiAQBsgA7WtJduv6rQNmAOJkbAmwDaMAcxcMnts47ChbgHXnhJcAiWLedHJ/vIvoXIR7s9w72iE9Zwbi9ZEwtAOjbgN89REJihmwhmCdtgAL0KPOAAo0lJoLZ8XDGP93CfyyHwDwEMjeHOIBwIwDY51VmAMBxTMWRAVe44CHIvQ3wF3/DNDAgvYVZsBxtzTmQAMN/FIARAyg10IBCyB2V3upgXULbo0R+EtmImT2YIIDIMAhfPnJsw19KyQwYwM3toMOAPtB5M6Djf3C4Yl/dLYAAtxBgABMjYFlAAJHjlQhOvPMo2NhAzhXGXcD5MJdA+7kVYd781xIDpkEWEPjmz0yoA2HeDLK5QEGFNDnmwAg0KN5I+RznHcBPTCSo0VuV+c8xJk35xjinRlAWbhhuU+mal13TTEQvQmBotYIcE4D1vRJwoun0hcqWDz+wsw+vi5gy6HLLVAAmH101if/dwuYdY55MMmE64Ei4HKLdOJd65efxShgF3JxOITLNM4a0KOFdI4HAAR1MiMeMw/I415jPt1aQjegonvvti0qh8uEAhcGLqvyEOiwCA2M1WSbLgm8b70vDhAgSdQVIK4/JQhrnrDLQnuyP0xRqYeZIhfTrVrmHfBAzBOTcKo9OqdmLsgN9wSBy25UOI2oDLhDb87MiIUL04UpMFtFyjbc6QgFCzwNp+HuTNxK6Chdhru0lWtxLmulxt3GDst7V9YjEFunsQYDnfKUK3MZwAEtvjyCAsJwN5aQB4x3Tn45jzAyudoUsGcxdpU6Fql0GP3OAtLaC7WWmUK9D3sroXg3/wkEa2NyMWBZlvDIDB+ckXRizCneA8LwKMIBDuCucWrTzKMUYqaHPDJyp09J78oIFF6AmzaS9zI7B6gN+QEH8MYObtDEk3gLAA6gu+DZ48p3noMe2A3gV0NdgEwHNAB1m97nBc1VVms+cfHJ09h3ldTzBmTP71AA9e6CPk2h6Vua844AVRQ8GBTPbg0Tlkxk4g++HeBOpVjVIpyFBfb0JDax0GAiPoiFBECDfCBMoQpXyMIWuvCFMIyhDGdIwxra8IY4zKEOd8jDHvrwh0AMohCHSMQiGvGISEyiEpfIxCaSwAG9aB0LdhEA2O2IXS0QAM9cYEUUULGLJqAi0ZwYjv+2COABhTtBF3OEFKJ1ESQPG5YUrwGWh7RgP85LARvj0oIcKeVHZNyK41CwPwB6oztS6o7LcjSpLCZDBiLUo9gCeZIERO6QKvAIIVMQycK4TFhLa0EeV6DJO1ZkjpQEBwISkEbFzSNAWyQB4kqQgFf6zgQaJBaBVgVK8rBjf3n85QlmSQJhliBmgEzlSUApAuUICXaslCKalHILdmlQZAJQwANiRIKKiaAyLhhlMzIGA64FxhZg3OGaIAQBLBYympnkZByx5jLaWcZ94bwNObOIDvh8ZiIEQOUOc+c9DG6jHOPzX8kIiblC0qMo0EsnfrhRyhV8hR0KTQH7sCQUYhD/yDYGWIZBlUlSJASIARCY11Wc0cqSuhQJbYkGvHrEDyy+9KY+cEBdcnchAkBAphnFqVB5kIwAIIUZDbDOVcA51KbuYHnP4MdaWjmRZDr1qljNqla3ytWuevWrYA2rWMdK1rKa9axoTata18rWETynlmPURVMEmgItMqQ54pKoGmPpSDvNwDkxEKMMENALm66gUjIwjmHV+ALC+sIFULxZc/RKJ1Rxka8qERddXXnXFkAxrmGc0IskawORLRYKuwGPu1LH2DAugC+ZC+0JrqPFQlpRbtozwbS6UzE3dkdqyymKYZdXSMSawI+6a60J7MKRORr3mG1MQRfVE9sVpPYF/8xVCwvMiMYXEDecC+Neb1tQy1eCtjAVg0gfpca5FRyFjxB6bb9uQJUnsuO0RegJeCjVmKAe1AT2vIdBH2oCMoVyoSpYyAm0eAJ5kbI783SlRomhSBUkbZOZdBmBS/Ai+GLymPNSgFWbkVsHnncEg3RBAygsShg4WAYvJuWPxEkC7cZYBR0ey4hEUN0Z3MQW3VTGJJvAqa0Vcn8BFuGGnwjLCBcyXPMyAYMBrKKKIhiX0HjLgiO8EHPS04unxDAKHIfFJZdsjPtTVYSl/OQxt9MFlhwxCrrcZtKp6MT9WsdICblnJtepBdo9MCk/5LMT1/UrLTlHSLkRZScUOVwtKv8vLEOWLQZEb1jz2OXDEpCjYJgKQH4tMAbnEQ/LYq1Ay6OOFkHNVxuhr2elPo4sbZKwTD8kjsikpS3NDDwO21qEzHQlq3WkZhKsxNPb6dux/WtHWV7PBKtsaZGs/EFzRulOv9gHcTz6HIe8hLUi4LaUGx1udry10xkV9wjQ6BBfssMbhDZeDbAhp0QBwCk8pewQOAVOdZRgmkJi13JETAJsapObZGHPAZ7jzHGNe8FnBC7DxDOnhgd3wS26hahuwbBfLkWhBt8m0cwJ8GqaQAH+RPEtDv5JKln8OWArzJDrWucSoFwGwSYk9MpiYhZQfM0l63ONFU5ZdEo7w0nymb7/UaATnSRFJFDgVOQu/GE1kvvLJuBjsqoe9LrOU1PbkHMhP+TfKTPdoS77UMqLOee1l4DXI8g520+g3YUjqOZ/c7t0jfLmu9/RRoFWAdhJIueHu0DrHFSx0Is5luSxk75QccpHlqGMwC/B0j9lTPLYgcpCxmNFFYb2+EY69quTwOy05Jt/SdId6nFUykD3MjpcttHOLzgfz8aly1YCgeqJOfW+7+NSLraCceReBQS9YDnxbgALLl4ErEQ2C6xs3dFnkR1AN3Y0gm9p5U/nGdxwCT5sE5G2YnW0Ubz3gbRYePO7//3wj7/850//+tv//vjPv/73z//++///ABiAAigU/9g0gMp0FZW3dAYIRMmAOzNiaAsIRDWlBW8Fd4c1VzJgV5t1THk1WJhVfHXyfLqlgFzCCxDoVoU1A8/lXbyAX8bWWCnoWennXfp2Ki6YKR8IbZrlSJ3FAp/lYqI1gzegDFlwXf1ETSrRYK9lQs41R7SlXsqFaaS2P7s1W+MVhToDXFZUhUXBN140R8hVeF2UXU1YFNGVhN7wAOvRAkbYAmS4XWbRXS7wXaIUXj53hVVSJx7GSemFdxUBEjNnhvDFIw4wXzggDTeoBPo1AvzFab+3bryhYLrnDTP2iCdnUKgXN6Y3d7gUe2u2YmhnYYHIekg3iWEEIGhWFCHWfrOGd/9n5l1MxQKgmE8vcGO1uIklU4ksYGO4iGnwtWMA0GM00IAO8IBV8Gj1w4kkkGTzBHdI8Wdctx2bmIlJUmWk1x1ZNkfUiBgfEYoNFmbRWHB993ZolopsVi/XFwNkBmeXxAJ0Fk531gJ5Rn2k9HzP2ElDZz/TF29AcwPrswxqcozgYWS6xmqUxgCWBi66dGu0hG6fBksGRY9TaGr99G2qtmvYBiGvhjUO4S/EUW21BiLXBBJWJWm3dHIPs5DARiWrBpGnRw5zsmzn+G8YdQLNNlH0GG20dHwAk4zXxmHXkHjlRnwVmWokoG6nd3VI2V/5kW7mtozRgw8l824Fxo9yRwP/ynEF/BYu+ORWtxBwUoYABKdy2SRyJRBodhc3X+lw0ghxG+crhlRxa3lxM6k4EcdxxbRzILdyZolx/zaX7HJzHFiWCMd4YTSXMAeTo1iXLSCYPUdKevmYKvBzLkCPKICWRbccR5cCoMQL20CCYyB1d0F1BSZ4mwh3iOdOnLln2zh4BnZl24EOZRd73hibUWOJiKF3WAdvnHmZ55CW2+WK96CbasR3iSh7YQR4G+iarKg4vVgCqYldItiPjpdicoB5F7N5KFSaNqkiXQR32nmNC9aL2wg/q+dQrqeNtBl6JVB7uGl8lgme23ee4xR8LICdegWfi5d805mMXuR8cKZ6/5U5neF5fYnEArzHfdTTnxHYoA76oBAaoRI6oRRaoRZ6oRiaoRraRHLzWBvqQ9jwU9LAoB/KQgfBIwSQiCVqohgBAG6xojqUEkUFozmUEtxwgjQKQtgQINxAnDn6QsemIiRqBBWIoyVIWuVUDRtYcB0YA4TFoKuWg+5FgoLlpDEYWEt6TC0YHzDooT4ohDtSg3Vyg0/Khju4XUoKWRb4hXEDpnDQhqvlW64FW2WIS32Ihr42hcLFW4X5grOlhXs6Zl7YYGD4EckFbSjwhrKlW2eIhXGnhsKoEizmhnxheUwXh5spqK7oNHB5h33aDHp4Xk/oh+y1mAV3hoRoiHKwiP+38wuOGI4BJonkSIn6qIw2iYnzZIvc2YkqUJ4AMIuzFVekCZu8aYq+tofEejk+Ql4lNh+wiF2TalEu9pxeRK2EV6u+ySXWmmMiAIyR6gbIiJxIxhtK5jL36GS9Oo3zNI/iiWXyoJ5z1o3syWHguKtFMY46U469OZP4+JLqiK8qEGcu8I6iFI8swK4OZI9NBmjsQWOvmDNX2QbhGmm7dpAJKYWa1pBN+ZCh1nVv15EUGTUWeXoYCZTwkFETKWv4QWt5mrEc+JrQV7E2mZK/Nk9y15Id2zAxWZPJBm08a3ObxpMlwko7SW0s62zUl21C6aJPeWojOwJLCWXH1bTQ55D/R0m19xaV7rY/oGQ2dLCV19CVJQKYYTmW78CXfYqZw4KYhrcdd9mp6CiX1ESXPXt6b9txkUmWLHd2fzm3gel2Ifep/bi2c5uYYeN3L+CYzgqZ3sNzizuZqdGvcSeCajtFmrm4nkkSoCkGoumio9hmg2esJBCd9uqxW2Z1YReOwFEYs9mrtXl6/YSbwzmZ+iq7dadvyGmTPvpvxvkCuTssyomg8wKzdWWtPIY2S7sCwLK41RmLcICfmTI+ttedoBesamR9qjsrXjdO0pes6JCep0tz8zoC7hmO+mm9Ptt79DlM/QMdw5efuGeZJcCfy3dHAEpeAtoC8nu9Qnt2B2pd//MZbgv6owRcwAZ8wAj8Q6aVwDVUX9vwS6bKwKrxY4ehDHsDFRIcG9gAUBlDhESRwa5Bb4Vhb0ToFLsLwoHRdFKxDMmLwhMceSTsNC4MGzsafudAhDMMG+hHWpKbwz78w0AcxEJMCkUKYxgYAxqIV7gAmmWapDlLg4Flgh7opUCYWFvaWF16g5GVpbVBDWN6Wc83TXiJpj24Aj9Yi0GIpHEAp1IDbv+mhHRKqFZYW3gqhR0ZqHYquJ3zp2x5TMM1qItaAmFYx91UqXUKXcjqpwUGqUvahrJoyHB4RpnahZtqhytAWydWXqjoqVC4An/YXirwXmORqsJZBqyaEa66vv8lEKsD9km6WLqXGL4c9pwO5YkT9rrH9bmDhr7Hao4gtqwscMqPywLWKYvRqgIOO8sqaK0Glsyuo6sNtsmWAR/fKrEDCWm4yYy87GeR1GbaC3sngLCq2z1aBs63ipwWaAD16r0oBrCzx5m+7K/b47r/eoMC25jyWrDedLDWmLCetbC72LCL67VzMLEFOWkFV2mX1qYiuWlWK2wuKWqdGGvE4W1GCdFP7GooC7IqC31Hy9Auy6TEa5Jwd5PNVLPFSrLDJs87273YTJMu3WtIi0E6OdOz5pNCq7TbhrUW7cZRG5RTS5RM6dJLyW5SmZdca5VGyrng0W9imylkux1imUz/gUsfldtMbNuWUna3camQWc2Y18DVcZe3Z0uYI9ciJUcyNge4aNtyh1m42ne46Zi4J1yV00fW+iuqkZt9k+sCV41jl1uZY5G5Qg0HnTustvpvp+kypMvOJMGaXze8Ysd0sinLfrnNihO7qqu4ovuwqnu7iNuYdV0ivRvaOBa81iXZWWS8wYi8ibi8gl0iyuO8bwC92jm9J+ed4yvb/ftfbWvZspS/sPy97QOv4ovZFAO+5hu/raxGAay6rGSfnvy+28XcPni/pq0L2M0/Mc1njYW9xYd9XPTc3Tek7rXEQ/wa2LAM+5TeXOFRCrAgGJFUEeze4HBSKRUVuILB9r0V/zElDVERIIjY31uhU3YxEVHxU/tM4EFRVEel3wwOGFCFOcvSohF+4Rie4Rq+4Rze4R7+4SAe4iI+4jKoxnfEC5vLhUnan0v3RS5QpST+A9yVqWtkJYlcIme3ZiuoOHXE11ziDC+wRyc2yDEeBMWc2B8ru/+y2y5qDc3nSM6c5EFe30VOA/c83MXUrrzK5L30AlGe5S++zlW+AzWN0R9ITPghs1KOsQxpmIJmTAPjDVS5kwU25ypHvGOeHtTxciYAT30Llmuut31JvmNB2ynw5W3CxS+d5zmwTuuI5X4uu/Ocr+EsDDPi5frExWrH6DpAv6p7Ud1NigXWUExuKd5DWf/5kQ/PB+qr157KzemwHuuyPuu0Xuu2fuu4nuu6vuu83uu+/uvAHuzCPuzEXqIiQwPHnlhLt05s2OqNxTDR4aILggMc4l9EAlNB4BvkNaTFIB8lErJOwOxc5OzBLILR7ghOsdTpPlhl1zfnzrf+KQPvDjTCUspK+BKKA5M+PtcPBgTXfsn7HufmZBdIoaJBMO/BGecAj477iAgeBUgBMtrQ6RBSNiLElx8K4CC9YvH1ECDU0SAbIjE64/FwxDkmYlVM4iQiD/Lq0AB8JCza0CUmvw5WlSVaBmqHgfMBUBGgdPLbsQ4hwiQd/1AcAnr7wWCpgfEab3Y3gjUFECWpkSL/DxUjVrIoYSsh28PyC5ILD28vyAmc3aoib1PtEUI0Mp8bn+Ib8cAfSoMA7gDyRtUhwpIioMc1N9ErNGIs8vAiPK9jul1MMVEjTY8OImPxKg8fPh/yEr8Fd7F1yXPk1+A1/+YStA0RetIYsrIpuDIAksJKam089gbb0OcmzJIszVcpwZYrmsErIHP6RokyQdksvkEplkIddkTxnv8bua/6PeL6wQYn9yYnnA92uT8j0yItAgABDXARmC8ym6L84HImmbIpvyIRuXD7psMAMDESwC8q2wMqIyEsjc9Bo3N6Jm0ZLvEgoV8joSuNayL9niIvvrK8y+84jIEyisL+va95/5oPAoAIGISAGIuRGiOgKEIRDAayAE5TpIU7MAoPBeAgAAgOAJoNkgA0EoaDoTA4Ep5RF7fr/YLD4jGSMYAcGQ+og2sQwOE+l5rNDQRE18YRMEAIDCzlARAgCXJdFYrguQSKPPoJPAzgVbo0Lg5KPjDoHSkaRl5RWhKKQIykRo5EZhqW0pwCCDUcCL4eijQo4C3AIS7y6QEGjwy9PBnQLAQgKG02Kj7W3m621igopZadYem6OVC5NLSNGF6jd7nmoSMgCjTQHhw8SWrmAiQoDIgaaz4gFGDNiEy5ePnq80nXvmTpGA2sJAvfLDIWL2IMIw7BvQW3FhBxhGdkCxceB/+AvEPoiiJJj3KxGhEKoiN4iK4EiAGnJE2KkjIpmjlKQM44PDUtigkuV9GdLg48KPCSkD89D+JIDWao5RWltBYUAJuiDR52m6YJgpr1mqoHDhg4ELTxXlUvmRae66mOi1l0kSIxgDBn5kMGClrUzXvt7mKqfq7K+XEkEgQE3PKN1CkAcc+Mnj9jDOCpgJFnIgpwG/EmjgwXpmmlpokaQKevumBCk+yzFbShAsCK4FjQ8VkBcUUYoQuuK3AAwne1iQeOt14kzZ8X8pEAl+MkjOTReqOV9mgcXl8MIOL9RQDUPhjkkTZZEAHt3Lk0EPQs/ujkiUmUNIA9jITEETqYHRX/yQEGquLDQDkcIM5CBzo2QBslTCdCfc5B8wcmnjwUAHg86OZKM9UN8tscDLIFmosvdkHaALYIUAd0F9loR0ELDBAhLdr4OJWGegioG4WJCDiUPrf4ONyQxQHAwAHagPKNkgkwaU5wA3DJkVdcJpAPlj1qqQ+P/DzkR5FS9iheXgUAGd0/wRFQkjYz5oFlfvHlgZaZ6d3nAjIA/DLPjP5lOEWPII4A5y3toGiCIxD0SByEUxZwQwswKPfQDUD8t8QBngRAT0WKIpAPm+PINJ8IJcyBWZ5Z7gajrbfiKgZjufLaq6+/AhujCAoMGKyxXpx3rLJfNLSss8+Ctiu001Jb/y1GQDJq7a/JahusCt2CG66445Jbrrnnopuuuuuy266778Ibr7VzIjHHRYCwVkACxVILD0YIZEvGCi4ikN8X9BqLgL29ZmoRwmIwwNHD8lJcsWd70VnRGGEq0EwAy2jca0teoEMvxthktK9dIXOxgMIuqHOyizJ3ETGwAFtEsxiEWdyzzxhlAcQIveDgGSui8dNHXA1gp48OO9BAUDzDLDEjCiBVtJ0CB/6YnlQEBCAFP0xnuERcIBrAjz1wON1AAy1w+bEjbk8G9oAC2F1IXCHBeYkLaVtNQpgDrIF32M7lZ87HH0uBBN2MLMPTAyUlAEh+CvgwAxDKPGFc0iKYYf/hk6/aQ1CecU/4s+qrgyFpAwQJtqAbI5W1TjBM3JDDDj38EMQDRoS1ggosPCAPAg6QdpULOvCAjiGv54CCCShwlLtSBLQB/S8FbCGN70TA0Nqrww8/vWrmZwHFE8nB93f15m1f/glTVBFKJQZcwQILhdw/NOw2tAAZ7dvObWqQuxx8hTMwywEE3NSaLfCMdRJcnV/kIo/auEAqrDkKJG7nGIQEoFCtWs4kBPIALFUOLyMox5MMoYBylEQd++hH2Sr4DkjIQz63qUhAGLGGk8UMIjfAA5pcMMO6ECYWl1AHKUyIlBHkriHVEIRgdCEkTdTIG0+URC8e0MNloKRP35j/IBl/VsEX8OgARVMN7QKgEJRVh3BYKdFNiCKQPNToRCPDi/NEsA80aMIwnLleB/9yHz/tyiCQ4kIQU2QEOGBHkEmpIz40o8Cf3HGLnxiGWh5xxisaYi4RXAIluBeDsUBJZ2VcJbvQUYcqFgE7GjSK7Zy0CBGd5ih+ksRr/vCy44iODnkoQB/70L4NiQ5DhIzSGqr4IB2+JGC9ZBHM5kAh1AgHO8lEIhZ8oKLgIOUK09SkPlCiIfsU4QjHAeUS+jNGKEIFCkpYTy86xcp7vosAPcKcDo4RsDEcjTir0qWr7lGqA+RBHD3iiEIzGLc+lopLDhrVpxgQKn1i6lKYg9Ij/1CFCVONriCj8skzKuUaHlmUhKLyxJh8xMQjHNRSXHCCH8+knwO4TRDslBGNNNnAcg7rFg0QIznxadSjllGVSAXNHJq11KdCNaowUqpULZIAHg1gYVXdKle76tWvgjWsYh0rWcsK1lQFoEwWMUBAEqDVMbxsWnEVg8ou0rfjCY0O/HrRxNLFvaaZNbDkooEDBFDPi4gjAUQBD44AqyybjUFaYVDAGm5QgIVJx2gmCw3LLsKte/VVsKKF1gFPg5GfmrZvhKicW07RHik4wByxzaAsvCmAujrHHmyNEpfMMTW5NS6t6cGh11qUgxkVtg95SEEvQujGH1DuaZmrLeIu4f/cN+ptuAjQ7RriIrq4VYEfq0WA8miw0aopIFXNOILWWmCAwVXObVVwrQ9iMNr7dks0YADZSN64nqekoU/rdZlzcHCFsMChOcOKDxECAAEGDMgA3EBGG4JHP9JUqRBaeAIKaNPgWYiDB2FyTPJuawSeWEEmnigee5ZAhMoIYUmbYeSG3dNOy773BTHAcJQE7Mb2HccwznEAljaTgB38xjoyaIYQiJCc9dQIv1KmlmRPw5oZwxGKHkNTS5BBrHvcQHYuSE0qpLWFb2URDRgMyhgbMcUWsRBFu2zFKVpiCDITigGtAUyXfPLl4UFAeZsYYk4E0RIIjOTO9ooE1f6gpEf/NOTLepgypZ115P228Y0S5ssjT3CPr4TFBy2xBiPzIq1A3FCUdlwIYRrRyUCpMB9zhkSd+2CIINZCMOc50g36SYKIbiIJcZCYrVnzRCW5hJKUscwPKu1sY6GmDwYo0yyd8gNC6Aub4BwZP0KiCAaAO2AslI5kefQE/WL4OOnsVCM2REDG5CQ4tcHQPZSSthH2c9zy6MMjc7PAa6DkCAMjZjthk81PE27b9gAENGoTFpWa6BT3fjbFfVWwW+xxDI7iUmWZRFQ6BcjE8yjWO/os2QcUjafsm1KhWp0nm7Zo4+1BackK+pTBYLx6XPKQLUaqJn4daUmvYpIyboGAkiL0/9Pco4fxdt4GMDkqSMpGBKwKsteKYz2wc/iWtcKkQl5JulxOJU3Wyz7aNF4dWvX4NK9SgC6uk0atZp873etu97vjPe96tzstjRYZXM0VRpDlAs72bvjDtw4P+XmrGMAWQseWegyDh1HGO4j4y2MeKQQEmgiO096uYc5wHE4c5BjXgqkpN3LLQ26O9QG3N2rOYMcl2+pFF4/iohfymd+9V/dCYDrTjoPoOPKRpYID6DlAevOjghWwcL/8kQ8x/ev8AUSspD0O0II8UDCOORxAIgj5eLwfv1j3ssfVzBFmonFZoxHwQgfEUARKXCQnnHiyOKt0j1V8BAhFSIJA98Gbwf8S+RHgV/keZrWR8LENwrGXAgDSgVhSOK3aJpzMyFzfG52RHP3dqwDbqxVVAYLgU6mDAgQM+m1gSDmceYBOO3jTdUjgOJ1MvDmHafDYHiXHceBSeKhGCxCcuxnawoVgEIoglyRdRuxF1JEFxk0US9HKS4lKEZ6MzMlTT+3RM/ACIgyUahDdn6BJyQWTEIJhGIrhGJJhGZrhGaJhGqrhGrJhG8LLP+ALB33BlYFCt+DMwFwEblkEdmXE2XhB4VkLH+ZKw8DVP5GBfhiiG6YLxqRHqaQdJtCARHxgrugMpO1VlVUZGCBM5bkBWCyaTQALVflBsABiGHxW65SNIqpL0ID/iCIQHBncBfYMFyPgXkGcTd/0wef1TejlTaPQgMGwjXc93f3c3kYxxnvRwNo8zhIITtSQANbQViU4yHrtiBsFgjNWl1p5joeU02GA3tccTsEkk2LFhx+lR0ksjuRQjuUUl+ZAmOAggQN8DuCQTUywzbTBY+iYQ6io4iIeAfQowqbZEUl0QSxuWI8dF41BwdtEEZIdX3cpXySdziB0n47JQIchA2P8hsK4jP58iyjETxVAxRvVU7wVGU+c5G8s2Qow3x7RQKakQvElGfJF5IV1BQQM1SLIZNHok9wMy/9gJPhN5EsYEA7YQIFlyCNIySZU2EemYj+eSwYSjTJc2VvF/yJNIBoeYEzQPU8f/MH7xd9MeRN3SJigZcKbaSQi4EEPkdIksRp24ZlSGNInzB8kbpJXuh8MPcn8sUJXEoMmRRERCOBY7tCTHFEN+UF6DUOaWUloQSW4ZOBVzMFA4oEcXiUFGtu/5QJXNOADdsEZNcIyWEMmeGBaQoQiueU9ZFwQySUo/kQE2hJLeGVntpkl9SUDktMeHIEHflKgGIIkhYqAwAXKQQixpeZjLiLorMH5VWVBnsKRJJxzRF4upCASrGB2cMENkiUPGoJ+Yee7zYKCHF2HMMj1qZW+lQ2U1dE3SaeTzEZ1GhMLWseK3GZ1ktN28CQ6aWdhLsI2lc3vSP8MLrjTcSJnVO6TqAliGFymm/UcYz1JLiChqEjUSrkGTqFJZW4hqlwVoLSIAFBKEcbUkChJQ0HRznnJnIDJldDKjpDJj9BDEk5oqTAhmdxmhBYVTXHhTeUUfxpCRYXKAdWTyjVmgbbhKYpLJopLU4UEkTIprxhpuCBpuGxoVjVplVrplWJplmqptqSfwOheGOAhGSSoF+ghaGDXTdDCl5LBXXnB5E0LIf5K4IFBmZIBzpSpAwwE41XLmDLLI5KBm2qilDne741BAwxgHl6dtPQValJe5PVoIl4EZdHCCLEdr0Spc0CqrQDqymhWh+rZ74yLY9pllmnibOZMYOnjk6j/mxgw1yX6IQmoDSSw19PAzfQxQjNGp0zcD9K0xNI0TQJIFzauVnr0UY5to9IEzt/EKnNJHDQSjnzR4nnZYl4BzsLtiZrIjXnZ1r7kmOa0BxLc1oBs16usQao6zlC1QHDtDXEZ4yw0jqftxNicqHGdRmxEKwrAV8G8zRcgY5EsQeRUq3MQBHkxY7/G174Wo4PMwnV141Ew62NAK3pplSwSwbiSwBoAq9tozsCSntnM4s80pQJd2oiNRBd0gq/BTPaswfZ0T598j0UuDEiupAuEj+bYAA4wD++omBAAj1PmbDHhQlHqzvYtDMu61Ug2CtICQZMh5KpqiMoSigxsAYyt/0HNAhkuPJhiCUJJNljWqsaEEUHIXlhyhMJBBmWLSAMR5M/78KcR4R/oVGxhxU97DMo6uExYGMj9GC0UtEdlJMXcMu3ZMsZJ7mQGKe3LXq1CRoGN6dfS/s5K2iQWHOTPMGYhrF/1XFkXyM6hYtEfwEMOEdUVLRCy9cRBNJf/1RslPc8+iqhvQsHpKsQNOU6l4uYjZGUAbGUHya50LICeKSwqJNo12K4q0OuZnZ4ZqFkrZtiRoGV4ZsM2+BE/VIW0bJe/AcAAPhrC9MWW4NA8rF1q+knz1sQu4KVupO71Bq9m5sGfvR4J1WXQ9YyqFcIC6kMbuYE+nQHQFRIoQhOs5f8F6TbGkGig+CyEkmyFrbXuQwzwJ1pexnGmLphAHEReIMxlrs0AVRhbJniSqWkMqsmF7ODESiwvTZRmRQTaWwSZN04vy+zRXmTvHKrlIs1llMASN+lCCY8vblKqn0Qw/T5oHvQaeOwSTkQg/FoMuiGKa2SuoIAIyj7JKznIGvRvwZUaAHsnU4wIQanUbw4T0IZIFo9ZFNNuMPlJdDaNKzWTGPMbUbTiwAqvIKBnuRUJEhsHIpBtm8kneOLHTfXJhaywa2QOaunBwr3wMvCFHVOTM3VXhECDDXsSOmlkw5VHIphDGbux+uqBCA1xgq1IrViMkE6i5j7HoWLURolDRk3/sUf9LyVp4R+oCpNosQHTwkMl8Cu3yfLQw0ZlXEOFb4My0oFqlA/0nCegytLh1Bs7h4nSK22knFCtXMeM8CZs6IXyUEgUio+2LYT0CL94YWFNHRJgjIeaFFKcMuZoio6Br6tMs//+nI2OAC+7ijE76G5gyQipaIsacVmJYtnts7ZsnRxSrqiqTtjhXT9jnUFXC9qV0ZOqjttt6UNDdERL9ERTdEVb9EVjdEZr9EZzdEd79EeDdEiL9EiTdEmb9EmjdEqr9EqzdEu79EvDdEyD6wahmJd4RrV52kUI9BxaxOTRaUaUIhf8Vcr4qbb8dBjs9BcENVFHSVGDAXYQhZ+y/1VUhEGYyJ1qbNB+saUX8FdntYJWPxcY4KlbiYGajoslSMRrMFMoc7Uv9MJe6QxCd4GouqRXg8EM2wVBcBa6SBYnsjVAJbVKzIOe7lcCqIOwHVYXjMVV6WklxAPLDKTfdEFczNYcdpoYbA0YQFgSXHUZZNFTmwG83AXXOSVotMTniR5vBdNeWCxb0aNwaI1A4CpBbIff1HXXrBat0gINvON1XWOunkZuCBeIsJYMUFcj1HZua2x1EYKvCjU/BIG3epM8/sG6ts0ObIJqPWOQiteQTI4fYUdxS+xuz4hOKVdw5McaaDesok79ZgRRqMM7TsEXYBBBV9NTtgxAE4p+k/8qGHQCVeUIKjJLERFeel/3xlbLXdTBa9AMyfY1ezkkCZhPyD7RpnnYUebOz4poSNaL+lSqqwWYHyDuRKYkh7/zc0JtGBkWgwWbMD+B0LAY1Q6tziLHEyQf11ZNExwkjIPuusFHifk4pLSPjcnEeiVu9j1ECijMGrBPHiRHYltvV4d15H0azWAQJi7APnR2QSwp4YGENM4hpXjjgE+iARgGYUPCGiHLnCh5jDluz/J3sNyFadgIzeCLBM/1P5bvYSPvO+3CE3zLYcaZF98DGOnRG+EBoXGZq+yfTrmmSypEBvYBnoUmM3ycIfTuA8EuPI0Z8cpKlVPklhnaESg6fTz/oz50+afdrqLxKHloGRH9ATTcxT/gNEA7YVGFBbgVYc140fd+AWrodxJsCstcFm1Yb4n6gCplxZbPA596BQYVMCtDC2OoANc1uP3mOW6ig/yGs+dGiQqDejqjkg4Nh7BB0vn2puV9eKQ3MAIPSWUuAFlcOi0Uj2AsMKkG0afbmSMNW711GotEgZhRag+PETvdhbmfgFlM2t9kGsms0KSbovtd9WvMBhjI4JqrexjQTET1Q19xC2kUtVcwxiZT2SywiWJ0wZ378AjZ54bQsSaZmx/4MUK+IjfR08dBhLZJp5/sp3p+HW6h8afFsRtBQz0pQj+tcQ6SSL3yoAEM/Q/f/0M/4YHOS0yF+a10+gWPZPtjgNN+zhtIBgfV21j7LHyjXJmt+5PulLWa/00VlVaMCLIX/JR3prw3Hftn3jWB/Lqv3/WcJNnOF5Qi+OSyHGP6aMjOOXUiHIGNyigonwxxFhiozLLkp/MLCBXOD5rHna8Vyl6KSjsJaAUwt4QXckQj3ElO9kifDTPowDIuc4kNKLO+51zmm1RDIR39xfvWyzOHXOFXUH5EGY/m60lOIkGqb0zHP4EVLBQYyOuczv4XXLxSC5WeKpTAC7gXNKieOpgyt+kBUErTAP/50gWfjtUcOLSyKOm1uDtfkb/ItP9asX211IBMV8ynWL+xTCmaK/82gck1CADiOAjjiabqqpbsqyoJTNewwtj6zvf+DwwKh8Si8YhMKpfMpvMJjUqn1Kr1is1qt9xuTwAuOAuIGiJ3AgsML8cAnUSA2SKEODWwJeAoxoxl8hIw8JdS0FCWgtBw5+X4CBmZRBAQsJC4dFYjkHdCGdAw0HhisFAwqlLpM6AwiMaA6YmiilJwgDpiiztC8JLQAFDQmxLwwPIQIKm8zNysMuxmoDCACGCQIJDMMDDgAPBAlyAXqiBW4DpzDSDgMG0iTV3GiTIMkNDpVm0ZIFAwnRxsGoMC3AIYWDQAIDYWLoSJSMDmXisRBNwoEFGQjogAhVQkAPhsFisxBRP/UOpoC8YtZyxbuswy7NdBAAgWrIPQIJm3AgukGQMA4SCbBxcZJLu3Ls+ggzZn1kxK78QlB4xKFUhwYE1WAEYBHJjhAIECBf0g2PmZkKGJpwBKUC1gYBiBGQ1mjO134gANvSvqcdWZ5y4CAgJiOQC5IoC3l4wbO0ZCicEle9N6zRMhYBuEwjYTXCzwoMGBPBDEzJtHK2ZlqLJICGjQyhKYPDUrTUPAdyPABQzw0hgwenLb14vl6gZA60SnF8tT+IVQKUCv1MQCAUL8OLv27S8IB2KggI1lfAfKuCjRwMSBBwXmDTutFGAv8OJZ85JK8IGa9nkEZAUjR3O0gNZAab+V/5VICS4AYBxyySRHwm8s+OUdGA5SVB0M2XDHYYcc+tWNNeNtlIMtJtxjE4NiILWVG1BRF2Jc9mEoAg7IAROMAfMUYFYdPLIBVwBoBLLVQiu4gICBJXTlEIPHCYmHhH0p91MZqaGSQEceaelhl14241dNb4wYzGiiBQLBHwkswAptBzQQyovy0cQmA2Tyws0BIDEw2gE6doIbcDqNNoABBoy2yAEHoJHWkYFgRVA/3NhJoyqHDhALWS8IcFFf3BByiKLA0BLAoqQ014JGX67Kaqsn3OEZq3eUsoMBqKJQ6BKarsCpq77+6uWa3OzCoZjl8QDeCjYuUUosI9SkKrDSTv9LbbXWXottttpuy2233n4Lbrjijktuueaei2666q7LbrvuvgtvvPLOS2+99t6Lb7767stvv/7+C3DAAg9McMEGH4xwwgovzHDDDtegoxrrqBHtCGqEkcQ9zj7M8cDSEQAygyBT0tfIhPkgnXWznNxxywQLQMByA7D8TIVXGQTON9QsxtEDI9lKgAxccaOAlTS7jLS/MMt8ND2fJDMzBITZyUADFYl8wAJB10SAqQsICYFNKSdNdr9Lk9C0Jya3RcAdEOglDDAxBzP32OtoNl3aZe8979kY6U0RiPXMzWAehNd9sgMENODAAXmrzHfk8BrwQNcm+EdAzoTzIvgIVh//lnnhFClFSTaUOKA1coBLzjq6H4dscjKbB65cPYcQAAEah+dRyuK2ELBA6na3Tnzxxh+PfPLKL898884/D3300k9PffXWX4999tpvz3333n8Pfvjij09++eafj3766q/PfvvLkDGCoTpkqcOtwUYHuft7X3ahIABBCAO/BIF/jxiAftagP9bxTxXi0A9yRtKWhBhASO6wBja0wY3ioCABVGHEIKoUCm/AQx9fkxhyROCGEFVhQQlU4HJUMYASdsVFdzlHoZ4iAJzoJBg9cZJyBvKArPDEUH6KlFM6k5UJzqkmcOESFIBDiBZKboFQQ1N0pvO/OfEvMwPYjA9dw5oS//isEmnxzMxYQx0DQMCBVmDDoRYjxbJRcTgUuVj/qHOZxpnHBAJ0wWVKEACyzIE+TroMdaxRKvtJAYBxdBlP7rCVBRmwDshBAx47ASUTfREjl+tECQRgijrEyDJ8eUAOZCS/JlEhECpsJNkaJyhOiiBUb7IGoi45SzNtpY+dlCVWgBOWOg2DGwngyZhsCRwnPkE0pnKlM58JzWhKc5rUrKY1r4nNbGpzm9zspje/Cc5winOc5CynOc+JznSqc53s5Fv+2tlOBQgQnuw05Tzpmc5Y3ROf5kSAKDbJT3QmcmaKDKg592nQgyZ0oQxtqEMfCtGISnSiFK2oRS+K0YxqdP+jHO2oRz8K0pCKdKQkLen3KMcRYqXgnSfQhHJQYAeTwgABlagYx7DiAAE8IEUSImAaUCVAWIREpgBgHOps2jCr5AKF8bDgBzeCnBKOUB5AtchD2LCNEMGMI+qwBxtSCEeOHstlpkzBW6wCyn70sBdYWcMRZ8QguszABTvpSVwK80fONLGjnMIOx2jxqaLGZgGzkeWdzHinSlXxbl3kI2Y8uYY1stSiBmgcUhn2C1kYcD95LWQnCJlYH8KQHcdywXsgi8jRfJSRD1tAIaaDI7h0lpQYEWFohzHaTO5SDLgpk1vptlH5tUWZSZ3GpETAJ+D8ybAYIYSYKOVT3FbRFtT/2EqpciCaM13qK8HtEx+ICt7wine85C2vec+L3vSqd73sba973wvf+Mp3vvStr33vay6a5gy/2mNcAgzE3+2xMMDX+xGBszeRA19vLApecKcaTL2lERPCFK6whS+M4QxreMMc7rCHPwziEIt4xCQusYlPjOIUq5hhG1txx85QUBc3zIwyJptPa8yxG+PYYTreMcN67OOE8QkCmAqykY+M5CQreclMbrKTnwzlKEt5ylSuspWvjOVy7scIMRWCcB8yA/p12QYujQJoDILlTwinOzUQqhDoNwJVqMLNNgCyEgyIOpU6GRp5kAiQplGOrc4AITyb4DXY8Jr0bMTQ8fuI/3PhhOh3GPdBR2GDYlgxy3+ggBNPzSlmvHHpgVQQAPkowzWeqgKe1CisFouOq/GHmVe/OhDZkDWs12HrW9c617TOdSV67Wtg8zrWwSb2sHFdbGQfe9e2Fnazjf3shsWkLowAZVGNEZa7IuBQBohU4QxSglIYaq0StBhheRIA0FxEFVuZyGjjWtQZbKUr5lZrZT3pjbkUtQFMIXVVTJHWIarAkH5VdrSZLWtnJxzaCzd4wxE+a4ZH3OETh7irFV5xX/ND4hfnuK41jvGOS1tIl1B0W8TCODoMY4yDkJ1rkLERY8yzs6gJQG8v9G7p1iaQzemsXVMkXQzBphKE7exKMf9ZcCh7R5Z09IwXcStIBNYDkFkEaBh7+WukX8i0uvGPGmLRWaIw4CdBd9Jmw2B0mGLyJ1X2S1lV/R3ZmSaUNPliCW5e5JmjtuY8EkNXcq4bHiUC7KjlCd3LDttZLpeOKjDQWNv+KgUoCtSEEsN17dGnfIOxVHqi0U9lWXPMw4nSdAx6oDpvMdQCYFminRNX+rT4AZ8AK83M8rV6aHt9xSr3vO+9738P/OALf/jEL77xj4/85Ct/+czvZ/PRBePnn4vG0jeXnavPretjX1va3z62uu/9ag25yOEvv/nPj/70q3/97G+/+98P//jLf/70rz879XtZ+3PIvwDWf6tk73//XWJgAbgqCUaAXsJgB4iAD6aAHSJhUdSAESiBE0iBFWiBF4iBGaiBG8iBHeiBHwiCIXheNIVmSbNlGvIDqEJnL1BmIWVUuOcyatZiL+UDvLQJMdZRj9cyfEZqTXUNG5IMpzZJNBFCyJVBnocRoMAIwdBy5jAIcbJf4uBRfUU203ZWAKdDhXRudlVEdMVD9aEcyRAaq/cgRXEUecAk/RdclpU0kVFyg1VYGJJXLJcWXPR0uBIIvQABI7CHBjIPtLJ7q5V00mYhbXFA/cA/ZAJIUVdZpeVYypGHX9QLpyUCdaGDGSVcEBiDJwAKipeIVwdKd0BTJbJLeOhvReUNr+EV/ybgIuvAJh61Xd/VMUEFe5/YWb90AA5AXWcCUFBUZP7EDWWAG7CxHAvAaiIICbSCjMsgNMvojM8IjdEojdNIjdVojdeIjdmojUswWdvoBPLkjVVgT+E4BfpEjlHgT2KAUOd4BAM1O+zoBOsIj5Axj/Voj/eIj/moj/vIj/3oj/8IkAEpkE6GQJjhRqoCZzzQgkTwZY7wEb/We4SzVfbQEaxFA+A3P8SVBWeXf1MWNCYwFslgIfBQh+RgGu3gAlMFV4kWCKGWaY3CQZA2MfbQQeHACoPYBABoewSwCAaQE6TXbsmwbd+wbjfUFMJoEwQkbuLGIN7QAMYwb1ADROsmldTq5m9wIY9LAEUaSWW9wA215iA3pwoEolqHhFgzAnPIIXOPtXPTQEeh50d5wDhIKAVulIsRKScOQnBewR6h5ySgNSOk4nJJ4XUA8pbxcZiMl5VNYJGQF2eU1nd/oSL2gJhmZ1szgndlMAxjJ3iUFJdb10tMsphJwErHeGV+IWdH8SY5YQ9s4pbU8VyhxXnyARzlQBN9slhw2UsEcUxVwEyy6H+jSQOzwlP4KJwzxSaXOJDLyZzN6ZzPCZ3RKZ3TSZ3VaZ3XiZ3ZqZ3byZ3d6Z3faTAhAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_61_28639=[""].join("\n");
var outline_f27_61_28639=null;
